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Abstract 
A library of ssDNA aptamers has been screened and a number of molecules which 
show high binding affinity to 14-3-3 proteins have been isolated. 
The mammalian 14-3-3 y protein modified by (His)6 tagging, was overexpressed in 
E.coli and purified to homogeneity. The recombinant 14-3-3 ' was characterised 
using a series of techniques ensuring that the expressed protein had similar physical 
and immunological characteristics to that of wild type 14-3-3 y. 
An ssDNA aptamer library was synthesised and aptamers selected following an 
adapted SELEX (systematic evolution of ligands by exponential enrichment) protocol. 
After 16 selection rounds, aptamers contained within the enriched pool were cloned 
and sequenced for further analysis. 
A sample of twenty of the sequenced aptamers were synthesised and biotinylated and 
their interaction with (His)614-3-3'y analysed by surface plasmon resonance and 
enzyme linked oligonucleotide assay (ELONA). The two aptamers showing the 
greatest association to (His)6 14-3-3-y were further analysed against all 14-3-3 isoforms 
using ELONA and by dot-blot analysis. 
The high affinity aptamer, S16-8, was used to affinity purify recombinant 14-3-3 
spiked into ovine serum albumin and wild type 14-3-3 in mouse brain homogenate 
and to detect and concentrate 14-3-3 protein in a scrapie positive cerebrospinal fluid 
(CSF) sample. The results of this work suggest that this aptamer could be used as a 




ATP - Adenosine 5' -triphosphate 
Bp - Base pair(s) 
BSE - Bovine spongiform encephalopathy 
CD - Circular dichroism 
CJD - Creutzfeldt-Jakob disease 
CNBr - Cyanogen bromide 
CSF - Cerebrospinal fluid 
CWD - Chronic wasting disease 
Da - Daltons 
DMSO - Dimethyl sulfoxide 
DMTr - Dimethoxytrityl group 
DNA - Deoxyribonucleic acid 
dNTPs - Deoxynucleotide triphosphates 
EDTA - Ethylene diaminetetraacetic acid 
ELISA - Enzyme Linked immunosorbent assay 
ELONA - Enzyme Linked oligonucleotide assay 
ES-MS - Electrospray ionization mass spectrometry 
FF1 - Fatal familial insomnia 
GSS - Gerstmann-Sträussler-Scheinker disease 
HIV - Human immunodeficiency virus 
HPLC - High performance liquid chromatography 
HRP - Horse radish peroxidase 
IMAC - Immobilised metal affinity chromatography 
IgG - Monomeric Immunoglobulin G 
IPTG - Isopropyl- 1 -thio-3-D-ga1actopyransoside 
LB - Luria Bertani 
MALDI - Matrix-assisted laser desorption ionisation 
MAP Kinase - Mitogen Activated Protein kinase 
MBH - Mouse brain homogenate 
NF-KB - Nuclear Factor- id3 
NTA - Nitrilotriacetic acid 
ORF - Open reading frame 
PAGE - Polyacrylamide gel electrophoresis 
PBS - Phosphate buffered saline 
PBSM - Phosphate buffered saline with magnesium chloride 
PCR - Polymerase chain reaction 
PKC - Protein kinase C 
PNK - Polynucleotide kinase 
PrPC - Prion protein, normal undiseased cellular structure 
PrPS - Disease associated form of prion protein 
PVDF - Polyvinylidine difluoride 
Q-TOF - Quadrupole time of flight 
RNA - Ribonucleic acid 
RP - Reverse phase 
RT - Reverse transcriptase 
RU - Response units 
Rpm - Revolutions per minute 
SDS - Sodium dodecyl sulphate 
SELEX - Systematic evolution of ligands by exponential enrichment 
SPR - Surface plasmon resonance 
ssDNA - Single stranded DNA 
Tar - Trans activation response element 
TCEP- Tris (2-carboxyethyl) phosphine hydrochloride 
TFA - Trifluoroacetic acid 
TOF - Time of flight 
Tris - Tris [hydroxymethyl] aminomethane 
TMB - 3,3,5,5 Tetramethylbenzidine 
TTF1 - Thyroid transcription factor 1 
TSE - Transmissible spongiform encephalopathy 
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Chapter 1: 14-3-3 Proteins; not just a number 
1114-3-3 Proteins, an Introduction 
14-3-3 proteins are a family of ubiquitously expressed regulatory molecules found in 
eukaryotic organisms. They are acidic, dimeric proteins that can modulate interaction 
between proteins involved in cell signaling and other functions, playing a role in 
many vital regulatory processes, including apoptotic cell death, cell cycle control and 
mitogenic signal transduction. 
14-3-3 proteins were first discovered in 1967, in the course of the systematic 
classification of bovine brain proteins by Moore and Perez.' The unusual name is 
based on the elution and migration pattern following two-dimensional DEAE-
cellulose chromatography and subsequent starch gel electrophoresis. 
Nothing was known of the role of 14-3-3 proteins until Ichimura and co-workers 
ascribed the family its first function in 1987.2  They had discovered a protein cofactor 
responsible for the activation of tryptophan and tyrosine hydroxylases, which are 
involved in the synthesis of many neurotransmitters including dopamine. 
Characterisation of this cofactor led to its identification as a 14-3-3 protein and led the 
group to clone the first 14-3-3 gene (the 'q isoform) in 1988, a major breakthrough in 
determining the role of 14-3-3 proteins in the cell .3  
There were significant advances in uncovering the role of 14-3-3 proteins in 
regulatory processes in the following years. In 1990 Aitken and co-workers, along 
with Toker and co-workers, showed that 14-3-3 proteins were involved in the 
inhibition of protein kinase C (PKC).4'5 PKC's are involved in the phosphorylation of 
a wide range of proteins leading and as such are involved in the control of many 
signaling and regulatory pathways. In 1992 Morgan and co-workers found that 14-3-
3's were stimulators of calcium dependant exocytosis, and another significant 
discovery was made in 1994 when the family was shown to co-associate with Raf, an 
activator of the MAP kinase pathway. 6,7 
To date more than 200 interacting partners have been identified for 14-3-3 proteins 
showing that 14-3-3 is involved in a vast range of cellular processes (see section 1.5). 
It has been suggested that perhaps the greatest challenge remaining for 14-3-3 
researchers, could be to define the precise role of 14-3-3 in cell biology.8 
1.2 14-3-3 Proteins in the Cell 
14-3-3 proteins are amongst the most abundant proteins within the neuronal tissues, 
comprising approximately 1% of the brains total soluble protein.9 Mammalian 14-3-3 
proteins exist as a family of highly similar yet distinct protein isoforms each encoded 
by their own gene.10 Seven human isoforms have been identified to date, and these 
are named after their elution pattern on reversed phase high performance liquid 
chromatography (HPLC) (0, E, 't, u, 'y, , ii)." Two other isoforms, a and 6, had been 
previously described, however work in 1995 by Aitken and co-workers showed that 
these were actually post-translationally phosphorylated forms of 0 and 'y.12 Including 
the seven human isoforms, more than 153 14-3-3 isoforms have been detected in 48 
species of multicellular organisms (correct as of 2000) including amoebae, plants, 
yeasts, nematodes, flies, frogs and mammals, to date no isoforms have been detected 
in prokaryotes. 13 
Mammalian 14-3-3 proteins have a typical monomeric mass around 30 000 Da 
(28kDa to 33kDa), containing between 246 to 249 amino acids, and have an 
isoelectric point around 4.5. In their native state the proteins are either homo- or 
2 
hetero- dimers. Many 14-3-3 ligands bind to specific 14-3-3 isoforms with different 
affinities, and this means that 14-3-3 hetero-dimers provide unique recognition motifs 
allowing two different proteins to be brought close enough to interact with each 
other. 14  This is a major point for 14-3-3 function and as such will be further discussed 
later in the chapter. 
14-3-3 proteins are predominantly located in the neuronal cells of the brain, however 
they are no longer considered brain specific proteins and appear to be expressed in 
almost all mammalian tissues including heart, liver and the testes.15'16 Two of the 
human 14-3-3- isoforms, 'r and o are present at only low levels in the brain and are 
instead detected predominantly in T cells and epithelial cells respectively. 17,19  14-3-3 
proteins are most abundant at the cytoplasmic compartment but have also been 
detected at the plasma membrane, nucleus and at the Golgi apparatus. 
1.3 14-3-3 Family Conservation 
14-3-3 proteins are very well conserved across a broad range or organisms (the human 
F, isoform and the Saccharomyces cerevisiae BMH 1 are approximately 70% similar at 
the amino acid level). 13,  The seven human isoforms are around 50% similar across 
the whole family but as high as 86% between isoforms P and (the human 14-3-3 
sequence alignment is shown in Figure 1.1). Wang and Shakes compared 50 of the 
available 14-3-3 sequences using a phylogenic tree to determine the evolutionary 
relationships among specific isoforms in different organisms. They discovered that 
the family contained five highly conserved sequence blocks (conservation of each 
block varies from 53.8% to 89.9%) across all species. When correlated with the three 
dimensional 14-3-3 structures, the conserved regions match with the internal "binding 
domain" regions of the dimer which are essential for dimerisation and ligand binding 
3 
(refer to Figure 1.2). The outer helices that are less well conserved, supporting the 
previous observation by Liu and co-workers in 1995 that the internal region of the 
dimer the most conserved region. 20  Many functionally important residues are found 
in the conserved regions, however there are subtle differences between isoforms, 
including the phosphorylation sites that may lead to isoform binding specificity. 
The N and C terminal regions contain the least well conserved amino acid regions 
across all species. Liu et al. suggested that the C-terminus, which shares little 
sequence conservation but is uniformly acidic in character, may serve to regulate the 
function of 14-3-3 by interacting with a basic cluster of residues contained within the 
dimer. 
K49 R56 
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Figure 1.1: 14-3-3 sequence alignment. The human 14-3-3 sequences were aligned 
using ClustalW.2' Black bars above sequences indicate a-helices. Some key residues 
(see section 1.5) have also been highlighted. 
1.4 14-3-3 Structure 
In 1995, the crystal structures of two 14-3-3 isoforms, t and , were solved by Xiao 
and co-workers and Liu and co-workers respectively. 22,20 The structures are very 
similar, leading to the suggestion that all 14-3-3 proteins share a similar tertiary 
dimeric structure, resembling a flattened 'U' shape as shown in Figure 1.2. 
Figure 1.2: 14-3-3 Crystal Structure. Shown are two images of a 14-3-3 homo 
dimer. Each monomer unit is represented by either the colour green or blue. The 
second image was obtained by rotating the first image by 900  relative to the plane of 
the paper, effectively viewing the image from above. 
n. 
Each 14-3-3 monomer unit consists of nine anti-parallel ci-helices, with a highly 
conserved inner concave surface and a variable outside surface. As shown in Figure 
1.2, the N-terminal region helix 1 (specifically residues 5-21) interacts directly with 
helices 3 and 4 of the corresponding monomer unit (specifically residues Ser58-
G1y89), leaving a negatively charged channel about 7A wide in the centre, which is 
surrounded by amino acids which are almost totally conserved across the whole 
family. The conserved inner region of the 14-3-3 monomer unit contains an 
amphipathic groove, 35A long by 35A wide by 20A depth, with polar residues on one 
side (helices 3 and 5), and the other side (helices 7 and 9) containing a cluster of 
hydrophobic residues. 20 The five conserved sequence blocks previously mentioned 
are helices 3, 5, 7, 9 along with the connecting loop of helices 1 and 2, itself an 
integral element in dimer formation. By analyzing the crystal structure of 14-3-3 
with ligand attached, Yaffe and co-workers suggested that the ligand interacts directly 
in the groove between Lys49 and Arg56 in helix 3 and with Arg129 and Tyrl30 in 
helix 5 (highlighted in Figures 1.3 and 1.4), a model confirmed by further co-
crystallisation experiments and by mutagenesis of the residues involved in ligand 
binding. 23,21,25  These residues form a basic cluster of residues within an otherwise 
acidic molecule, suggesting that ligand serine/threonine phosphorylation could act as 
molecular switch controlling ligand binding. Interestingly, co-crystal studies using 
unphosphorylated ligands, show binding at the same highly conserved sites, 
suggesting that other residues of the protein may aid ligand: 14-3-3 interaction. 
26 
7 
Figure 1.3: 14-3-3 Basic pocket. Residues Lys-49, Arg-56, Arg-129 and Tyr-130 




Figure 1.4: Crystal Structure of a 14-3-3 monomer unit with bound peptide. 
Image A shows the bound peptide, B is a structure of the free peptide ligand and 
image C shows the peptide in space fill. 
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1.5 14-3-3 Ligand Interactions 
The history of 14-3-3 proteins has been a series of rediscoveries expanding the roles 
played by the family. The findings that 14-3-3 proteins inhibit PKC's, co-associate 
with Raf and middle T-antigen implicating a role in DNA damage response, caused an 
explosion in interest in the family. 27  The mid 90's brought many publications 
showing that the 14-3-3 family interacted with a range of protein kinases, 
phosphatases and other signaling proteins and led to the suggestion that 14-3-3 
molecules were a novel type of dimeric scaffold protein that could modulate 
interaction between kinases and other signalling proteins. 1,28 
In 1996 Muslin and co-workers suggested that because the 14-3-3 family has so many 
binding partners, some of which are very similar, it would be reasonable to propose a 
common binding determinant that mediates contact. 29 They deduced the recognition 
motif from a 1 5-mer Raf- 1 peptide. Their work and that of Yaffe and co-workers in 
1997 led to the discovery of two specifically phosphorylated motifs that are present 
(or very close matches are present) in more than half of the 14-3-3 ligands established 
to date .30'3' The motifs, RSx[pS/pTxP and RxDx[pS/pT]xP (where x can be any 
amino acid, S is serine, T is threonine, P is proline, R is arginine, the symbol p 
represents a phosphorylated amino acid and 1 denotes aromatic or aliphatic amino 
acids), appear to be recognised by all 14-3-3 isotypes. The arginine at -3 or -4 from 
pS/T is obligatory for 14-3-3 interaction whereas the proline at +2 is dispensable, 
although the Kd is increased when this amino acid is present. 32 
It should be noted however, that many ligands bind to 14-3-3 isoforms using drastic 
variations from this motif some phosphorylated and some unphosphorylated. It 
should also be noted that the affinity of non phosphorylated ligands can be similar to 
those of phosphorylated ligands. Two main motifs have been found for such 
Oj 
unphosphorylated interactions, those ligands that contain cysteine rich domains 
(CRD's) such as Raf and ligands which can interact through acidic residues such as 
ExoS ADP-ribosyltransferase.7'33 Phage display library experiments have shown that 
phosphorylation is not required in peptides containing many acidic residues, 
especially those that are Glu rich, and this explains the affinity of 5-phosphatase, an 
unphosphorylated 14-3-3 ligand containing the binding motif RSESEE.24 Table 1.1 
gives just some of proteins found to interact with 14-3-3 to date. 
14-3-3 molecules are predominantly dimeric in nature, with two ligand binding sites, 
occupied by either two different ligands or by a single ligand with two recognition 
sites. Many examples exist of ligands that contain a single binding motif. Ligands 
such as Raf, BAD and Cbl are bidentate and contain two high affinity recognition 
motifs. In contrast the protein Cdc25B is a ligand which contains a high affinity 
binding site and a second, lower affinity motif that serves to aid binding. 
14  This is 
discussed later in the context of the anvil/gatekeeper hypothesis. As a result of the 
phospholigand-binding discovery by Muslin and Yaffe, 14-3-3 proteins were 
redefined as the first phosphoserine/phosphothreonine binding molecule, suggesting a 
key role for the molecule in the control of intracellular signal transduction.35  
In 2004, Pozuelo Rubio and co-workers were able to identify over 200 human 
phosphoproteins that bind 14-3-3 proteins by affinity chromatography. 
36  In their 
study proteins were identified by passing crude extract human HeLa cells through a 
14-3-3 sepharose affinity column (containing the two Saccharomyces cerevisiae 
isoforms), then eluting the bound proteins by addition of a 14-3-3 binding 
10 
phosphopeptide (ARAApSAPA). Interestingly, they found that when the purified 
proteins were dephosphorylated, they lost their ability to bind to 14-3-3. 
Table 1.1 14-3-3 binding partners. This is not a complete list and shows just a slice 
of the 14-3-3 ligands established to date, adapted from Aitken et al.37 
Target Protein and Category 	 Binding Motif 
Protein Kinases 
BCR 	 RSQSTPSEQ 
PKCjt (PKD) 	 RLpSNVS, TRSpSAELpS 
PKC 	 RHDMpSYMP 
c-Raf-1 kinase 	 RSTpSTP, RSApSEP 
Phosphatases 
PTPHI, tyrosine phosphotase 	 RSLpSVE, RVDpSEP 
Cdc25A cell-cycle dual-specificity phosphotase 	 RSPpSMP 
Cdc25C cell-cycle phosphotase 	 RSPpSMP 
Receptors and related proteins 
Exoenzyme-S, ADP-ribosylation 	 DALDL 
Insulin growth factor I receptor S VPLDPSASSSpSLP 
RAS effector protein RINI 	 RSMpSAA 
Nuclear receptor (Nur77) RLPpSKP 
Apoptosis-regulating proteins 
BAD, apoptosis-regulating 	 RHSpSYP, RSRpSAP, RRMpSDFE 
Apoptosis signal-regualting kinase I (ASKI) 	 RSIpSLP 
Adaptor Proteins 
KSR (kinase suppressor of RAS) 	 RSKpSHE, RTEpSVP 
Cbl 	 RHpSLPFpS, RLGpSTFpS 
Transcription factors and nuclear proteins 
Forkhead transcription factor (FKHRLI) 	 RPRSCpTWP, RRRAVpSMD 
Nuclear factor of activated T-cells (NFAT3) RRYpSpSpS, RRGpS 
p53 tumour-suppressor/transcription factor 	 KGQSTpSRH/G 
Enzymes and others 
43 kDa inositol polyphosphotase 5-phosphotase 	 ELVLRSESEEKW 
Middle T antigen, polyoma virus 	 RSHpSYT 
Tyrosine hydroxylase 	 RRAVpSELD 
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1.6 The Mechanism of 14-3-3 Action 
14-3-3 proteins are currently believed to have 5 major roles of action: 
14-3-3 binding can alter the ability of the target protein to interact with other 
proteins through sequestration (binding) or modification of the target protein. This 
mechanism can be demonstrated by the 14-3-3 interaction to BAD.38 BAD is 
sequestered by 14-3-3, preventing binding of BAD to the anti-apoptic protein Bcl-2. 
Introduction of the protein phosphotase PP2A, dephosphorylates BAD which leads to 
the release of 14-3-3 and binding of 14-3-3 to Bcl-2. 
14-3-3 can control the subcellular localisation of target by masking a targeting 
sequence, inhibiting ligand relocation. Release of the target allows subcellular 
movement. 14-3-3 has been shown to play a role in nuclear retention of tobacco 
DNA-binding protein phosphatase 1 and in protein shuttling in 
cytoplasnilmitochondrion, cytoplasm/nucleus, cytoplasm/plasma membrane and 
endoplasmic reticulum/plasma membrane. 39 The cytoplasm/nucleus movement of 
this cell cycle protein Cdc25C provides an example of the scenario. 
40 
14-3-3 can act as a phosphorylation dependant scaffold to bridge two proteins 
together. This has been demonstrated for Raf-BCR interactions. 
41 
4)14-3-3 regulates the catalytic activity of the target ligand, enhancing or inhibiting 
its function. For example 14-3-3 has been shown to increase the binding affinity of 
p53 for DNA.42 
5) 14-3-3 can shield the target sequence and protect it from further modifications, 
such as dephosphorylation and proteolysis.28  
In 2002, Yaffe proposed two models for the mechanism of 14-3-3 interactions, 
namely gatekeeper phosphorylation and the molecular anvil hypothesis, models that 
12 
rely heavily on the dimeric nature of 14-.3-3 proteins. 31 As mentioned previously, 
some ligands including BAD and Raf contain two ligand binding sites, making 
possible the interaction of a single protein with both monomer units in the 14-3-3 
dimer.43 Comparison of synthetic phosphopeptides with one and two 14-3-3 binding 
motifs showed that the bidentate ligand interaction was 30 times tighter. 30  Similarly, 
point mutations in one of the binding sites have been shown to impair 14-3-3/ligand 
function. 25 
The molecular anvil model proposes that 14-3-3 dimers are capable of altering the 
enzymatic activity or masking/revealing functional motifs by altering the 
conformation of bound bidentate ligands. It is suggested that 14-3-3 dimers are very 
rigid due to the plethora of interacting forces between the a-helices, lending to the 
distortion of bound ligands without self-deformation. When such a ligand binds, its 
conformation is changed enough to facilitate a process that was not available to the 
unbound ligand. Figure 1.5 shows a diagrammatical representation of the molecular 
anvil hypothesis. The second site binding to 14-3-3 protein causes a change in the 
ligand structure, revealing an active site that was previously inaccessible. 
The gatekeeper hypothesis can be explained using the protein Cdc25B. This is one of 
a range of molecules containing high affinity and lower affinity 14-3-3 binding 
motifs. The high affinity region is proposed to bind to a 14-3-3 monomer unit, acting 
as a gatekeeper and allowing the lower affinity motif to bind 14-3-3 more easily due 
to its proximity, making a secondary contact which would not be as stable without the 
primary interaction. 
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5  2 1 6 	2 
Figure 1.5: A representation of 14-3-3 working as a molecular anvil. The 
numbers 1 and 2 represent ligand binding sites of a 14-3-3 dimer initially interacting 
at one site of a bidentate ligand. 
Aitken et al. have shown that specific 14-3-3 isoforrns differ in their preference for 
homo- and hetero dimerisation, with particular heterodimers forming at the expense of 
others. 14 They proposed that because ligands generally have different affinities for 
each 14-3-3 isoform, populations of specific hetero-dimers may alter which two 
interacting proteins that are brought together, possibly resulting in long term changes 
in cell signalling. 
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1.7 14-3-3 Proteins in Human Disease 
Changes in the expression levels of specific 14-3-3 proteins in human plasma, has 
been used for early diagnosis for a range of disorders. 44  Elevated levels of 14-3-3 
proteins are detected in the Cerebrospinal fluid (C SF) of patients suffering 
neurodegeneration, caused by diseases including Creutzfeldt-Jakob disease (CJD), 
Alzheimers disease and Parkinsons disease. Some epithelial cancers can be detected 
by monitoring the expression levels of 14-3-3cy since downstream gene silencing of 
this gene is proposed to play an important role in the onset of carcinogenesis.45'46 
Patients who suffer from AIDS dementia complex or cytomegalovirus encephalitis 
also show specific 14-3-3 isoform expression patterns in the CSF.47 Other diseases 
where 14-3-3 proteins have been used as markers include herpes simplex encephalitis, 
acute ischematic stroke and paraneoplastic neurological disorders. 45 
1.7.1 Prion Diseases 
Transmissible Spongiform Encephalopathies (TSE's) or Prion disease are a family of 
fatal neurodegenerative diseases, characterised by spongiform degeneration of the 
brain (microcavitation), neuronal loss, astrocytosis and the build up of PrPSC  (scrapie 
prion protein) an atypical form of PrPC  (the native, protease-sensitive, normally 
expressed form of PrP) in the central nervous system. 48 
Prion diseases are unique in that they differ from viral and other neurodegenerative 
and infectious diseases. Prions unlike viruses do not require a nucleic acid code 
necessary for self perpetuation, they cause no inflammatory reaction and do not 
succumb to radiography as would an infectious disease, and they are capable of 
transferring between human-human and human-animals unlike most 
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neurodegenerative diseases characterised to date. Although they have relatively low 
incidence rate (1 in a million), the transmissibility of prion diseases causes them to be 
considered a significant risk to public health. In 1967 it was first suggested that the 
infectious agent was not a living organism but was instead an abnormal protein, later 
coined a prion in 1982 by Pruisner.49'50 Two popular models exist for the Prion 
hypothesis, adapted from Aguzzi and co-workers are shown in Figure 1.6.51  The 
current favoured model is the seeding mechanism; PrPSC  is an infectious agent capable 
of self-propagation by converting PrPC  to itself (PrPsc and PrPC  have the same amino 
acid chain yet a post translational modification is capable of taking the native a-
helical protein and converting it to j3-sheet structure that is nuclease resistant and 
causes insoluble aggregates) catalysed by physical interaction with PrP. The 
conversion mechanism is not fully understood however it is suggested that PrP 
aggregates serve as templates for the ordered aggregation of PrPC.  The Prion 
hypothesis is still to be fully accepted and will remain controversial until PrP sr-
proteins are successfully taken from an infected donor, purified in vitro added to a 
recipient, causing new Prion growth. Recent studies by Legname and co-workers in 
2004 and by Castilla and co-workers in 2005 come close to achieving that goal and 
proving the hypothesis. 52,53  For more detailed information on Prion diseases and their 
possible therapies, two very good reviews are available from Aguzzi and co-workers 
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PrP' 	(Very slow) monomeric PsPs seed 
(fast) 
Model A: The Nucleation Polymerisation or Seeding Mechanism; PrPC and PrPSC 
are in reversible thermodynamic equilibrium. If several PrPsc monomers are mounted 
into a highly ordered seed then further monomeric PrPsc can be recruited to form an 
amyloid. Fragmentation of the amyloid, increase the number of seed nuclei that can 
recruit further PrPS  and thus results in apparent replication of the agent. 
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Conversion 	
I prevented by 
Amyloid; not barrier 
high energy 	
j 	
Siiii.i...4iir. 	-•-- 	I I iJ 	r 	




Model B: The Template Assisted or Refolding Mechanism; An interaction between 
exogenously introduced PrPSC  and endogenous PrPC,  induces  PrPC  to transform itself 
into further PrPS. 
Figure 1.6: The two models of the Prion hypothesis with a brief explanation. The 
proposed mechanism of each is described within. 
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Prion diseases effect both humans and animals, examples include; sporadic CJD, 
iatrogenic CJD, new variant CJD, familial CJD, in humans, bovine spongiform 
encephalopathies (BSE) in cattle, scrapie in sheep and chronic wasting disease 
(CWD) in elk and deer. Other human TSE's include the now almost extinct Kuru and 
the inherited disorders Gerstmann-Sträussler-Scheinker disease (GSS) and fatal 
familial insomnia (FF1), both of which caused by a mutation of the PrP gene. 
Most common of the human Prion diseases is sporadic CJD (sCJD) which has a 
worldwide annual incidence rate of around one case per million. 
54  It is a fatal 
disorder of the central nervous system, typical onset between 45 to 75 years, 
characterised by a rapidly progressive dementia and a case fatality greater than 90% 
within the first year. In 1996, a new variant CJD (vCJD) was identified, which has to 
date been detected in the United Kingdom, France, the Republic of Ireland, Hong 
Kong, Italy, the United States and Canada. 55  vCJD affects younger patients and has a 
longer clinical course than its sporadic equivalent, it has over 150 UK individuals to 
date and is believed to derive from consumption of BSE contaminated neuronal 
tissues.56 
The primary UK vCJD epidemic appears to have peaked in 2000 (as shown in Table 
1.2), although much concern remains about a secondary epidemic caused by blood, 
tissue, or organ donation, or by treatment using contaminated instruments. 
57  The only 
current definitive diagnosis for spCJD and vCJD are obtained by post-mortem 
neuropathological examination of brain tissue. There is a need for an effective pre-
mortem diagnosis to prevent hospital acquired infections of CJD (iatrogenic CJD) and 
prevent the spread of BSE, scrapie and CWD throughout the world. It has been 
suggested that proteins used as surrogate markers could be used for early detection of 
18 
CJD, leading to a prolonged onset of disease, possibly providing a better quality of 
life for suffers and preventing the avoidable transmission of prion diseases. 
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1.7.2 14-3-3 Proteins as Surrogate Markers 
Detection of Pr Sc P, as a marker for vCJD, in blood and peripheral tissues poses 
significant problems. Among the complicating factors are that there are no current 
antibodies uniquely specific for PrPS  and the very low levels of the abnormally 
folded PrpSC  compared to PrPC.  For classical immunodetection methods to be useful, 
this necessitates the removal of the interfering PrP' typically by limited proteolysis. 
Alternatively concentration of the PrPSC  can be achieved by selective precipitation in a 
complicated and lengthy procedure that provides best case concentrations that lie in 
the lower limits of sensitivity for immunoassay detection. 
58 
A number of proteins found in the CSF of patients with neurodegenerative disorders 
have been considered as possible surrogate markers for prion disease detection. 
These include 14-3-3 proteins, S-100b, neuron specific enolase and Tau protein. 
Among these markers, it was found that 14-3-3 proteins have the highest sensitivity 
and specificity in pre-mortem spCJD diagnoses, leading the World Health 
Organization (WHO), in 1998 to revise its clinical criteria for the diagnosis of 
probable spCJD to include 14-3-3 detection in the cerebrospinal fluid (CSF).59 The 
use of 14-3-3 proteins as a surrogate marker of vCJD is less attractive since only 
about 50% of vCJD patients have detectable 14-3-3 levels in their CSF. 
Of the seven human 14-3-3 isoforms, six are normally found in the brain,  
and i, and only the f3, y,  c and i isoforms are present in CSF of spCJD patients, with ' 
being the most abundant. This may suggest that the pathway from the neuron may be 
isoform specific. 60 
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1.7.3 Current Detection Methods for 14-3-3 Proteins 
Numerous studies have highlighted the importance of the 14-3-3 assay in the 
diagnosis of spCJD, however debate continues regarding the claim that the assay is 
not sufficiently specific in large populations to be used as a true diagnostic test. 
61,62 
Western blotting is the current technique of choice for detecting 14-3-3 proteins in the 
CSF, but this method is unable to detect the small changes in 14-3-3 levels in the 
early stages of spCJD and vCJD. In the Western blot procedure, the proteins are first 
denatured, separated electrophoretically, then transferred to nitrocellulose and 
detected using a anti-14-3-3 antibody coupled to a detection system. 
ELISA's (enzyme linked immunosorbent assays) have been developed for the 
quantitative detection of CSF 14-3-3, however to date they lack the sensitivity of 
Western blotting. 63  An added problem is that CSF contains a heterogeneous mixture 
of dimeric 14-3-3 isoforms complexed with other interacting proteins making 
untreated (non-denatured) CSF not as amenable to 14-3-3 determination by ELISA as 
by Western Blot. 
A number of antibodies have been raised against a range of epitopes on differing 14-
3-3 isoforms. Table 1.3 shows a range of 14-3-3 antibodies that have been used in the 
detection of 14-3-3 proteins. 64  It is apparent from the table that most isoform specific 
antibodies have an epitope close to the N-terminus which poses a problem for the 
isoform specific detection of native state 14-3-3 dimers. As discussed in Section 1.5, 
the interface necessary for dimer formation uses parts of helices 1 and two, meaning 
that the epitope used for detection of the protein is blocked by the corresponding 
dimer unit, highlighted in Figure 1.7. This is why the Western blots, where the 
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proteins are denatured allowing antibodies to interact with their epitopes, have a 
higher sensitivity than the quantitative ELISA using un-denatured material. 
Antibody Epitope Position Specificity 
C-629 (anti-13) KSELVQKAKLAEQAERYDD 4-22 Cross-reaction with y,  c, 	, r 
an Purified brain 14-3-3 Raised against a mixture of brain 
isoforms 
C-628 (anti-13) LTLWTSENQGDEGDAGEGEN 226-245 Specific for 13 
199 Ac-MDKSELVQKAC 
________________________________  
2-11 Specific for 13, low level of cross-
reaction with 
2042 Ac-TMDKSELVC 1-8 Specific for alternative start of I 
C-731 (anti-,y) LWTSDQQDDDGGEGNN 231-245 Cross-reaction with Tj 
1005 Ac-VDREQLVQKAC 1-10 Specific fory 
C-1019 (anti-,y) AGDDKKGIVDQSQQAY 134-159 Probable cross reaction with 13 
1002 Ac-MDKNELVQKAC 1-10 Low level cross reaction with 13 
C-1020 (anti-F-) TGNDRKEAAENSLVAY 137-152 No reaction with standard containing 6 
2025 Ac-MDDREDLVYQAKC 1-12 Specific for 6 
CGEEQNKEALQDVEDENQ 238-254 Specific for 
2 Ac-GDREQLLQRARC 1-11 Specific for ri 
C-732 (anti-'r) TSDSAGEECDAAEGAEN 228-245 Cross reacts with other isoforms 
197 (anti-'r) Ac-MEKTELIQKAC 1-10 Specific for r 
789 Ac-MERASLIQKAC 1-10  
Table 1.3: 14-3-3 antibodies and their epitopes. Antibodies specific for more than 
one isoform have their cross-reactivity shown. 
B 
Figure 1.7: 14-3-3ç: Helix 1 has been coloured in red and parts of helices 3 and 4 
have been coloured in yellow in each monomer unit. Images A and B illustrate how 
close both helix 3 and 4 are to helix 1 and thus can interfere with epitope recognition. 
Controversy remains regarding the suitability of 14-3-3 detection for differential 
diagnosis of CJD, some groups have suggested that the assay gives too many false 
positives and false negatives to be of value. 
A study in 2005 by Van Everbroeck and co-workers involved the use of 52 spCJD 
and 201 control patients in whom definite diagnosis had already been made to 
compare the sensitivity of ay specific antibody against commercially available anti-
14-3-3 antibodies SC-731 and CJ31.65 The experiment was carried out by both 
immunoblotting and a sandwich ELISA technique both of which gave comparable 
results. The results are shown in Table 1.4. 
SC-731 CJ31 y 14-3-3 
Diagnosis N 	 Pos 	Neg Pos 	Neg Pos 	Neg 
sCJD 52 	 51 	1 50 	2 50 	2 
Sensitivity (%) 98 96 96 
Controls 201 	 30 	171 16 	185 15 	186 
Specificity (%) 85 92 93 
PPV (%) 63 76 77 
Dementia 140 	 14 	126 5 	135 5 	135 
Specificity (%) 90 96 96 
PPV (%) 78 91 91 
OND 61 	 16 	45 11 	50 10 	51 
Specificity (%) 74 82 84 
PPV (%) 76 82 82 
Table 1.4: Comparison of the sensitivity and specificity of a 14-3-3 y specific 
antibody for the detection of spCJD. (OND, other neuronal disorder; PPV, positive 
predictive value). The results show that a ' specific antibody increases the specificity 
without impairing the sensitivity of the assay 
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Work by Green and co-workers in 2002 used a capture assay to compare the viability 
of the 14-3-3 surrogate marker for detecting spCJD and vCJD. 66  Greens results and 






Figure 1.8: CSF 14-3-3 detection in sCJD and vCJD. Combined scatter and box 
and whiskers plots of CSF 14-3-3 ' detected by protein capture assay in vCJD control 
patients (0 ), in vCJD patients (s), in spCJD control patients (LI), and in spCJD 
patients (•). The boxes represent the 25th-75th quartile,divided horizontally by the 
median, the whiskers represent the range and the adjacent scatter plots represent the 
individual values from which the boxes and whiskers are derived. The horizontal 
dotted line represents the cut-off absorbance of 0.5. 
CSF 14-3-3 results in patients with either va riart or sporadic CJD and appropriate cortrols 
spCJD 	 veJD 
Capture assay 	Western blot 	Combined assays 	Capture assay 	Western blot Combined assays 
Definite CJ[) (&tn) 	45/55 	 45 	 50/55 	 16/26 	 15/26 	 20/28 
Controls (n/tn) 	2f32 12 3/32 1/13 1/13 1/13 
Sensitivity (%) 82 	 89 	 91 	 65 	 55 	 77 
Specificity (% 	94 97 91 92 92 92 
ppv (% 	 96 	 98 	 86 	 94 	 94 	 96 
NPV (1,10 75 24 78 52 52 66 
Efficiency {% 	86 	 92 	 87 	 89 	 69 	 52 
Figure 1.9: Sensitivity and specificity of CSF 14-3-3. Detection of 14-3-3 ' in the 
CSF of patients with spCJD (n = 55) or vCJD (n = 26) and in sporadic control patients 
(n = 32) or vCJD control patients (n = 13) using Western blot analysis and the protein 
capture assay. The sensitivity, specificity, positive predictive value, negative 
predictive value and efficiency of both methods were calculated using the number of 
positive results/total number. PPV, positive predictive value; NPV, negative 
predictive value; nitn, number of positive results/total number. 
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Green's results show that although vCJD gives a less sensitive response in the 14-3-3 
assay, it can still be used in the detection of the disease. 
For the 14-3-3 CJD assay to gain worldwide acceptance, a specific, sensitive method 
is required that can detect small levels of changes of 14-3-3 proteins in the CSF in an 
isoform specific manner. Recent antibodies are capable of detecting 14-3-3 to a level 
of 3.1±2.9 ng/ml using the ELISA technique. Although this is suitable for detecting 
the changes in CSF levels for sCJD, much smaller changes occur with vCJD and the 
current antibodies do not provide the sensitivity required for definitive diagnosis. 
We propose to use an oligonucleotide alternative to antibodies, namely aptamers, and 
we aim to use them to provide a detection method capable of detecting native state 
14-3-3 protein from CSF with sensitivity comparable to the current antibody 
equivalents. 
25 
Chapter 2: Aptamers 
2.1 Aptamers, an Introduction 
Aptamers are RNA or DNA oligonucleotides which bind to other molecules with high 
affinity and specificity. The theory of aptamer production is simple - a very large 
population (library) of synthetic oligonucleotides is screened and the candidates with 
the desired binding properties are isolated and identified. However this is not 
practical unless some kind of selective enrichment of oligonucleotides with the 
desired properties is incorporated in the procedure. The systematic evolution of 
ligands by exponential enrichment (SELEX) process, which is described later in this 
chapter, involves the sequential amplification of sequences in the library with high 
target affinity at the expense of those of lower affinity. This relies on the fact that 
DNA oligonucleotides can be faithfully amplified by the polymerase chain reaction 
and, in the case of RNA aptamers, that these can be converted to and transcribed from 
their DNA counterparts. 
Aptamers were first described in 1990. Tuerk & Gold and Ellington & Szostak 
demonstrated the in vitro screening of large libraries of RNA oligonucleotides for 
RNA ligands that bind T4 DNA polymerase and a variety of small organic dye 
molecules respectively. 67,68 Both groups showed that by using the SELEX process 
they could identify individual nucleic acid sequences which showed selective target 
binding from very large random sequence nucleic acid libraries. Although the idea of 
using artificial evolution to select highly specific and selective oligonucleotides 
ligands against a target molecule was a new concept at that time, the idea of the 
potential therapeutic use of small nucleic acid ligands for biomolecular targets was 
not. Studies on HIV and adenovirus in the 1980s had found that these viruses 
encoded small, structured RNAs which bind to viral or cellular proteins with high 
affinity and specificity. Such RNAs were shown to modulate the activity of proteins 
essential for their replication or to inhibit the activity of proteins involved in the 
cellular antiviral response. In 1990, Sullenger et al. published novel work which 
described the overexpression of one such HIV RNA ligand.69 The HIV-encoded tat 
gene product is a potent trans-activator of viral gene expression. To function, tat 
must directly bind to a cis acting RNA target called TAR (trans activation response), 
which is encoded in the first 60 nucleotides of the viral RNA transcript. In a case of 
"intracellular immunisation", Sullenger managed to overexpress an RNA species' 
encoding the TAR sequence, and used it as a decoy to bind to tat, preventing tat 
binding to the TAR sequence encoded by the viral RNA, inhibiting HIV-1 replication. 
Sullenger's work was seminal showing (in advancing the concept that) nucleic acid 
ligands could play a role in modulating the activity of clinically active proteins, and 
they could act like antibodies in selecting a target with high selectivity and specificity. 






Figure 2.1: TAR decoy RNA aptamer preventing Tat protein from binding to 
viral TAR RNA. By inhibiting the TAR-Tat interaction the aptamer inhibits HIV 
RNA transcription and replication. 
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It should be noted here that natural nucleic acid-protein interactions, such as the tat-
TAR case, are generally reversible allowing gene regulation, whereas the aim of an 
artificial aptamer-target selection may be to obtain the strongest binding sequence in 
vitro and thus selection of tighter binding sequences is possible. 70  In principle the 
generation of a suitable high-affinity aptamer requires no previous knowledge about 
the properties of the target, its structure or how it interacts with or recognises its own 
natural ligands. It seems reasonable that if aptamer-target interactions can be selected 
that such features as such as association rate, dissociation rate and affinity for the 
target and lack of affinity to a closely related target could be selected for by carefully 
selecting the selection/partitioning methods. 
The affinity of published aptamers varies widely according to the choice of target. 71 
Perhaps unsurprisingly, aptamers to nucleic-acid binding or heparin binding 
molecules generally have the strongest affinities, typically in the high picomolar to 
low nanomolar range. Non nucleic-acid binding proteins often have affinities in the 
higher nanomolar range, whereas aptamers against small molecules have affinities 
generally in the micromolar range. Examples of each are cited in Table 2.1. The 
KGF binding aptamer deserves special attention for binding in the femtomolar range, 
300fM, an interaction encroaching on that of streptavidin-biotin binding, to date the 
strongest published interaction. 72 
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Ligand Nucleic Acid Affinity Kd 1pM] 
3D Structure, PDB 
accession number 
Reference 
Theophylline RNA -0.3 NMR, 1EHT 











NMR, 1OLD, 2ARG 
NMR, 1KOC 80 








Neomycin B RNA —0.115 NMR, 1 NEM 
HIV-1 Rev peptide RNA 0.004 NMR, lULL, 484D 
84 
HTLV-1 Rex peptide RNA 0.025 NMR, 1C4J 
85 
MS2 Coat protein RNA - X-ray, 5-7MSF 
86 
Thrombin DNA -0.025 
NMR, 148D 
X-ray, 1HAO 88 
Argininamide DNA NMR, 1DB6 
89 
Vitamin B12 RNA 0.9 X-ray, 1DDY 
90 
Tetramethyirosamine RNA X-ray, 1F1T 
91 
Biotin RNA X-ray, 1F27 
92 
HIV-Tat RNA NMR, 1NBK 
93 
Streptomycin RNA X-ray, 1NBT 
94 
Nf-Kb(P50)2 RNA X-ray, 100A 
KGF RNA 0.0003 
72 
Table 2.1; Current aptamer affinities and structures. Adapted from Hermann and 
Patel .73  PDB is the Research Collaboratory for Structural Bioinformatics protein data 
bank, a database here all protein crystal structures solved to date. 
Aptamers have been shown to have remarkable specificity for interaction between 
very closely linked molecules. There is evidence of the ability of aptamers to 
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differentiate enantiomers, L- and D-arginine have a 16 000 fold difference in their Kd 
values. 78 Aptamers can differentiate very similar enzymes, u-thrombin can be 
distinguished over -y-thrombin, aptamers have also been shown to differentiate very 
similar small molecules. 87  One of the most commonly quoted examples is that of the 
theophylline aptamer which has a 10,000 fold greater affinity over the affinity of the 
same aptamer for caffeine, a molecule which differs by a single methyl group (see 
Figure 	Hydrogen bonding between a cytosine residue in the aptamer and the 
purine like theophylline provides a pseudo base pair, where the aptamer and the small 
molecule both provide a bonding partner. In comparison, caffeine contains a bulky 
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Figure 2.2: Theophylline and Caffeine. Theophylline (A) differs from Caffeine (B) 
by a single methyl substitution. 
2.2 DNA or RNA Aptamers 
Aptamers make the ideal starting molecules for combinatorial chemistry. They differ 
from organic libraries in that they have their own genetic code needed for their own 
amplification and they contain the blueprint necessary for their improvement and 
optimisation. Antisense nucleic acid molecules have similar chemistries however 
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they are considered linear molecules capable of blocking transcription by following 
the Watson-Crick model of DNA as opposed to forming intricate tertiary structures 
that bind targets like aptamers. Organic molecules have inherent limitations to the 
number of tertiary structures available and limits to the options of chemically 
synthesised derivatives that can be use in an aptamer library because of the necessity 
for the library to interact with nucleic acid polymerase enzymes. 
Biological DNA is almost exclusively an informational macromolecule and is 
structured as a base paired duplex. Single stranded DNA is a rare commodity in 
nature and a ssDNA molecule that can form a structure and carry out a functional role 
is even more unusual. It is generally accepted that DNA has a limited number of intra 
molecular structures because of the molecules rigidity and the availability of bond 
donors/acceptors, however the publication of the human genome led to the belief that 
other structures of DNA may be possible. Only 1-2% of the complete human genome 
codes for proteins, leaving questions regarding the function the remaining 98% of 
human DNA. Recent evidence regarding the ability of DNA to form quadraplexes, 
sequence dependant, structurally stable complexes built around guanine residues, has 
brought to light the ability of DNA to form unique structures that are biologically 
active (the crystal structure of a g tetrad is shown in Section 2.4.2). Shafer and co-
workers have shown that such structures exist in the human genome, are present in 
areas such as the telomeres, where they protect chromosomal DNA from 
exonucleolytic degradation, and they also have the potential to interact with 
regulatory regions, involving them in gene regulation, an example being the argument 
that they have position upstream from the P1 promoter for the c-myc oncogene.96 
It is generally accepted that RNA can form a wide variety of intricate and functional 
structures due to the combined use of Watson-Crick pairing, non-standard base 
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pairing (for instance Hoogstein), and a variety of non-covalent contacts involving 
phosphates, ribose oxygens and cationic metals. The 2' hydroxyl of the ribose group 
plays an important role in building structures, acting as either a hydrogen bond donor, 
or as an acceptor, increasing the diversity of the structure forming potential. 	It 
should be noted that nature has its own, recently discovered, structure dependant RNA 
aptamers termed riboswitches.97 Riboswitches are part of an mRNA molecule 
capable of binding a small target molecule, whose binding affects a genes activity. 
Ligand binding causes a structural change in the mRNA which directly regulates gene 
expression often as part of a negative feedback control. 
Natural RNA (and to a lesser extent DNA) has the very real problem of 
phosphodiester bond hydrolysis. The reaction, which breaks the spine of the nucleic 
acid, is catalysed by ribonucleases found in biological fluid. The predominant 
nucleases in biological fluids are pyrimidine specific, so introducing a modification at 
the reactive 2' position of pyrimidine nucleotides prevents degradation of aptamer 
molecules. Enhanced stability aptamers (those modified at the 2' position by either 
2'-amino, 2'-O-methyl or 2'-fluoro functional groups) have been successfully selected 
from SELEX libraries.98 Attachment of a benzoyl group at the C-5 position of 
pyrimidine is another common modification as it appears to be tolerated by the 
enzymes used in amplification.99 Another challenge facing aptamer chemists is the 
fact that nucleic acids have uniform hydrophobicity and low p1, factors that can be 
changed with the clever use of modified nucleosides. For a comprehensive revue of 
modified ribonucleosides see Eaton and Pieken.100 
A further method used to create nuclease resistant aptamers has spawned the term 
spiegelmers, involving a very clever method of selecting nuclease-resistant L-ribose 
aptamers, first described in 1996 by Klussmarm et al. '°' 
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2.3 The SELEX Approach 
2.3.1 The Aptamer Library 
The process of aptamer selection typically begins with a random sequence 
oligonucleotide library obtained by the combinatorial synthesis of DNA or RNA. The 
library, generally of defined length oligonucleotides, is synthesised by solid phase 
oligonucleotide methods. A typical aptamer library sequence contains a 'core' 
randomised region of length N, encased by 5' and 3' fixed 'flanking' regions which 
are generally 1 5-2Ont in length and which are necessary for the polymerase chain 
reaction (PCR). The flanking regions are designed specifically to minimise primer-
dimer formation during amplification and to eliminate base pairing between the fixed 
regions. The randomised sequence in the oligonucleotide libraries can be obtained by 
using a mixture of activated monomer units, instead of a single species, during 
synthesis. The maximum theoretical size of the library is related to the number of 
randomised positions and the oligonucleotide diversity (y). A library of, for example, 
40 randomised positions has a maximum theoretical diversity of ji', and therefore 
contains 440 = 1.2 x 1024  different molecules. This diversity and complexity far 
outweighs that of commercial small organic molecules libraries (typically —16,000 
molecules), peptide libraries used in phage displays, and even the estimated amount of 
antibodies that a mouse can generate, which is believed to be between 109 and 1011 
molecules. 102  The real power of the process lies in the diversity of the starting library. 
There are so many different molecules with differing tertiary structures contained 
within the library that it would be reasonable to assume that at least a few molecules 
can form the desired structures necessary for binding to the target. 
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The length of the randomised region should be large enough to ensure that the library 
contains the maximum number of molecules possible to manipulate in a standard 
molecular biology laboratory, in the order of 1015,  and assuming errors in workup this 
diversity may be estimated to reduce to 10'-101 . N needs only to be around 22-24 
monomer units to achieve this, however, a further caveat is added as the DNA or 
RNA library must be large enough to fold into a complex tertiary structure capable of 
specific interaction with the target. Most libraries used tend to have N equal to or 
larger than 35nt. Due to limitations in the efficiency of oligonucleotide synthesis, 
starting with an aptamer library much larger than 35nt could cause incorrectly 
synthesised molecules to have an impact on the library quality. There is also a 
possibility that larger molecules may have two distinct folds complicating the method 
of in vitro selection, leading to the suggestion that a practical limit of around 80nt 
should be used. 103 
Whereas most aptamers, an example being the streptomycin-binding aptamer, are in 
the region of 30-46nt long, successful aptamers with sizes out with this suggested size 
limit have been found for some targets. 104  Indeed, without including the flanking 
regions, which may add another 50nt, aptamer sizes can differ radically. At one 
extreme the successful thrombin aptamer (see Section 2.4.1) is a 15mer, and at the 
other, the minimum binding region for an aptamer that binds serine protease in blood 
(protein C) was as long as 99nt.105"06 
Aptamers in general have a molecular weight around 1 OkDa, much smaller than the 
antibody alternative (around 50-6OkDa), which may prove advantageous in clinical 
uses. 
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2.32 The ssDNA SELEX cycle 
There are numerous reviews available regarding the selection of aptamers by the 
SELEX process. The most complete include the works of James, Jayasena, Breaker 
and Famulok and the reader is directed to those for detailed information. '04' 107, 108, 109 
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Figure 2.3: The ssDNA SELEX approach. The method can be broken down into 4 
distinct steps; Step I: Protein/Target incubation, Step 2: Partitioning/Eluting 
aptamers, Step 3: Amplification of binding candidates, and 	: Separation of 
dsDNA. Completion of Step 4 leads back to the start of a new cycle. 
To start the screening process, a random sequence oligonucleotide library is incubated 
under pre-defined conditions with the target of interest. The conditions should be set 
depending on the diagnostic use of the aptamer to be used. The time of incubation, 
buffer, pH, temperature are among the variables which must be set by the investigator 
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before starting the process. The stringency of selection can also have an influence on 
the number of SELEX cycles required for aptamer identification but generally 
enrichment is commonly reached within 8-16 cycles (using more cycles is not 
unheard of). 
The second step involves removing all those aptamers who do not bind and collecting 
those that do. Different techniques have been used for the SELEX partitioning step, 
although all methods have their own limitations and are not perfect at separating 
bound from unbound ligands. A common method for selecting aptamers against 
proteins involves using a nitrocellulose filter. Proteins, unlike DNA/RNA are 
retained well on nitrocellulose allowing unbound aptamers to be washed through and 
bound aptamers to be collected.110 Some reports suggest that substantial amounts of 
oligonucleotides may be non-specifically trapped by the membrane causing problems 
with this method. Alternatively, immobilising the protein on a resin can be used for 
easy separation of the bound from unbound nucleic acids and allows procedures such 
as competitive elution which can be helpful in setting affinity and specificity 
parameters. Immobilisation also facilitates "counter-SELEX", an attractive strategy 
that improves recognition specificity. The problem with immobilisation is that it 
hinders the mixing process by reducing the mobility of the protein and producing 
steric hindrance to aptamer binding. Mixing the protein/aptamers in solution pre-
immobilisation may help with this. Finally, two more recent published methods 
involve 1) the use of expensive robots in what is claimed to be an automated high 
throughput method of screening aptamers as pioneered by Cox and co-workers and 2) 
the use of capillary electrophoresis as a more direct and much quicker process of 
selecting aptamers. 111,112  This method appears advantageous as it is easy to monitor 
and finds suitable candidates after just 1-2 cycles, saving much time. 
When bound and unbound candidates are separated, the successful aptamers are led 
onto step 3, which involves amplification using the polymerase chain reaction (PCR), 
obtaining an enriched dsDNA library to be prepared for the next step. The definition 
of SELEX (systematic evolution of ligand by exponential enrichment) suggests that 
some form evolution will take place between in the aptamers between the starting 
library used and those aptamers collected at the end of the overall process. This 
evolution comes about by using error prone enzymes in the amplification, ensuring 
mutations occur during PCR. Each step of the SELEX cycle retains a small fraction 
of candidates with favourable properties. The mutations caused in the amplification 
generate additional diversity which could mean that the sequence of the best candidate 
at the end of many cycles was not present at the start of selection cycles. 
Step 4 involves the separation of the dsDNA. This is generally done by using a 3' 
primer biotinylated at its 5' end, the dsDNA can be immobilised on a streptavidin 
resin as first reported by Espelund and co workers.' 3 All that remains then is for the 
duplexes hydrogen bonds to be broken and the 5' strand to be collected. An 
alternative method used can be to use asymmetric PCR to obtain an excess of one of 
the strands as shown by Fukusaki et al. 114 
Upon optimisation, each cycle of the SELEX approach can take 2 days and when 
cloning and sequencing steps are added the whole unautomated approach can take up 
to 3 months to complete, faster than the amount of time to generate a cell line for a 
monoclonal antibody and its purification. 
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23.3 Modifications for an RNA SELEX 
To start RNA SELEX, the initial DNA starting library is in vitro transcribed to get a 
corresponding RNA library. A promoter for an RNA polymerase is engineered within 
the 5' flanking region of the starting library to afford transcription (although unused 
throughout this study, a T7 RNA polyrnerase site was engineered into the aptamer 
starting library). 
The library is subject to the necessary partitioning method and those RNA aptamers 
with the desired binding properties are collected. The successful RNA pool is 
amplified by RT-PCR and subject to further transcription before the enriched pool is 
applied to the target for a further round of selection. The transcription step replaces 
the strand separation step used in selecting ssDNA aptamers. 
Often RNA libraries are chemically modified to enhance the nuclease resistance of the 
resulting aptamers (see Section 2.2). RNA aptamers are more common than the 
ssDNA counterparts, largely due to the belief that RNA can form a wider variety of 
structures than ssDNA. Interestingly, RNA and ssDNA aptamers both screened 
against thrombin interact at different sites on the protein. 115 
2.3.4 Considerations of the SELEX Approach 
During SELEX, there is no guarantee that a successful aptamer may be obtained at 
then end of the selection process. The chances of finding a target binding sequence 
from the initial library seem to vary enormously depending on the target and exactly 
what the successful criteria is. It is often estimated that the chances of finding a target 
binding sequence is around 1 in 10h11012,  DNA or RNA binding targets appear to 
have a greater chance of success. 116  It is estimated that a library containing 40 
random bases could have 1 x 1024  different sequences, suggesting that the library pool 
should contain sufficient aptamers to make it through to the following round. The 
early stages of selection should be used for library manipulation and not to reduce the 
diversity of the library far below its theoretical maximum. 
The selection criteria used is also a fine balance between either too stringent or not 
stringent enough. By using wash steps that overly harsh, intermediate binding 
sequences that may have evolved beneficially for the library, could be wiped out. 
Washing in conditions that are too lenient would prevent the highest binding aptamers 
from being separated from those that are low affinity, and possibly prevent the 
efficient selection of those favourable aptamers. 
The mutation necessary for the evolution of the aptamers is also a process that can be 
fraught with problems. The amount of mutation must be sufficient to ensure progress 
towards an evolved aptamer library, too few mutations will hinder the diversity of the 
sampled sequence space. On the contrary, if too many mutations occur, the library 
may completely overshoot the optimum sample space. Another PCR related problem 
may be that some molecules may be better at replication and as such it would be 
possible for less functionally effective molecules to be over-represented in the library 
used for the next stage of selection. 
Aptamer libraries contain scope for structural pleiomorphism. If a specific aptamer 
can fold into more than one structure, and each structure has similar AG properties, 
problems could arise with selection issues. Although this could be a potential 
problem, using ssDNA aptamers instead of RNA limits the possible aptamer intra-
structures available. 
2.4 Aptamer Structures 
As previously mentioned, many aptamers have had their structures solved, either by 
X-ray crystallography or more commonly by NMR. Two aptamer structures which 
received detailed study are discussed here and the reader is directed to the paper by 
Patel and co-workers for details on RNA aptamer structures and a further review by 
Hermann and Patel for a detailed discussion of further solved aptamer complexes.' 
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2.4.1 Thrombin aptamer 
The thrombin aptamer was one the first known aptamers, it has been extensively 
studied and is often used as a control in the validation of novel aptamer analytical 
applications. The aptamer is a 1 5mer (d(GGTTGGTGTGGTTGG)) and forms two 
tightly stacked G-quartets with 3 loops of T-T base pairing between the two minor 
loops, thought to be stabilised by the addition of metal ions. The dissociation 
constant, Kd, has been determined to be between 1.4 and 6.2nM and has shown potent 
anticoagulant properties in vivo. 118  The G-octet is a common feature among DNA 
aptamers, an inhibitor of the integrase enzyme of HIV-1 also has a similar sequence 
and structure to that of the thrombin aptamer. 
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Figure 2.4: X-ray crystal structure of the thrombin binding aptamer A shows a 
 'v.p. 
III
diagrammatical representation of stacked g-quartet. B shows the NMR stacked 
thrombin aptamer, with G residues in blue and T in yellow. C shows the same 
aptamer inhibiting thrombin. 
I 	 _ _ 
- 
- 	 P4 
42 
2.4.2 Crystal structure of the G-tetrad 
The X-ray crystal structure of the G tetrad is shown below. The distances between 
each oligonucleotide are 1.8 to 2.0 A. 
Figure 2.5: Crystal structure of the G-tetrad. The hydrogen bonds are highlighted 
in green. 
2.4.3 HIV-1 RT Aptamer 
Two different RNA aptamers (for HIV protease) have had their NMR structures 
solved, when bound to a 17 residue peptide derived from human immunodeficiency 
virus type 1 (LIlY-i) Rev protein. 84  The Rev peptide which is generally unstructured 
in solution binds in an a-helical conformation to the RNAs. The peptide inserts into 
the RNA deep groove, widened through adaptive formation of non Watson-Crick 




Figure 2.6: The NMR structure of the RNA aptamer interacting with liv-! RT. 
Figure A has highlighted the aptamer as a blue chain and shown the truncated enzyme 
in yellow. Figure B has the arginine residue side chains highlighted. 
44 
2.5 Aptamer Technology 
2.5.1 Aptamers versus Antibodies 
When considering the possible therapeutic and diagnostic values of aptamers, it is 
important to acknowledge the massive contribution that antibodies have made to these 
fields in the past 30 years, especially monoclonal antibodies. 119  The importance of 
antibodies cannot be understated, they provide standard diagnostic tests based on 
molecular recognition and remain invaluable in clinics worldwide. What has become 
apparent since the introduction of aptamers, is that they provide a real alternative to 
antibodies in many (not just niche) areas, and show signs of improving upon the 
current antibody technology already in place. 108 
Both classes of molecules, are biopolymers which can recognise targets with high 
affinity and specificity. They both bind with dissociation rates (Kd) in the low 
picomolar to low nanomolar range, however the binding of an aptamer appears to be a 
more specific interaction, with the potential ability to discriminate between closely 
related proteins sharing common sets of structural domains. 
Aptamers, or more specifically DNA aptamers, are relatively stable compounds which 
can be heated or cooled (reversible denaturation) without damage to the sequence. 
Aptamers have a long term storage lifetime and can be transported at ambient 
temperatures. In contrast antibodies are temperature sensitive proteins with a limited 
shelf life and they can undergo reversible denaturation, often a costly and frustrating 
issue. 
Aptamers are produced by total chemical synthesis and the reproducibility of this 
means that uniform activity is possible. Because aptamer selection is carried out in 
vitro, almost any molecule can be targeted, and the selection conditions can be tuned 
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for in vitro diagnostics. Antibody selection requires the use of a biological system, 
making it difficult to raise antibodies to molecules that have reduced immunogenic 
responses or molecules that are toxins, as well as limiting the physiologic conditions 
for optimising antibodies for diagnostics. The other problem with antibodies is that 
performance can vary batch to batch, meaning that immunoassays may need to be 
reoptimised with each new batch. 
Other advantages of using aptamers include: (a) Aptamers, unlike antibodies, can be 
subjected to a wide range of chemical modifications; (b) No evidence of 
immunogenicity exists for aptamers and a method of isolating cross-reactive 
compounds has been developed for aptamers named toggle SELEX.'2°  
25.2 Aptamers as Therapeutics 
Aptamers have potential as therapeutic agents. Truncated aptamers are smaller than 
antibodies, 	l5kDa compared to '-50kDa, and this may be beneficial for tissue 
penetration and shorter residence time in the blood. Another major advantage is that 
aptamer specific antidotes can be rationally developed to reverse the inhibitory 
activity of a drug, helping to provide safe, tightly controlled therapeutics. 
The process of turning a therapeutic concept into a clinical application is remarkable 
achievement, and aptamers will soon be a class of molecules that have accomplished 
this feat. Fifteen years after the seminal work by Sullenger on the TAT/Tar nucleic 
acid sequence, new drug applications were filed on two aptamer compounds, 
Macugen and E2F decoy, both of which are non naturally occurring nucleic acid 
ligands. Macugen had now been approved by the US food and drug administration, 
although Corgentech recently announced that E217 failed phase III trials. 
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Table 2.2 shows a selection of aptamers and their progress in clinical trial to date. 
The table, adapted from Nimjee et al. includes aptamers against a range of many 
different therapeutically relevant targets. 122 
Target Oligo Clinical Data Selection For Treatment in Reference 
Type (rounds)  
HIV-1 Tat RNA in nature Antiviral 
HIV therapy  
HIV-1 Tat RNA in vitro (11) HIV therapy 123 
HIV-2 Tat RNA in nature HIV therapy 124 
HIV-1 Rev RNA Phase I in nature HIV therapy 123 
response 
element  
Hepatitis C RNA in vitro (6) Hepatitis C Virus 126 
NS3  (HCV)  




a-thrombin DNA Phase I (2005) in vitro (5) Anticoagulation 128 
Vascular RNA Drug Available, in vitro (12) Antiangiogenisis, 129 
endothelial Macugen Age related macular 
growth (FDA approved degeneration (AMD) 
factor Dec (2004)) 
(VEGF)  




Transcription DNA! Failed Phase III in nature/in Antiproliferation 
131 
Factor E2F RNA vitro (13) 
Cytotoxic T RNA in vitro (9) Immune 
132 
cell antigen 4  Modulation  
Table 2.2: Current aptamers as therapeutics. Many more aptamers are currently 
undergoing early stage assays for clinical testing. Only a select few have been 
highlighted in this tale to show the range of targets/treatments where aptamer therapy 
may be of use. 
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2.5.3 Analytical Applications of Aptamers 
In future aptamers may provide clinically relevant alternatives to antibodies in 
therapeutics, but at present the main interest in aptamers derives from their potential 
as ligands for diagnostic and related applications. They are currently in use or 
development for many different detection and/or capture assays. A few examples are 
discussed below. 
2.5.3.1 Chiral Selection 
The ability to study the different physiological behaviours of enantiomers of the same 
chiral molecule is of great interest to the pharmacological industry. The most suitable 
technique for separation of enantiomers is high performance liquid chromatography 
(HPLC) using various types of stationary phase chiral selectors (crown ethers, amino 
acids, etc). An alternative method would be to use a stereospecific aptamer that binds 
to only one enantiomer. This aptamer immobilised on a resin and used with HPLC 
can separate a racemic mixture, allowing analysis of the non-binding enantiomer 
(contained in the void volume) and the binding enantiomer (retained on the resin). 
This technique has been used to select the D isomer of arginine-vasopressin from the 
L isomer. 133  It has also been used to select tyrosine from numerous analogues. 134 
2.5.3.2. Affinity Chromatography 
Protein purification by affinity chromatography is a well developed tool in protein 
chemistry, due to the speed of the process and the quality of the purified product. 
Classic examples include the use of nickel affinity resins to purify recombinant His-
tagged proteins and antibody resins in the purification of fusion proteins. These 
techniques make possible the one step purification of proteins from whole cell lysates. 
There are numerous post selection modifications of aptamers possible, allowing many 
differing methods for aptamer immobilisation on resins. One such method involved 
the purification of L-selectin from unfractionated human serum by a ssDNA aptamer 
giving a 1500-fold enrichment with 83% recovery in the initial purification step. 135 
2.5.3.3. ELONA 
ELISA's (enzyme-linked immunosorbent assay) were first described in 1971 and 
since then they have revolutionised clinical diagnostics in medicine. 
136  They allow 
simple and rapid measurement of a variety of analytes with exceptional specificity 
and sensitivity. The most common ELISA used is the sandwich ELISA, involving 
two antibodies that bind simultaneously to the analyte. First, an immobilised antibody 
captures the protein and holds it near the surface of the microtitre plate, and then a 
secondary antibody, coupled directly to a specifically chosen enzyme will be used to 
bind to the protein. The analyte is now sandwiched between the two antibodies, and 
the enzyme coupled to the secondary antibody will provide a method for detection. 
The ELONA (enzyme linked oligonucleotide assay) replaces one of the antibodies 
with an aptamer. 137 ELONA's have similar precision and accuracy to standard 
sandwich ELISA's, but have the advantage that aptamers can be easily modified to 
include useful moieties which are easily detected. Modifications can simplify the 
process, improve the detection limit and error of the assay. ELONA's have been used 
in the detection of VEGF, (shown in Table 2.2) with accuracy, precision, and 
specificity well within the limits expected of a typical enzyme linked assay. 
2.5.3.4 MALDI-MS 
Matrix Assisted Laser desorption ionisation mass spectrometry (MALDI-MS), can be 
adapted to use aptamers as ligands for protein capture and analysis as described by 
Dick and McGown.'38 They used a thrombin-binding DNA aptamer modified matrix 
to selectively capture thrombin from human plasma, then released the protein for 
analysis. By simply washing the surface matrix under the correct conditions, the 
experiment can be repeated on the same spot using the same aptamer that had been 
previously loaded. A similar procedure has been used to selectively capture human 
insulin from extracts of pancreatic cells. 139 
2.5.3.5 Signalling Aptamers/Molecular Beacons 
Molecular beacon aptamers are oligonucleotide sequences engineered to recognise a 
protein and to generate a fluorescent signal on binding, making them useful as 
signalling probes. 140  An aptamer with a fluorescent tag, when not bound to its target, 
forms a duplex with a complementary strand containing a fluorophore quencher. 
Addition of the target causes the aptamer to release its complementary 
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oligonucleotide, and bind preferentially to the target. In the process the fluorophore is 
released indicating binding. 	Conversely, an aptamer may contain both the 
fluorophore and quencher at opposite ends of the strand. In solution, the aptamer is 
minimally structured and the two signalling molecules are kept apart, meaning the 
aptamer is fluorescent. Addition of the substrate will cause the aptamer to form a 
stable 3-D structure, possibly bringing the quencher and fluorophore close enough to 
interact, and preventing the generation of the signal. An aptamer beacon has been 
produced by Hamaguchi and co-workers by modification of the existing thrombin 
binding aptamer. '4' Nucleotides complimentary to the 3' end of the aptamer were 
added to the 5' end of the DNA aptamer along with a fluorophore, a quencher was 
added to the 3' end. In the absence of thrombin, the aptamer forms a stem-loop 
structure but the addition of thrombin causes a conformational change leading to a 
parting of the fluorophore/quencher and the generation of a fluorescent signal. 
2.4.3.6 Surface Plasmon Resonance 
Unlabelled aptamers can be used to detect a target using SPR (surface plasmon 
resonance). In two examples using different targets using the BlAcore SPR system the 
target was immobilised on a gold film chip and challenged by aptamers in solution 
across the flow channel. 142  As the aptamer binds to the target, it causes a mass change 
on the gold film which leads to response signal. Conversely, having the aptamer 
immobilised to the chip and the target in the solution phase should also provide a 
measurable response. SPR has also been used to isolate the high affinity aptamers in 




24.3.7 Aptamer-Modified Gold Nanoparticles 
Metal nanoparticles possess strongly distance dependant optical properties and have 
extinction coefficients (of their surface plasmon absorption bands) over a 1000 times 
larger than those of organic dyes. Disperse gold nanoparticles appear red, but as the 
particles aggregate the colour changes to purple. GNP aggregation based sensors 
provide sensitivity and selectivity comparable to fluorescence based techniques. 
GNP's modified with an aptamer have been used to detect platelet derived growth 
factors (PDGF) in the low nanomolar range. 144  Addition of the target protein in a 
solution of modified GNP's will cause a visible change, measurable with UV-vis 
extinction spectra. 
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Chapter 3: Materials and General Experimental Methods 
3.1 General Reagents 
All chemicals and solvents were purchased from Sigma-Aldrich, Fischer, Pharmacia, 
Promega, Qiagen, Biorad, Invitrogen and New England Biolabs unless specified. 
3.2 Equipment 
PCR reactions were carried out in a Perkin Elmer DNA thermal Cycler or a Thermo 
Electron Corporation PCR Sprint Thermal Cycler. Electrophoresis carried out using a 
Biorad Protean minigel system (protein) or for pre cast protein gels an Invitrogen 
XCe11 SurelocklM  Mini-Cell system. Electrophoresis of DNA was carried out using a 
GIBCO BRL H5 system. A Delaney BR401, Sorvall® RC-5B, and a DuPont 
Microspin 12 were used for centrifugation. A Savant SpeedVac® Plus SC11OA 
gyrovap was used for drying DNA and protein precipitates. UV/Vis scans were 
conducted on an ATI Unicam UV/Vis spectrometer (UV4). 
3.3 Sterilisation 
Flame sterilisation was employed when sterile conditions were required, for example 
the inoculation of overnight cultures. Equipment and broth were sterilised using the 
autoclave (121°C for 15 mins at 15 psi). All inoculations were carried out under 
sterile conditions. 
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3.4 Solutions and Buffers 
3.4.1 General 
Ampicillin: a stock solution (100mg/mi) was prepared, filtered through a 0.2jim 
membrane to sterilise and stored at 4°C. A final concentration of 1 00tg/ml was used 
in various media. 
Kannamycin: a stock solution (33mg/mi) was prepared, filtered through a 0.2tm 
membrane and stored at 4°C. A final concentration of 33 jig/mI was used in various 
media. 
Ethidium Bromide: a stock solution (10mg/mi) was made and used at a final 
concentration of 5 jig/mi and stored in a dark bottle at 4°C. 
IPTG: A stock solution of isopropyl-3-D-thiogaiactopyranoside (100mM) was 
sterilised by filtration (0.2jim filter) and stored at 4°C. 
Ix NuPAGE® MOPS SDS running buffer: 20x WAGES MOPS SDS running 
buffer (50ml, Invitrogen) was diluted with distilled waster (950m1). 
Ix NuPAGE® transfer buffer: 20x NuPAGE® Transfer buffer (50ml, Invitrogen) 
was diluted with methanol (lOOml) and distilled water (850m1). 
PBS: Phosphate Buffered Saline tablets (pH 7.4, Oxoid), were dissolved in distilled 
water (1 tablet/lOOml) and sterilised by autoclaving. 
PBST: Tween-20 was added to PBS to a final concentration of 0.05%v/v. 
PBSM: MgC12 was added to PBS to a final concentration 1 mM. 
PBSTM: Dried skimmed milk (Marvel) was added to PBST to a final concentration 
of 5%w/v. 
SDS running buffer: Tris-HCI (25mM, pH 8.3), glycine (192mM), SDS (1%w/v). 
SDS sample buffer: Tris-HC1 (0.5M, pH 6.8, 1.0 ml), glycol (2.0 ml), SDS (10% 
w/v, 1.6 ml), 2-3-mercaptoethanol (0.4mi), bromophenoi blue (0.05%, w/v, 2.0 ml). 
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Tris-Cl: Tris adjusted to the required pH with hydrochloric acid (pH 7.5). 
TAE: Tris-Cl (40mM, pH 7.5), acetic acid (20mM), EDTA (1mM). 
TE: Tris-Cl (10mM, pH 7.5), EDTA (1mM). 
3.4.2 Protein Purification Buffers 
Buffer A: 	Tris-Cl (50mM), Triton X-100 (0.05% wlv), Imidazole 
(20mM), and one Complete TM  Proteinase Inhibitor Cocktail 
tablet (Roche) per 200m1, (pH 7.5). 
Buffer B: 	Tris-Cl (50mM), Triton X-100 (0.05% wlv), NaCl (0.5M) and 
Imidazole (20mM), (pH 7.5). 
Buffer C: 	Tris-Cl (50mM), Triton X-100 (0.05% w/v), Imidazole 
(250mM), (pH 7.5). 
3.4.3 SELEX Buffers 
SELEX buffer A: Tris-Cl (50mM), NaCl (1 50mM), (pH 7.5). 
SELEX buffer B: 	Tris-Cl (50mM), NaCl (1M), (pH 7.5). 
SELEX buffer C: Tris-Cl (50mM), Guanidinium Chloride (6M), (pH 7.5). 
Strand Separation buffer: 
Tris-Cl (50mM), NaOH (0.19M). 
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3.4.4 ELISA/ELONA Buffers 
PBS Coating buffer lOx stock: 	PBS (50mM), NaCl (0.14M), KC1 (2.7mM), 
KH2PO4 (1.5mM), Na2HPO4. 2H20 (8.1mM), 
(pH 7.2). 
Diluent/wash buffer lOx stock: 	NaCl (0.5M), Na2}-12PO4.2H20 (2.5mM), 
Na2HPO4.21420 (7.5mM), Tween-20 (0.05% 
Blocking Buffer: 	 Coating Buffer (xl) with 5% (w/w) Casein. 




3.5.1 E.coIi Media 
Agar plates: Bacto-agar (15g/1) was added to the specified media with the 
appropriate antibiotic to prepare agar plates. 
Luria Bertani broth (LB): bacto-tryptone (lOg), bacto-yeast extract (5g) and sodium 
chloride (lOg) were dissolved in 1 litre of deionised water and the pH was adjusted to 
7.5 using sodium hydroxide. 148 
2YT broth: bacto-tryptone (1 6g), bacto-yeast extract (lOg) and sodium chloride (5g) 
were dissolved in 1 litre of deionised water and the pH was adjusted to 7.5 using 
sodium hydroxide. 148 
SOC broth: bacto-tryptone (20g), bacto-yeast extract (5g), sodium chloride (0.5g), 
magnesium chloride (5g) and glucose (3.2g) were dissolved in 1 litre of deionised 
water and the pH was adjusted to 7.5 using sodium hydroxide. 
148 
S-Gal/LB/amp plates: a pack of SGalTM/LB  Agar Blend (Sigma C-4478) was 
dissolved in SOOml of deionised water and autoclaved. The solution was cooled to 
around 40°C and ampicillin was added before the plates were poured. 
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3.6 Bacterial Cell Lines 
Strain Genotype Description/Applications 
Top 1 OTM F'mcrA D(mrr-hsdRMS-mcrBC) Used For transforming DNA 
(Invitrogen) 801acZAM1 5 AlacX74 deoR recAl ligations. 
araD139 A(ara-leu)7697 gal/U gal/K 
rpsL endAl nupG 
DH5a145 F'phi8OdlacZ delta(1acZYA-argF)U169 Used for transforming DNA 
(Invitrogen) deoR recAl endAl hsdRl7 (rk-, m k+) ligations and storage of 
phoA supE44 lambda-thi-1 gyrA96 plasmid stock 
relA 1/F' proAB+ laclqZdeltaM 15 
TnlO(tetr) 
JM109 e14—(McrA—) recAl endAl gyrA96 thi-] Used for transforming DNA 
(Stratagene) hsdR] 7 (rK— mK+) supE44 relAl A(lac- ligations and storage of 
proAB) [F' traD36proAB lacIqZAIvI]5]. plasmid stock 
BL21(DE3) F omp Thsdsb (rB MB-)  gal dcm (DE3) General purpose expression 
(Invitrogen) host. 
Table 3.1 Cell Line Information 
3.6.1 Storage of Bacterial Stocks 
LB or 2YT medium containing the appropriate antibiotics were used for the short-
term storage of transformed E. coli. Colonies of bacteria were stored on inverted 
paraflim sealed agar plates at 4°C for up to 28 days. For long-term storage, strains 
were frozen at -80°C in LB or 2YT containing 30% glycerol. 
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3.7 DNA Vectors and Plasm ids 
The plasmid used for the storage of 14-3-3 y  was the GST fusion plasmid pGEX 4T1 
(Amersham biosciences). 14-3-3 7 was cloned into, and over-expressed in pQE-30 
(N-terminal His-tag fusion, Qiagen). TA cloning vectors pGEM-T easy (Promega) 
and pCR2.1 (Invitrogen) were used to clone and sequence selected aptamers. 
3.8 Oligonucleotide Primers 
The following oligonucleotide primers were used. Endonuclease restriction sites in 
3.8.1 Sequencing Primers 
pQE For 	 5'- GGAGAAATTAACTATGAGAGG-3' 
pQE Rev 	 5'- GTTCTGAGGTCATTACTGG-3' 
pGEX For 	5 '-GGGCTGGCAAGCCACGTTTGGTG-3' 
pGEX Rev 5' -CGGGAGCTGCATGTGTCAGAGG-3' 
pGEM For 5'- TAATACGACTCACTATAGGG-3' 
pGEM Rev 5' -ATTTAGGTGACACTATAGA-3' 
pCR2.1 For 5'-GTAAAACGACGGCCAG-3' 
pCR2.1 Rev 5'-CAGGAAACAGCTATGAC-3' 
The pQE 30, pGEX, pGEM and pCR2.1 primers were used to sequence pQE 30, 
pGEX 4T1, pGEM T easy and pCR2.1 plasmids, respectively. 
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3.82 Primers used for cloning 14-3-3 y 
RS 1 	 5'- GATCGGATCCGTGGACCCCGAGCAACTGGT-3' 
BamH I 
RS2 	 5'- GATCGTCGACTTAGTTGTTGTTGCCTTCTC-3' 
Sal I 
3.8.3 Primers used for SELEX 
RS9978R 	5'-AGGG ATCC GCCT GATT AGCG ATACT-3' 
Barn HI 
RS9979R 	5'-BBBC CCCT GCAG GTGA TTTT GCTC AAGC-3' 
Pst I 
RS9981R 	5'-CCCC TGCA GGTG ATTT TGCT CAAG C-3' 
Pst I 
The B in RS9979R designates Biotin from biotin phosphoramidite, this primer along 
with RS9978R were used in SELEX PCR. RS9978R and RS9981R were used in 
cloning the aptamer library for sequencing purposes. 
3.9 Transformation of E .coIi competent cells with 
recombinant DNA 
Competent cells were transformed according to the manufacturer's instructions. DNA 
(up to Song) was added to an aliquot of competent cells and gently mixed. This was 
left on ice for 30 minutes before the cells were heat shocked (42°C, 30s), then placed 
back on ice for 2 minutes. The cells had 80tl SOC medium added and were allowed 
to incubate at 37°C for 1 hr whilst agitating at 220 RPM. The cells were spread on 
selected agar plates and allowed to grow at 37°C for 16 hours. 
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3.9.1 Growing cells 
Overnight cultures were grown up by inoculating in sterile conditions. A sterile 
pipette tip was used to pick a colony from a transformed agar plate and then added to 
a disposable centrifuge tube (50m1, Fisherbrand) that contained LB media (10 ml) 
with the appropriate antibiotics. The cells were grown at 37°C for 16 hours. For 
larger cultures the same procedure was scaled up by the necessary factor. 
3.9.2 Preparation of Plasmid DNA (Mini Prep) 
Cultures were grown by inoculating 2YT broth (lOml), containing the appropriate 
antibiotic, ampicillin (lOOjig/ml), in sterile conditions, with a single transformed 
colony and agitating at 37°C (220rpm, 18hr). The cells were harvested by 
centrifugation (13000rpm, 1 5mm, 4°C) and the supernatant discarded. The plasmid 
DNA was extracted using either a QlAprep® Spin Miniprep Kit (Qiagen) or 
ChargeSwitch® NoSpin Plasmid Micro Kit (Invitrogen) following the manufacturers 
guide. The DNA was always eluted with 70p1 TE. 
3.9.3 Digestion of DNA with restriction endonucleases 
The required amount of DNA (0.2-1.0Ig) was treated with the appropriate amount of 
endonuclease and buffer and incubated for at least 3 hours at 37'C. Blue/Orange 
Loading Dye (Promega) was added and the sample was subjected to electrophoresis 
on 1% agarose gel. The gels were visualised under UV light. 
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3.9.4 Electrophoresis of DNA 
The required amount of agarose (Sigma), typically 1 g/l 00m1, was added to TAE 
buffer and heated at 100°C until completely dissolved. The solution was allowed to 
cool to 55°C, followed by the addition of ethidium bromide (final concentration of 
0.5pg/ml). The gel was poured into a casting cassette and allowed to set at room 
temperature. DNA was loaded and the gel was ran at 100 V until the adequate 
separation was achieved. 
3.9.5 Purification of DNA 
DNA was purified from agarose using a QlAquick® Gel Extraction Kit (Qiagen) 
following the manufacturer's instructions. 
DNA was also purified directly from PCR using either QlAquick® PCR Purification 
Kit (Qiagen) or the ChargeSwitch® PCR Clean-Up Kit (Invitrogen). 
3.9.6 Amplification of DNA 
Typically each reaction contained 2 Ready-to-GoTM Taq Polymerase beads 
(Amersham Biosciences), Sopmoles of each primer and 100ig of the template DNA. 
The reaction volume was made up to 50fl with deionised water. Reactions were 
subjected to a 5 minute 95°C preheating step followed by up to 30 cycles of 95°C for 
1 mm, 54°C for 1 min and 72°C for 2 mins. Reactions were terminated with a 10 
minute 72°C extension step. 5j.il of the PCR mix was then checked on an agarose gel 
allowing the remainder to be purified. 
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Alternatively, high fidelity amplification was carried out using a different enzyme. 
The same concentrations of primers and template was used along with 5jtl Pfu Turbo 
buffer (1 OX), 1.25 pd  10mM dNTPs, 1 tl (2.5 units) Pfu Turbo polymerase (Stratagene) 
and the reaction volume was made up to 50pJ with deionised water. 
The annealing temperature was varied depending which primers were to be used. For 
aptamer amplification the cycle was as follows: 95°C (1 mm), 60°C (1 mm) and 72°C 
(1.5 mm). 
3.9.7 Cloning of PCR Products 
Direct Cloning- PCR products were directly cloned into either vector pCR 2.1-TOPO 
using the TOPO TA® Cloning Kit (Invitrogen) or into vector pGEM® T-Easy using 
the pGEM® T-Easy Cloning Kit (Promega) following the manufacturers guidelines. 
The relevant restriction sites had been engineered into the PCR primers allowing 
efficient endonuclease digest. 
Indirect Cloning- Purified PCR products were digested with the relevant enzymes 
for at least three hours and then ethanol precipitated. The required plasmid was cut 
with the enzymes, ethanol precipitated and then subjected to shrimp alkaline 
phosphatase (Sigma-Aldrich) following the manufacturers instructions. After another 
ethanol precipitation, the insert and plasmid were mixed in a 2:1 ratio and mixed with 
high concentration T4 DNA ligase (New England Biolabs) in no more than lOpi 
following the manufacturers protocol. This was allowed to incubate for 16 hours at 
21°C before a sample (4pi) was added to a high efficiency, competent bacterial cell 
line and transformed following the manufacturers instructions. 
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3.9.8 PCR screen 
Colonies were picked from a plate, and then touched against another agar plate at a 
known grid position. The remaining colonies on the pipette tip were resuspended in 
50p1 of water. The cell resuspension was boiled for five minutes and the solution 
centrifuged (13K) for two minutes. A sample (Spi) was taken and used as a template 
in a PCR reaction to amplify the required gene using the appropriate primers. The 
resulting reaction was run on an agarose gel and visualised using UV light. 
3.9.9 DNA sequencing 
Sequencing reactions were carried out on an Electron Corporation PCR Sprint 
Thermal Cycler. Each sequencing reaction typically contained DNA template (5 
pmoles, 4tl), primer (3.14 pmoles, 1.il), BigDye Version 4.1 (2.il; PE Biosystems, 
UK) and ddH20 (2p1). The reaction was cycled 30 times at 95°C for 30 sec, 45°C for 
15 sec and 60°C for 4 mm. Automated DNA sequencing was performed on an ABI 
prism 377 DNA sequencer using the Sanger dideoxy chain termination method. 146 
Sequence data was analysed using Contig-Express within the Vector NTI Advance TM 
V9 software package (Invitrogen). 
3.9.10 DNA precipitation! Ethanol precipitation 
DNA was precipitated with an equal volume of 3M sodium acetate (pH 5.3): ethanol 
(0.1:2 v/v), which was mixed well with the DNA solution and kept at -80°C (1 hour). 
The solution was then centrifuged (13K, 30mins, 4°C) and the supernatant carefully 
discarded, so as to avoid agitating the pellet. The precipitated DNA was then washed 
with ice cold 70% ethanol (lOOp!), centrifuged (13K, Smins, RT) and again the 
supernatant was carefully discarded. The DNA pellet was dried under vacuum 
allowing resuspension in chosen buffer. 
3.9.11 DNA concentration analysis 
DNA (1tl) was diluted to lOOpi with distilled water and the concentration was 
measured using an Eppindorf Biophotometer (0D260 x SOmg/ml x dilution factor = 
DNA concentration (ng/ml), 0D260 1 = 50 ng/ml).'47  
3.9.12 Crush and Soak 
Using a clean, sterile scalpel the band of interest was excised from the gel and 
transferred to a sterile 1.5 ml centrifuge tube (eppendorf). A disposable pipette tip 
was used to crush the excised band against the side of the tube, before 0.4m1 of 
'elution buffer' was added (0.5M ammonium acetate, 10mM magnesium acetate, 
1mM EDTA pH 8.0 and 1.0% SDS) allowing incubation at 37°C for 1 hour. The 
solution was centrifuged at 13K, 1 mm, 4°C before careful removal of the supernatant 
using a drawn out Pasteur pipette. 0.9ml ice cold ethanol was added to the excised 
band and the solution then gently agitated at 4°C for 30 mins before centrifugation 
(13K, 30mins, 4°C) allowing careful removal of the supernatant. The pellet was 
resuspended in 200[d TE pH 7.6, then 25jil 3M Na Acetate pH 5.2 and 450t1 ethanol 
were added. The solution was incubated for 30 mins at 4°C before another 
centrifugation step (13K, 30mins, 4°C) and again the supernatant was carefully 
removed. The pellet was rinsed with 100[d 70% ethanol, spun at 13K, 5 mins, the 
supernatant was removed and the pellet was resuspended in 60ji1 TE. 
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3.10 Recombinant Protein Expression and Purification 
310.1 Protein Expression in Ecoli host 
3.10.1.1 Mini Induction 
2YT broth (imI), containing ampicillin (100tg/ml), was inoculated with a single 
colony and agitated at 37°C (250rpm) until an 0D600 between 0.6 and 0.8 was 
reached. A control (0.5m1) was taken and the remainder was induced with IPTG 
(1mM) and agitated at 37°C (250rpm, 3hr). The supernatant was harvested by 
centrifugation (13 000, RT, 10mm). The supernatant was discarded and the cell pellet 
was resuspended in SDS sample buffer (50pJ) and distilled water (SOpi), boiled 
(10mm), then loaded (20p1) onto a SDS-Page gel (12%) and subjected to 
electrophoresis. 
3.10.1.2 Large Scale Preparation (2L) 
2YT broth (300m1), containing ampicillin (100g/ml), was inoculated with a single 
colony of (His)614-3-3'y and agitated at 37°C (250rpm, 18hr). The medium was 
distributed evenly between 2YT broth (4 x SOOml in 21, flasks) containing ampicillin 
(100ig/m1) until an 0D600 between 0.6 and 0.8 was reached. A control (0.5ml) was 
taken and the remainder was induced with IPTG (1mM) and agitated at 37°C 
(250rpm, 3hr). The cell pellet was harvested by centrifugation (5K, 1 5mm, 4°C). 
The supernatant was discarded and the cell pellet was stored at -20°C until the protein 
was purified according to its requirements. 
3.10.1.3 Purification of 14-3-3y 
Cells over-expressing 14-3-3y were resuspended in buffer A (20m1) containing a 
single Complete TM  Proteinase Inhibitor Cocktail tablet (Roche) and allowed to mix 
gently for 1 hour at 4°C. The cells were disrupted by sonication (10 pulses of 20 
seconds with 20 second intervals) at 4°C and the cell debris was removed by 
centrifugation (15 000 rpm, 20 mm, 4°C). The supernatant was passed through a 
0.45 jiM membrane before the addition of excess nickel nitrilotriacetic acid (Ni-NTA) 
superfiow beads (Qiagen). Following the bead manufacturers protocol, the beads 
were washed with 10 column volumes of Buffer B and eluted with Buffer C. 
Uninduced, induced, supernatant, wash and elution fractions were electrophoretically 
separated on a SDS-PAGE gel. Eluted 14-3-3-y was dialysed (3 times in 2L of 
solution) against phosphate buffer pH 7.5 using SnakeSkin membrane (MW 15 kDa, 
Pierce) and stored at 4°C. 
3.10.1.4 Polyacrylamide gel electrophoresis (PAGE) 
SDS-PAGE was used to analyse proteins on the basis of their molecular mass. The 
technique used was the discontinuous buffer system of Laemmeli.'48 Alternatively, 
proteins were analysed on precast 12% Bis-Tris Nu-PAGE® gels (Invitrogen) 
according to manufacture's instructions. 
To analyse overexpression, a sample cell pellet was resuspended in 20p1 1 x SDS 
sample buffer per 0.1 unit of 0D600 measured pre centrifugation (for example, an OD 
of 0.8 would mean that a lml pellet would be resuspended in 160jt1 of 1 x SDS 
sample buffer). The samples were denatured by boiling for 10 minutes and a sample 
for each (20jil) was loaded onto the gel. 
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Gels were visualised using Coomassie blue or GelCode Blue Stain reagent (Pierce). 
3.10.1.5 Protein Concentration Determination 
The protein concentration was determined according to Bradford using bovine Serum 
Albumin as a reference (BioRad Protein Assay, Bi0RAD).'49 
3.10.1.6 Mass Spectrometry 
3.10.1.6.1 Electrospray Mass Spectrometry 
Electrospray mass spectrometry was performed on a micromass Platform quadrupole 
mass spectrometer equipped with an electrospray ion source. The cone voltage was 
set to 70V and the temperature to 65°C. A Waters 2690 HPLC unit with a Waters 
486 Tunable Absorbance Detector was connected to the mass spectrometer. Protein 
samples were separated on a Jupiter 5g C-S 300A column at a constant TFA 
concentration of 0.01% using a linear gradient of 10-100% acetonitrile in water over 
40 min with a flow rate of 0.05 ml/min. The total ion count of all ions in the range 
m!z 500 to 2000 and the UV chromatogram at 280nm were recorded for the reverse-
phase HPLC separation. The mass spectrometer was scanned at intervals of 0.1s, the 
scans accumulated, the spectra combined and the average molecular mass determined 
using the MaxEnt and Transform algorithims of the MassLynx software. Robert 
Smith and Dave Clarke helped with this service. 
3.10.1.6.2 Protease digestion and peptide mass mapping 
The peptide mass mapping for digested gel bands were conducted using a MALDI-
TOF MS (Tof-Spec 2E, Micromass). The excised band was digested with trypsin (100 
tg/m1) and chymotrypsin (100 Vg/ml), performed at 37 °C in chymotrypsin digestion 
buffer (50mM Tris-HC1, 10mM MgCl2,  50mM KC1, pH 8.0), and allowed to proceed 
for four hours, before termination by addition of 0.05% TFA. For analysis of the 
reduced proteolytic digest 1 p1 of the peptide mixture was removed and reduced with 
100 mM TCEP. For MALDI-MS analysis oxidized and reduced peptide digests were 
desalted and concentrated using C18 ZipTips (Millipore Corp.). 1 tl of analyte and 1 
pJ of matrix solution (a saturated solution of a-cyano-4-hydroxycinnamic acid in 50% 
acetonitrile with 0.1% TFA) were mixed, left to air-dry on a MALDI plate and 
MALDI-MS results were obtained in the positive mode. Andy Cronshaw helped with 
this service. 
3.10.1.7 CD spectrometry 
Protein samples were in assay buffer (10 mM sodium phosphate, pH 7.5) throughout. 
CD measurements were made in the far UV (190-260 nm) region on a Jasco 
spectropolarimeter at protein concentrations of ca. 15-20 tiM. 
3.11 SELEX 
3.11.1 Preparation of aptamer library 
The DNA was prepared using solid phase synthesis on an ABI ExpediteTM 8909 
Nucleic Acid Synthesis System. 
Phosphoramidites (Sigma-Aldrich) were dissolved in anhydrous acetonitrile to a 
standard concentration (0.067M). The 5'-DMTr group of the 5'-terminal base was 
removed with 3% trichioroacetic acid in dichloromethane. The next phosphoramidite 
in the sequence was activated by reaction with 0.45M tetrazole and reacted with the 
free 5'-OH of the previous phosphoramidite. Coupling was 30 seconds per base. 
Acetic anhydride and N-methylimidazole were used to cap free hydroxyl groups left 
unreacted. 	The phosphite triester was oxidised to the stable pentavalent 
phosphotriester by the use of 0. 1M iodine in THF/pyridine/water thus completing a 
single cycle. 
The aptamer library is as follows: 
5' -CCGAAGCTTAATACGACTCACTATAGGGATCCGCCTGATTAGCG 
ATACT-[40N]-ACTTGAGCAAAATCACCTGCAGGGG-3'. 
The 40 random bases were produced from a single pot containing an equimolar 
concentration of the four available phosphoramidite bases. 
After complete synthesis the aptamer library was cleaved from the support with 
concentrated anmioniuim hydroxide at room temperature (l6hr). The pool was 
purified by HPLC and stored lyophilised. 
Aptamer generation carried out with the help of Professor Tom Brown and Dr Dorkus 
Brown (University of Southampton, Chemistry Department). 
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3.11.2 y- 32p  labelling DNA 
All work was carried out in a controlled radiation room, behind a Perspex shield. 
500pmoles of the aptamer library (20j.tl) had 'y32P-ATP (30tci, 3jil), ligase buffer 
(lOX, 5jil), 20 units T4 PNK (2111) and water (19.0) added. This was incubated at 
37°C for 15 mins before the addition of ATP (100mM, ipi). The solution was 
incubated for a further 45 minutes at 37°C, before running on gel. 
The 12% acrylamide/7M Urea gel was prepared gel was prepared following the 
protocol in Maniatis145. A loading buffer was prepared with 0.05% bromophenol blue 
and 0.05% xylene cyanol made up in 500p1 H20, which then had formamide (500tl) 
added. 50j.tl of this buffer was added to the 50J11 labelled DNA and ran on the gel. 
The bromophenol blue runs with an approximate mass of 15 oligonucleotides and the 
xylene cyanol with a mass of around 40 oligonucleotides. After the bromophenol 
blue band ran off, the gel was removed from the tank and stored overnight at —20°C 
wrapped in saran wrap. 
The following day the gel was carefully removed from the cassette, and moved into a 
suitable autoradiography cassette. The gel was then subject to exposures of 20s, 40s 
and 2mm, and each film was developed. Dark bands were visible showing the 
migration of the labelled aptamer library. The relevant band was removed following 
the "crush and soak" method (Section 3.9.12) and diluted in 50111 of buffer. 
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3.11.2 ssDNAlProtein Selection 
The 14-3-3 y stock solution was maintained at a concentration 14.2mg/mi. 8p1 of this 
stock (0.1mg, 2.15 x 1015 molecules) had 20t1 of the 32P y-radiolabelled aptamer 
library added (1.5 x 10 14 molecules). 22il of sterile TE was added to the solution and 
then this was allowed to agitate gently at 4°C for 16 hours on a blood rotator. 
Ni2tSepharose beads (Amersham Biosciences) were washed according to the 
manufacturers instructions. 10.tl of the bead solution (capacity to bind 0.4mg His-
tagged protein, 4X excess) was washed into 50il sterile TE solution. This added to 
the aptamer-protein solution and allowed to gently agitate for a further hour at 4°C. 
The solution was spun at 6.5K for 2 mins and the supernatant was carefully removed 
and collected as fraction A0. 50p1 of 'SELEX Buffer A' was added to the beads and 
this was allowed to agitate for 5 mins on the blood rotator. Again, the solution was 
spun at 6.5K for 2 mins and the supernatant was collected as fraction Al. The 
wash/spin procedure was repeated a further 3 times with 'SELEX Buffer A' (fractions 
A2-A4). SOp! of 'wash buffer B' was added and the wash/spin procedure was 
repeated a further 4 times (fractions B1-B4). SOp! of 'SELEX Buffer C' was added to 
the beads and this was allowed to agitate for 1 hour at 37°C before the supernatant 
was collected. This was repeated with a further SOp! 'elution buffer C' for 30 mins, 
and the fraction was pooled with the previously collected sample, labelled Cl. 
Sample Cl contains the denatured ssDNA to be used in further rounds. 
Aliquots of all fractions had their radiography counts per minute (CPM) read using a 
TRI-CARB 21 OOTR scintillation counter (Perkin-Elmer). 
72 
3.113 Preparation for PCR 
The ssDNA was eluted in a high concentration guanidinium chloride solution which 
would inhibit PCR. The ssDNA was desalted using a Supelco supelclean LC-1 8 SPE 
3m1 tube, prepared following the manufacturers instructions using a peristaltic pump. 
To fraction Cl, 500tl of sterile H20 was added. This solution was then added to the 
desalting column, and washed with 1 Omi of sterile water, ensuring there was enough 
solution to keep the beads immersed. The column was removed from the pump and 
placed into a clamp. Acetonitrile/DCM (75:25) (600j.tl) was added to the beads and 
allowed to pass through by gravity. This was collected in 2 x 300p1 fractions. The 
organic solution was evaporated using a gyrovac (30 mins, 42°C), and the pellets 
were resuspended in 2 x 20.i1 sterile TE fractions, before being pooled together. 
3.11.4 a-32P dCTP labelling DNA 
All work was carried out in a controlled radiation room, behind a Perspex shield. 
Redivue deoxycytidine 5' [a-32P]- triphosphate, triethylammonium salt was used to 
label DNA (Amersham Biosciences, AA0075). 
A sample of the aptamer library (20jil) had primers 00979R (5.3 p1, 500 pmoles) and 
00978R (8.6p1, 500 pmoles) added, along with 5'[cL-32P]dCTP (1p1, 10.tCi), water 
(15p1) and two ready-to-go taqTM polymerase beads added. The solution was 
amplified by PCR; 95°C for Smins then 12-18 cycles (95°C-30s, 54°C-20s, 72°C-
60s), and ran on an agarose gel for visualisation and purification using the QiaQuick 
gel purification system. 
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3.11.5 Separating the dsDNA 
0.5m1 Streptavidin magnetic beads (New England Biolabs) were prepared following 
the manufacturers instructions. The equilibrated streptavidin magnetic beads were 
added to the PCR pure product and allowed to gently agitate on a blood rotator for 1 
hour. The beads were washed 6 times with 0.5ml wash buffer according to the 
manufacturer's instructions, then dsDNA was separated by the addition of 2 washes 
of dsDNA strand separation buffer (300d), 15 min incubations at room temperature. 
The supernatant contained the starting library for the next round of selection, while 
the 3' biotinylated strand remained immobilised to the streptavidin beads. 
The library was eluted in a buffer that would have been inhibitive for the next round 
of selection. To prepare the ssDNA, it was ethanol precipitated (Section 3.9.10). 
ssDNA was resuspended in 50p1 PBSM and the final concentration was calculated 
using the extinction coefficient at Abs. 260nm (0D26° x 33mg/mi x dilution factor 
ssDNA concentration (ng/ml), 0D26° 1 = 33 ng/ml). 
3.12 Aptamer Determination 
3.12.1 Surface Plasmon Resonance Analysis 
Surface plasmon resonance analysis of aptamers was carried out on a BiacoreX 
(Biacore, Sweden) using an NTA chip (Biacore, Sweden). The running buffer used 
was PBSM and the washing buffer used in between injections was glycine (10mM, 
pH 2.0). The temperature was maintained at 25°C, and unless stated elsewhere, the 
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flow rate was kept at 20p1/min. All aptamer samples were heated to 95°C for two 
minutes and cooled on ice before application. 
The NTA chip contains a matrix of carboxymethylated dextran pre-immobilized with 
nitrilotriacetic acid (NTA). The NTA surface was charged with Ni2 by the addition 
of NiSO4 (0.25M, 5 minutes), followed by chelation of recombinant (His)6  l 4-3-3 y 
(1mg/mi, 5ti/min 10 minutes). Aptamer responses were recorded by addition of 
aptamer (l0tM (unless otherwise stated), 3 minutes). 
3.12.2 Aptamer Affinity Purification 
500 jtI of sample (either MBH or Ovine CSF spiked with 14-3-3 (lOpi, 14.2 mg/ml)) 
had 1 0jtl of 1 O0tM biotinylated aptamer added and was mixed with gentle agitation 
for 2 hours at room temperature. 50p1 of magnetic streptavidin beads (Roche) were 
washed from their ethanol solution into 50il wash buffer (Tris-Cl (50mM, pH 7.5), 
NaC1 (150mM)). The beads were added to the protein aptamer solution and allowed 
to gently agitate (lhr, RT). The solution was applied to a magnet and the supernatant 
was removed and collected. The beads were washed 5 times with lOOpi wash buffer, 
and the resultant beads were collected and resuspended in 50ji1 wash buffer. For 
analysis, 40pi from; flow through, each wash fraction and the collected beads had 3X 
SDS sample buffer added (20pi) before heating at 95°C for 5 minutes. The samples 
were spun at 13K for 2 mins and 40pi from each was loaded onto two 4-12% Bis-Tris 
gel (Invitrogen), 20pi per gel. One gel was used to stain with GelCode blue, the other 
followed the procedure for a standard Western Blot. 
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3123 ELISA 
Doubling dilutions of (His)6 14-3-3 y  were applied in triplicate to an Immulon 4HBX 
96-well plate (Thermo-Electron Corporation). All wash steps were carried out on a 
MRW strip washer (Dynex technologies) using the set wash programme (six 
200 jil/well wash cycles with 30 second soak periods between washes) using ELISA 
wash buffer. 
An Immulon plate was coated with K-19 antibody (Santa-cruz biotechnology (100 j.il 
in 1 Oml of coating buffer, 1 00tl per well), 1 hour at 37°C then at 4°C overnight. The 
plate was washed as directed then blocked by the addition of casein (5% w/v) in 
coating buffer (lhr, 4°C) lOOj.il per well, before another wash cycle, followed by the 
addition of the 14-3-3 protein. The 14-3-3 stock (14.2mg/mi) had 60p1 removed and 
was diluted down to 4mg/mi with diluent buffer. 2p1 was added to 398p1 diluent 
buffer and heated to 55°C for ten minutes. This solution (fraction 1) had 3 x 501 
aliquots applied to the plate and 200pJ was added to 200pJ diluent buffer (doubling 
dilution) to make fraction 2 which had 3 x 50d fractions added to the plate and had 
200pi added to 200pi diluent buffer to make fraction 3 and henceforth. When all 
protein fractions are applied to the plate, the plate was incubated at 37°C for 1 hour 
before a further wash step. K-19 anti-14-3-3 antibody (rabbit polyclonal IgG) diluted 
1:1000 was added to each well (50p1), incubated for 1 hour, before a further washing 
step followed by addition of goat anti-rabbit HRP conjugate antibody, diluted (1:10 
000) (50jil), which was allowed to incubate for 1 hour. The plate was subjected to a 
further washing step before addition of 3,3,5,5 Tetramethylbenzidine(TMB) substrate, 
which was incubated for 15 minutes, before the reaction was quenched with the 
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addition of 0.18M H2S04000pi). The absorbance at 450nm measured on a Wallac 
victor II spectrophotometer. 
3.12.4 Enzyme Linked Oligonucleotide Assay (ELONA) 
Identical concentrations (0.25mg/mi) of (His)614-3-3 y  were applied to a 96 well 
Immulon-4HBX plate (Thermo Electron Corporation) and the aptamers used were 
applied in triplicate with doubling dilutions. Identical wash steps were carried out as 
per the ELISA procedure. 
The plate was coated with K-19 antibody (lOOpi in lOml coating buffer) for 1 hour at 
37°C then stored at 4°C overnight. After washing, the plate was blocked by the 
addition of casein (5% w/v) in ELISA coating buffer (lhr, 4°C) and was subjected to 
a further washing step before addition of the 14-3-3 protein. 176ii1 of 14-3-3 
(14.2mg/ml) was added to lOml of wash buffer and 100d was added to each well 
followed by incubation at 37°C for 1 hour before a further wash step. The 
biotinylated aptamer (400p1, 100tM) was heated to 95°C, cooled to room temperature 
and subjected to doubling dilutions in diluent buffer, following the same procedure as 
ELISA. 50p1 of each aptamer concentration was applied in triplicate to the plate and 
incubated for 2 hours at 37°C before unbound aptamers were washed off. 
Streptavidin horseradish peroxidase was then applied to each well (1:10 000, lOOpJ) 
incubated for 30min at 21°C before washing. TMB (100[ d) was added to each well 
and left at room temperature for 15 mins before the reaction was quenched with the 
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addition of 0.18M H2SO4(100p!). The absorbance of each well was checked at 450nm 
on a Wallac victor II spectrophotometer. 
3.12.5 14-3-3 isoform analysis by ELONA 
An Immulon-4HBX plate pre-coated with K-19 (1 OOjtl in 1 Omi Coating Buffer) and 
blocked with casein (5% w/v in blocking buffer) had 14-3-3 isoforms loaded. Each 
isoform (0.5mg/ml) was heated to 60°C for 5 minutes before addition to the plate 
twice in triplicate (50tl per well) (two aptamers were getting analysed thus A: 1-3 for 
one aptamer and A:4-6 for another aptamer for that 14-3-3 isoform). After a 1 hour 
incubation period (37°C) and subsequent wash, aptamer S16-8 or S16-2 was added 
(10tM, 50t1), pre heated to 95°C for 5 minutes and cooled on ice, and incubated for 2 
hours at 37°C (S16-2 was added to wells A-H, 1-3 and aptamer S16-8 A-H, 1-6). The 
plate was subjected to a further wash step before the addition of streptavidin 
horseradish peroxidase, applied to each well (1:10 000, lOOpi) and incubated for 
30min at 21°C before washing. TMB (lOOpi) was added to each well and left at room 
temperature for 15 mins before the reaction was quenched with the addition of 0.1 8M 
H2504(100pi). The absorbance was checked at 450nm on a Wallac victor II 
spectrophotometer. 
3.12.6 Protein Blot analysis with S16-8 
Each recombinantly expressed 14-3-3 isoform (4j.tg) was made up into 40jfl of IX 
SDS Sample buffer. The samples were boiled for 5 mins before addition to two Bis- 
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Tris 4-12% Gels (20p1 per gel). 	The protein samples were separated 
electrophoretically, one gel was stained with gel code, and the other transferred to 
PVDF membrane (Amersham) following the western blotting protocol. The 
membrane was blocked using casein (5% w/v in PBST, 1 6hr, 4°C) before washing 
steps similar to the western procedure. The western procedure was copied except 
instead of the primary antibody, biotinylated S16-8 was used (diluted to 1 0OpM in 
lOml PBST) and the secondary antibody was streptavidin-HRP (1:10 000 in PBST). 
3.12.7 Gel Filtration Analysis 
Analysis carried out on a Pharmacia AKTA purifier (GMI) using gel filtration column 
16/60 SuperdexTM 75 (Dextran-agarose column, 1 2Oml, Amersham Biosciences). 
The column had a flow rate of 1.2 ml/min using running buffer: Tris-HC1 (pH 7.5), 
NaCl (50mM) and Triton X 100 (0.05% v/v). Absorbance was recorded at 220nm, 
260nm and 280nm. 
The controls of 14-3-3 ? alone (25ji1 14.2 mg/ml, diluted in 975p1 running buffer) and 
S 16-8 alone (25p1, lOOjiM, diluted in 975p1 running buffer) were recorded. 
S16-8 (25p1, 100pM) was added to (His)614-3-3 y  (25p1, 14.2mg/ml) and diluted to 
lml using running buffer. The solution was agitated on a blood rotator (lhr, room 
temperature) before addition to the column. 
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3.12.8 Aptamer sequence alignment 
Aptamers were aligned using either Align X in the Vector NTI 9 suite or ClustaiW. 
Both programs use a ClustaiW alignment algorithm. 
312.9 Aptamer phylogenetic tree 
A phylogenetic tree was automatically generated upon preparing a sequence 
alignment with Align X in the Vector NTI 9 suite. The tree was generated using the 
sequence distance method and the Neighbour Joining Algorithm.'66 
Chapter 4: Results and Discussion 
4.1 Cloning, Expression and Purification of 14-3-3 y 
The expression and purification of 14-3-3 proteins has been carried out in a number of 
earlier studies. High expression has been achieved using 14-3-3 fusion proteins. 150 
At the start of this study, a library of all the human 14-3-3 genes and some other 
mammalian 14-3-3 genes cloned into a range of different expression vectors, was 
made available by Professor Alastair Aitkin (Division of Biomedical & Clinical 
Laboratory Sciences, University of Edinburgh). Of the seven human isoforms, six 
were available as GST fusions, and epsilon, was available as a maltose binding 
protein fusion. Baxter and co-workers have previously shown that 14-3-3 isoforms 3, 
E, y, il are all detected in the CSF of patients with sporadic CJD.6° However the ' 
isoform is most abundant in the disease state and so it seemed logical to select an 
aptamer for this isoform. 
In the previous studies, the mammalian 14-3-3 ' gene had been cloned into a GST 
expression vector, pGEX-4T1 (Figure 4.3); affording the fusion plasmid pGEX-
4T1/14-3-3i. GST, glutathione-S-transferase, is a soluble enzyme that catalyses the 
conjugation of reduced glutathione in a detoxification pathway in cells. GST gene 
fusions have been extensively used to co-express target proteins. These fusions 
confer useful properties: (a) they tend to be well expressed, thus many hard to express 
proteins cloned downstream from the GST gene are often better expressed as a GST 
fusions; (b) they frequently confer solubility to otherwise insoluble targets; (c) GST 
provides an excellent carrier protein for crystallisation and (d) the GST domain 
provides a useful ligand for the immobilisation (GST affinity chromatography) of the 
fusion protein, and for detection of the fusion protein using anti-GST antibodies.' 51 
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However for aptamer selection the GST 14-3-3 y  fusion would be an unsuitable 
substrate, GST is expressed with a mass of 28 kDa, thus trying to select aptamers to 
14-3-3 y  (also 28kDa) when fused to GST would inevitably lead to many aptamers 
specific for the GST sequence. Although in principle, counter-selection steps could 
be used to eliminate GST specific aptamer enrichment, it would involve extra steps in 
the SELEX procedure and perhaps eliminate good 14-3-37  binding aptamers from the 
library. In addition, a proportion of the 14-3-3 ' protein surface area would be 
sterically hindered by the positioning of the GST protein, preventing aptamer access 
and thus reducing the number of potential binding sites. There would also be a small 
possibility that some aptamers could interact at the GST/14-3-3 7 interface leading to 
false results when the SELEX process was complete: such aptamers might work well 
on an assay with the 14-3-3/GST fusion, but not with the wild type 14-3-3 
4.1.1 Cloninq 14-3-3 v 
ATGGTGGACC 	CCGAGCAACT 	GGTGCAGAAA 	GCCCGGCTGG 	CCGAGCAGGC 
GGAGGGCTAC GACGACATGG CCGCGGCCAT GAAGAACGTG ACAGAGCTGA 
ATGATCCACT 	GTCGATGAGG 	AACGAAACCT 	TCTGTCTGTG 	GCCTACAAGA 
ACGTTGTGGG GGCACGCCGC TCTTCCTGGA GGGTCATCAG TAGTATTGAG 
CAGAAGACGT 	CTGCAGACGG 	CAATGAGAAG 	ATTGAGATGG 	TCCGTGCGTA 
CCGGGAGAAG GTAGAGAAGG AGTTGGAGGC TGTGTGCCAG GATGTGCTGA 
GCCTGGTGGA 	TAACTACCTG 	TACAAGAATT 	GCAGCGAGAC 	CCAGTACGAG 
CGCAAAGATT TGTACCTGAA GATGAAAGGG GACTACTACC GCTACCTGGC 
TGAAGTGGCC 	ACCGGAGAGA 	AAAGGGGCGA 	CGTGGTGGAG 	TCCTCCGAGA 
AGGCCTACAG CGAACGCGAG ATCAGCAAAG AGCACATGCA GCCCACCCAC 
CCCATCCGAT 	TAGGTCTGGC 	TCTTAACTAC 	TCCGTCTTCT 	ACTATGAGAT 
CCAGAACGCC CCAGAGCAAG CGTGCCACTT GGCAAGACCG AGTTCGAGGA 
GGCCATCGCC 	GAGCTTGACA 	CCCTCAACGA 	GGAGTCCTAC 	AAGGACTCCA 
CGCTCATCAT GCAGCTCCTC CGCGACAACC TCACGCTCTG GACGAGCGAC 
CAGCAGGACG 	ACCACGATGG 	GGAGAAGGCA 	ACAACAACTA 	A 
Figure 4.1: 14-3-3 y gene. The gene containing 742 bases 
MVDREQLVQKA RLAEQAERYD DMAAAMKNVT ELNEPLSNEE RNLLSVAYKN 
VVGARRSSWR VISSIEQKTS ADGNEKKIEM VRAYREKIEK ELEAVCQDVL SLLDNYLIKN 
CSETQYESKV FYLKMKGDYY RYLAEVATGE KRATVVESSE KAYSEAHEIS KEHMQPTHPI 
RLGLALNYSV FYYEIQNAPE QACHLAKTAF DDAIAELDTL NEDSYKDSTL IMQLLRDNLT 
LWTSDQQDDD GGEGN 
Figure 4.2: 14-3-3 y amino acid sequence. The protein contains 247 amino acids. 
Information available at UniProtKB/Swiss-Prot entry P61981.152 
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The 14-3-3 ' gene was cloned from the GST fusion plasmid however tagging the 14-
3-3 T protein with a smaller fusion is attractive for several reasons. Tagged proteins 
can be attached to resin, facilitating protein purification. It also seemed an attractive 
idea to use a resin bound protein for this SELEX approach. The 'His' tag system, 
where a base sequence encoding five or six histidine residues is expressed at the 5'- or 
3'- end of an ORF is one of the most commonly used tagging systems in current use. 
The fact that His tags facilitate purification and are relatively small and thus generally 
do not interfere with protein folding appears to recommend their use in this type of 
experiment. 
As described in Chapter 2, many partitioning methods have been used for SELEX 
including; filter absorption, non-denaturing gel electrophoresis, immunoprecipitation 
and centrifugation (in the case of entire cells). 153  Target immobilisation on 
chromatography beads has also been used and this allows counter selection elution 
steps to further improve the specificity of the nucleic acid/ligand interaction. Target 
immobilisation was used successfully by Bock and co-workers in selecting aptamers 
to the classic thrombin aptamer.'°5 
GST 
Lac 1q 	 Not pGEX-4T1 
4969 bp 
psg Amp 
Figure 4.3: Flasmid pGEX M. The ampicillin resistance gene (Amp) is present on 
the construct and the 14-3-3 gene was cloned between the BamH I and Sal I 
restriction sites. 
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The 14-3-3 ' gene was amplified from the pGEX-4T1/14-3-3 7 template by PCR 
using the forward primer "RS01" (incorporating a Barn HI restriction site), and 
reverse primer "RS02" (engineered with a Sal I site). The PCR product was then 
ligated into the N-terminus His tag expression vector pQE-30 (Figure 4.4) using the 
Barn HI and Sal I restriction sites. The resulting plasmid was named pQE30/14-3-37 
and DNA sequencing of the insert from the forward sequencing ('type hilly') primer 
for pQE vectors confirmed that the gene had been faithfully transcribed by PCR. 
L. 
PT5 	lac 0 lac 0 RBS ATC, r.:a MCS 
POE-30 - - 
713QE-30, 




Figure 4.4: Plasmid pQE-30. The plasmid was digested at the Barn HI and Sal I 
sites allowing the 14-3-3 1'  gene to be inserted in the MCS. Plasmids pQE-31 and 
pQE-32 contain additional amino acids between the 6 x His sequence and the MCS, 
used to ensure the gene is inserted 'in-frame'. 
Trial expression was performed in various E. coli cells (DE3 lysogens). Optimum 
protein expression was obtained using the BL21 (DE3) strain, induced with isopropyl-
1 -thio-3-D-ga1actopyranoside at 37°C. 
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(His)6 (12) BamH 1(37) Pst 1(248) 	 Sal 1(775) 
(His)6 l4-3-3y 
778bp 
Figure 4.5: Schematic Representation of cloned pQE30/14-3-37 gene. The 
endonuclease restriction sites present in the cloning region of pQE30 are highlighted. 
4.1.2 14-3-3 y Purification 
The pQE30/14-3-37 cell lysate was fractionated by IMAC (immobilised metal affinity 
chromatography) using a nickel-NTA resin. The protein was eluted using 250 mM 
imidazole, and was immediately diluted 1:1 with 50mM PBS and dialysed against this 
buffer. SDS-PAGE analysis indicated that the 14-3-3 7 purity was? 90%. The final 
yield of 14-3-3 y was typically around 14 mg/L of cell culture. 
MRGSHHHHHH GSVDREQLVQ KARLAEQAEG YDDMAAAMKN 
VTELNEPLSN EERNLLSVAY KNVVGARRSS WRVISSIEQK TSADGNEKIE 
MVRAYREKVE KELEAVCQDV LSLVDNYLYK NCSETQYERK 
DLYLKMKGDY YRYLAEVATG EKRGDVVESS EKAYSEREIS KEHMQPTHPI 
RLGLALNYSV FYYEIQNAPE QACHLAKTEF EDAIAELDTL NEESYKDSTL 
IMQLLRDNLT LWTSDQQDDH DGGEGNNN 
Figure 4.6: pQE30/14-3-37 amino acid sequence. The sequence contains an 
additional eleven amino acids (shown in bold) including the 6 x His residues, to the 
wild type 14-3-3 y sequence. 
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350 	 40.0 	 43.0 	 50.0 	 _5 5 
Figure 4.7: Chromatogram of 14-3-3 IMAC. The chromatogram shows two peaks 
for 14-3-37. Both peaks were identified on SDS-Page to confirm the estimated purity 
of the expressed protein suggesting that they correspond to the monomeric and 
dimeric forms. 
4.1.3 Characterisation of Purified (His)6 14-3-3 y 
Prior to starting lengthy, time consuming SELEX selection of aptamers it was 
important to ensure that the overexpressed protein was correctly folded. 
The collected peak fractions were run on an SDS-Page to confirm the identity of a 
species with similar molecular weight to 14-3-3 protein (Figure 4.8). A further SDS-
Page gel was transferred to nitrocellulose for antibody probing. Rabbit produced K-
19 (also known as SC629; Santa Cruz shown in Table 1.3) was used as the primary 
antibody with biotinylated goat anti-rabbit HRP (horse radish peroxidase) the 
secondary. Treatment of the membrane with TMB allowed imaging. 
The western blot clearly shows that the expressed protein, is recognised by the anti 
14-3-3 antibody; K-19. The K-19 antibody is labelled as an anti-f3 14-3-3 antibody, 
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however as mentioned previously, the antibody which has an N terminal epitope, is 
not isoform specific allowing use in detection of the y  isoform. The early epitope is 
not a problem with detecting the protein as the proteins are denatured as part of the 
process of running the SDS-Page gel. 
kDa 	1 	2 	3 	4 	kDa 	1 	2 	3 	4 
175 - 
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33— 	 33- 
25— 	 25 
17— 	 17- 
7— 	 7— 
Figure 4.8: SDS-Page and Western blot of 14-3-3y. A shows SDS-PAGE carried 
out under denaturing conditions. Lane 1, marker P7708, Lane 2 Control pQE30/14-3-
3y uninduced, Lane 3 Induced pQE30/14-3-3y clone 1 and Lane 4 Induced pQE30/14- 
- 1 clone 2. B a 1 minute exposure of an identical gel transferred to nitrocellulose 
and Western blotted using anti 14-3-3 antibodies. 
4.1.4 Mass Spectrometry of 14-3-3 y 
Electrospray MS revealed the presence of one species with a molecular weight 
29639.8 ± 2.34 (Figure 4.9), corresponding to full length 14-3-3 y  with 6 histidine 
residues attached (29936.13 Da). A further experiment was set, a tryptic digest of the 
protein sample followed by MALDI-MS confirmed that the digested protein was 14-
3-3, peptide fingerprinting used the Mascot search engine (www.matrixscience.com). 
The MALDI-TOF spectrum is not shown, however the digested peptides used in 
fingerprinting are as follows: 
816— (LAEQAER) 903 - (VISSIEQK) 1080— (YLAEVATGEK) 1189 - 
(DSTLIMQLLR) 1277 - (EHMQPTHPIR) 1644 - (NVTELNEPLSNEER) 2167 - 
(TAFDDAIAELDTLNEDSYK) 
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Figure 4.9: LC-MS of (His)614-3-37. 14-3-3 analysed by electrospray mass 
spectrometry. The calculated molecular weight (29639 Da) corresponds to full length 
recombinant (His)6 14-3 -3y. 
88 
4.1.5 Circular Dichroism of 14-3-3 y 
Circular dichroism (CD) was used to estimate the secondary structure of the expressed 
recombinant (His)6 14-3-3 y.  Far UV region (180-240 nm) CD analyses the peptide 
bond adsorption; features such as a-helixes and 13-sheets give rise to patterns of 
characteristic shape and magnitude of CD spectrum. For more information on 
circular dichroism the reader is advised to read the review by Kelly and Price. 154 
The family of 14-3-3 proteins are highly a-helical molecules (see Chapter 1). The 
observed spectrum for (His)6 14-3-3 ? was typical of a protein that is predominantly a-
helical, characterised by a far UV scan that has a trough between 200 and 230nm. 
Analysis of the spectrum using the programme DICHROWEB showed that 
recombinant protein was 70% a-helical and 4% 13-sheet, similar to the results obtained 
by Robinson et al. in their analysis of the secondary structure of other 14-3-3 proetein 
isoforms.'56' 157 
t'Ct.?C 
100 	195 	200 	205 	210 	210 	220 	220 	ZOO 	230 
	2,40 
I Helix2 II Strandi  II Strand2 Erns IderedI 'rtI 
0.50 	0.20 	1 0.02 	II 0.02 
Figure 4.10: Circular Dichroism of 14-3-3 y. 	CD results processed by 
DICHROWEB155, suggest that recombinant 14-3-3 ' is 70 % a-helical and 4 % 13-
sheet. '56 
42 Recognition of 14-3-3 V  by antibodies 
As further confirmation that the conformation adopted by the bacterial recombinant 
(His)6 14-3-3 y  was identical to that of the mammalian protein, the interaction of the 
un-denatured protein with several commercially available antibodies was evaluated. 
4.21 Surface Plasmon Resonance 
Surface Plasmon Resonance was used to study the real time interactions of His-tagged 
14-3-3 y with commercially available antibodies on a Biacore® X system. 14-3-3 -y 
was immobilised via the N-terminal hexa-histidine residues to a Ni-NTA chip and the 
interaction with four different anti-14-3-3 antibodies examined. Antibodies; K-19, C-
16 (also known 5C629 and SC731, both Santa Cruz), KK 1106 (PAN antibody) and 
SLAK, were used. C-16 is the only one of these which is 14-3-3 ' specific. 
In Biacore systems, the surface plasmon resonance (SPR) phenomenon occurs when 
polarised light, strikes an electrically conducting gold layer at the interface between 
media of different refractive index: the glass of a sensor surface (high refractive 
index) and a buffer (low refractive index). 157  The polarized light is directed toward 
the glass face of the sensor surface, reflected light is detected within a Biacore system. 
The SPR signal can be explained by the electromagnetic coupling of the incident light 
with the surface plasmon of the gold layer. The plasmon is influenced by a layer just 
a few nm over across the gold-solution interface, causing a reduction in the intensity 
of the reflected light, producing a sensorgram. The signal is directly proportional to 
the size of the ligand molecule immobilised. 
Each SPR chip contains two flow cells; fcl is for reference and fc2 for measurement. 
Initially the protein is loaded onto both flow cells, before an antibody solution is 
passed through only f62. When the antibody binds the protein there is a change of 
mass and indirectly, the mass change between f62 and fc 1 gives a response difference 
shown on a sensorgram. A high mass antibody molecule, will give a greater response 
than that of a low mass antibody molecule, therefore to get a clear picture, both the 
molecular mass and concentration of antibody solution must be known. 
All the antibodies used had measurable association with the recombinantly expressed 
protein. The association curves were reproducible, under specific washing conditions 
and were concentration dependent. The SLAK antibody was most sensitive (1:2000 
dilution, 350RU), or at least gave the largest response difference under very dilute 
conditions. KK 1106 (PAN) antibody gave a response at higher concentrations, 
however the response curves were unusual (1:40 dilution, 100RU). K-19 gave 
intermediate responses and appeared to be the best binder albeit at relatively high 
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Figure 4.11: Chromatogram of repeatable results using antibody KK 1106. 3 
30p1 injections with flow rate 10i.tl/min are shown. Glycine buffer (10mM, pH 2.0) 
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Figure 4.12: Comparison of the four anti 14-3-3 antibodies by SPR. All had 30p1 
injections, with a flow rate of 1 O.tl/min. 
Figure 4.12 provides compares four of the available anti 14-3-3 antibodies and 
provides a basis for possible comparison of a successful aptamers against the best 
antibody alternatives. The heavily diluted SLAK antibody gave the greatest response 
difference. Diluting SLAK any lower than 1:2000 led to inconsistent responses. 
Since the recombinantly expressed 14-3-3 ' had the correct DNA sequence, had a 
secondary structure (by CD) consistent with that of published 14-3-3 isoforms to date 
and interacted with expected antibodies, it seemed likely that the protein was correctly 
expressed and folded. 
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4.3 SELEX 
4.3.1 The SELEX Approach 
In Chapter 2 I describe the outlining principles of the SELEX process, a technique 
that appears, at first sight, to be technically simple. It should be noted however, that 
in the 13 years following the discovery of aptamers and this technique of selection, 
only around 40 protein-aptamer studies were published. Given the potential of 
aptamers in protein detection and diagnostics, this indicates that the selection process 
available is not technically simple to perform. Indeed aptamer selection has only 
recently become routine using high throughput methods as shown by Cox et al. using 
automated selection techniques.11 ' 
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Clone and Sequence 
Figure 4.13: The SELEX cycle with counter selection. The Figure is adapted from 
Figure 2.3, the counter selection steps have been added to the diagram for clarity. 
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An alternative approach was taken in the study presented here, adapted from the 
method used by Murphy et al. Murphy and co-workers selected DNA aptamers to 
thyroid transcription factor 1 (TTF1), the protein was expressed as a his-tag fusion 
and was immobilised on Ni-NTA magnetic beads, a magnet was used to separate 
those aptamers bound to the protein and those still free in the solution. 158 
Attaching the target protein to an insoluble resin by his-tagging affords a SELEX 
procedure performed without the use of robotics and gives a procedure that appears 
robust and susceptible for any protein capable of immobilising on a resin. 
The starting library and primers were similar to the library used by Green et al. in 
selecting aptamers to vascular endothelial growth factor.159 The library "RS997R" 
was prepared using the solid phase phosphoramidite method first described by Sinha 
et al. 160 
5 'CCGAAGCTTAATACGACTCACTATAGGGAICCGCCTGATTAGCG 
ATACT-[40N]-ACTTGAGCAAAATCACCTGCAGGGG-3'. 
Figure 4.14: RS997R; Aptamer Staring library. The synthesised pool contains a 
completely randomised 40 base cassette - [40N], flanked by known primer annealing 
regions containing restriction sites, I3amH I and Ps! I. 
An equal mixture of the four phosphoramidites was used to generate the random 
positions. Here it should be noted that there is some argument about the ratio 
necessary for completely random incorporation, Szostak has suggested an ACGT ratio 
of 1.5:1.5:1:1 and this has been disputed by James.104 The different ratios required to 
achieve complete randomness is a feature of the synthetic chemistry involved, minor 
differences between laboratories would be expected. For that reason an equal mixture 
of the bases was used in the random cassette. 
The PCR primers used were "RS9978R" 5'-AGGG ATCC GCCT GATT AGCG 
ATACT-3', the biotinylated reverse primer "RS9979R" 5'-BBBC CCCT (WAG 
GTGA TTTT GCTC AAGC-3' where B designates Biotin from biotin 
phosphoramidite and "RS9981R" 5'-CCCC TGCA GGTG ATTT TGCT CAAG C-
3', the unbiotinylated reverse primer used in cloning and sequencing. The primers 
were designed with restriction sites, Burn III in the 5' primer and Psi I in the 3' 
primer. The incorporation of these sites was based on the contingency that they could 
be used for excision and cloning in the event of problems with TA cloning. 
The Green library template was used as there seemed little point in redesigning new 
flanking regions when previous art has shown this to be a successful starting library. 
As discussed earlier, starting libraries must be carefully designed to minimise the risk 
of the starting pool having intra-molecular structures. The 5' flanking region 
provided scope for RNA aptamers instead of ssDNA aptamers by containing a T7 
promoter sequence for in vitro transcription. A contentious point of using the 
library/primers of Green et al. is that their 3' primer contains 3 biotin molecules (for 
use in strand separation). Strand separation is generally carried out using biotin to 
immobilise the dsDNA on a streptavidin resin before disruption of the hydrogen bond 
and collection of the free strand (although asymmetric PCR can be used). Generally a 
single biotin molecule appears sufficient to carry out this step successfully, so using 3 
biotin molecules may seem over excessive, although Green might argue that using 3 
biotins still enabled a successful SELEX process. 
The ssDNA library was purified on an 8% polyacrylamide/7 M Urea gel. The band 
was visualised under UV light, excised from the gel, eluted by the crush and soak 
method (Section 3.9.12), ethanol-precipitated and pelleted by centrifugation. The 
pellet was resuspended in phosphate-buffered saline supplemented with 1mM MgCl2- 
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The first selection had approximately SOOpmoles of 5' y-32P end-labelled (for the 
radio-labelling technique see 3.1.17), purified on a 12% acrylamide/7M Urea gel, 
visualised by autoradiography and the radioactive band was eluted and resuspended in 
total 50jii TE. The concentration of DNA pg/pJ was estimated using UV absorbance 
at 260nm and the specific activity recorded in dpm1pg. 20j.il of the radiolabelled 
DNA stock (around 200pmoles) was heated to 95°C for 5 minutes, chilled on ice for 1 
minute before addition to 8i1 14-3-3 y (2nmoles). In the early cycles of SELEX, a 
molar excess of protein molecules over DNA molecules was used, ensuring that any 
aptamers that have a chance of binding should have the opportunity. In the first cycle, 
a i OX molar excess of protein over ssDNA. This ratio of target to aptamer is in line 
with the recommendations made by Irvine et al. who examined the effects of different 
target:DNA ratios in some detail. 161 
The solution containing the protein and radiolabelled DNA was allowed to equilibrate 
with gentle agitation overnight at 4°C, followed by 30 minute incubation at room 
temperature. Ni-NTA beads previously equilibrated with SELEX buffer A, were 
added to the mixture and allowed to gently agitate at room temperature for 1 hour. 
The 1 .Sml microcentrifuge tube containing the solution was gently spun to collect the 
beads and the supernatant carefully removed. The beads were subjected to further 
washing steps before the bound DNA was eluted and transferred to PCR tubes. 
After completion of each cycle during the early rounds of SELEX, the radioactivity in 
each wash fraction was measured by scintillation counting. The results are shown in 
Figure 4.15 for rounds two through to four. The early results show that there 
appeared to be an enrichment up until the 4th cycle as each elution fraction (Cl) 
contained more radioactive counts than the previous cycle. However, care must be 
taken in interpreting this as a positive result, the counts recorded were relatively low, 
not significantly above that of the control. Further rounds of SELEX gave less 
impressive scintillation counts and less apparent enrichment (see Table 4.1). 
Monitoring SELEX rounds 2-4 
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Figure 4.15: Scintillation results for SELEX rounds 2-4. Supernatant fraction A0, 
wash fractions Al -A4, B 1 -B4 and the eluted fraction Cl are shown against the counts 
per minute for three rounds. 
4.3.2 SELEX Counter Selection 
An important step during the SELEX process is that of counter selection, eased by 
target immobilisation. Counter selection was used to remove aptamers that bind Ni-
NTA beads after rounds 3, 6, 9 and 12. A 50pJ aliquot of alO% slurry of Ni-NTA 
beads, pre-equilibrated into PBS-T, was added to the ssDNA in PBS-T and incubated 
with mild agitation for 20 minutes. The beads were discarded and those aptamers 
contained in the supernatant were collected and used in the next round of selection. 
Similar counter selection steps were taken in cycles 5 and 10 against His-tagged ferric 
binding protein C, removing any aptamers that bind the hexahistidine residues. 
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Counter selection provides an opportunity to improve specificity of ligand binding. 
Counter selection steps against other 14-3-3 isoforms should ensure that successful 
aptamers were 14-3-3 ,y specific. 
4.3.3 Development of the Radiolabelling technique 
In their studies on selecting aptamers to VEGF, Green et al. incorporated a new 
radiolabel by having the 5' primer y-32P end-labelled after each selection round thus 
affording a labelled pool of ssDNA after each PCR step. End-labelling DNA is time 
consuming and involves separation using an acrylamide/urea gel, requiring patience, 
skill and using hazardous chemicals that it would be better to avoid. An alternative 
method was developed in which the labelling of DNA was carried out during the PCR 
step. [a-32P]-dCTP was added, to the PCR cocktail, affording radiolabelled cytosine 
to be incorporated into the aptamer pool during amplification, thus generating 
radiolabelled ssDNA. This procedure has the potential of saving time without 
compromising the integrity of the SELEX procedure. 
Cycle A4 B4 Cl 
1 20 16* 28 
2 39 20 125 
3 37 79* 181 
4 63 40 33 
5 22 22 28 
6 87 24 61 
7 36 25 78 
8 44 28 93 
9 33 20 28 
10 20 18 37 
11 22 19 28 
12 68 36 48 
13 18 23 20 
14 27 28 20 
15 39 22 33 
16 39 28 43 
Table 4.1: SELEX scintillation results. 
The Cycle number is shown along with the 
counts per minute from fractions A4 (wash 
4, low salt), B4 (wash 4, high salt) and Cl 
(eluted aptamer fraction). Fractions B4 for 
cycles 1, 2 and 3 used low salt buffer (*), as 
the conditions were deliberately gentle in the 
early stages. 	Care must be taken in 
interpreting these results as they are not 
significantly above the control. 
The results shown in Table 4.1 led to a revision of the planned SELEX procedure. It 
had been hoped that there would be an almost exponential enrichment of aptamers, 
shown by a continuous increase in the counts in the supernatant fraction Cl. What 
actually happened was that the counts in this fraction remained almost constant 
throughOut. Some of the apparent trends can be accounted for by the experimental 
protocol; the counts increase gradually from cycle 1 to 3 but then decline at cycle 4 
before gradually increasing again through to cycle 8. This may be accounted for by 
cycles 1 to 3 using only low salt buffer in the washing steps, whereas cycle 4 onwards 
introduced a further high salt washing step leading to more stringent selection. The 
recovered aptamer counts increase gradually again from 4 to cycle 8, after which no 
apparent trend was clear. The experimental volume/procedure used in cycles 4 to 8 
were identical, trying to enrich the library without tampering with conditions. By 
cycle 8, the recovered aptamer radioactivity in the supernatant was apparently again 
on the increase which was taken as an opportunity to introduce further stringency 
steps, and change the ratio of aptamer to protein. 	Up until cycle 8, the 
protein/aptamer ratio always had the protein molecules in a 10 molar excess but at this 
point things changed. 
During the SELEX protocol, it became clear that measuring the radioactivity in the 
supernatant was not giving useful results and those that were obtained may not have 
been entirely related to the concentration of ssDNA contained within the eluted pool. 
A factor could be that during the PCR, where the radioisotope was incorporated, only 
the cytosine residue was labelled and although perhaps this might be a small effect, 
the evolution may have been pushed towards cytosine deficient probes. 
The results obtained from radioactive monitoring indicate that the particular method 
used, in this case, does not give a good indication of the fraction of aptamers making 
it through each selection round. 
It is noteworthy that Murphy et al. chose not to monitor cycle by cycle but instead to 
clone a sample after 5, 10 and 15 cycles and check to see if SELEX was driving the 
library towards a consensus sequence. They found no enrichment after 5, modest 
enrichment after 10, and they stopped enrichment after 15 cycles. Many SELEX 
experiments have followed a similar idea of intermittent in vitro monitoring rather 
than step by step. 
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The SELEX method used was continued and from cycles 9 onwards, the 
concentration of ssDNA was also recorded pre and post selection by checking the 








9 16.8 0.00204 0.0121429 
10 12.4 0.00272 0.0219355 
11 4.91 0.00302 0.0615071 
12 1.68 0.001 0.0595238 
13 0.585 0.0123 2.1025641 
14 0.065 0.009 13.846154 
Table 4.2 and Figure 4.16: Absorbance results for SELEX cycles. The absorbance 
was calculated for ssDNA pre and post selection to allow calculation of the % of 
ssDNA retained after the washing steps. 
It is noteworthy that Vianini and co-workers report similar results to those obtained 
here in their process of selecting DNA aptamers to L-tyrosinamide.'62 They recorded 
the percentage of DNA recovered at the end of each cycle and found that as the cycles 
were manipulated, the percentage recovered were directly affected, similar to the 
results shown in Table 4.1. 
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4.3.4 Clone Analysis 
After eleven rounds, post PCR dsDNA was cloned and sequenced to analyse for a 
possible consensus motif The dsDNA obtained at the end of cycle 11 was subjected 
to PCR with primers "RS9979R" and "RS9981R". The DNA was purified and an 
aliquot of the aptamer pool dsDNA was ligated into pGEM T Easy vector, a TA 
cloning vector. The resultant plasmids were used to generate E. coli clones which 
were spread on S-Gal plates. Thirty-four positive colonies were picked, grown 
overnight and their DNA was extracted and digested with Pst I and Nco I. The 
restriction results are shown in Figure 4.18. 
Of the 34 clones, 14 contained an insert with the approximate size of an aptamer from 
the library (114 bp's). Each of these was sequenced using the pGEM forward and 
reverse primers. The sequence alignment of ten aptamers, those with readable data 
are shown in Figure 4.19. 
pGEM-T Easy Vector 
T7Trancription Start 
5'.. . IGTAA TACGA CTC WAG G3CGA ATTGG GCCCG ACGTC GCATG CTCCC GGCCG CcATG 
3'.. . AICATF ATGGT GAGTG ATAf C CCGCT TAACC CGGGC TGCAG GGT.AC GAGSG CCGGC GGTAC 
17 Fmmctr 	 I 	II 	II 	I 	I II 
Ape 	AarII 	SciiI £ZI 	Ncc'I 
GC3GC CGCGG GAATT CGATT3 'c!Qfl d inmrtj ATCAC TAGTG M1TC GCGGC CGCT GCAGGTCGAC 
CGCCG GCGCC CTTM GOTA \ 	J3'1T.TG ATCAC 1TAG CGCC GCOGA CGTCC AGGTG 
I 	III 	I 	 I 	II 	I' L2aI  
cII EcoRI SpI EcoRI 	 ' 	9d  
Betz I 
SPTrarciip1ion Start 
CATAT GGGA G AG OT CCCAA GGCGT TG GAT GCATA GCTTG AGTAT TG TAT IPIGTGT GACCT AMT. .. 3' 
GTATA CCCI CTCGA GTT GCGA ACCTA CGTAT CGAAC TGATA AGATA TGACA GTGGA TTTA.. .5' 
I 	I 	I II 	I 	 SP6 Promoter 
'deI Seal set X I 	NiI 
Figure 4.17: The promoter and multiple cloning site of pGEM-T Easy Vector. 
The dsDNA from PCR had A' overhangs allowing ligation into the T overhang 
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Figure 4.18: Digested cycle 11 clones. An aliquot of dsDNA was used after the 
completion of cycle 11 for SELEX analysis by ligating into a cloning plasmid then 
transformed allowing screening of plasmids. 34 clones were picked, 14 of the 
plasmids contain inserts around 120bp's, used for DNA sequencing. The marker is 








S11.11Rrc(603) GATANT-- T ITTGGAGNNTGAGGGA GGGAANGATTA TGAG( 
S11.lRrc(582)GAT TCC C TTTTTNGNATCCTTGG.GGN 
	
AGGA—GCCCTTGA TGAG( 
S11.12rrc(569) CAT T-- T 
	
TGGG:GGCATATCCNTTC TTTGTCGTCAA TGAG( 
S11.3Rrc(572) CAT T-- C_,_ GAATAZ\AT CCGTAGA/AC( 
	
GATGGC ---AA   TGAG( 
S1 1.2R rc (573) GAT T--C C TGNNNTNTNTNGACGGAA CTTTAGGTGAAAA TGAG( 
I S11.8Rrc(601) GAT T--GATC ACATACGAAGTAANNATGGTCGTTGTGICATGGAC TGAG( 
S11.9Rrc(584) GAT T--TTAG CCACATAGG GAATGGACATATAT GAT TAAGAGA TGAG( 
S11ARrc(593) GAT T--CAAG GCTT AATC CGATNAGNATAGGATGCGTTCACTGAG( 
S11.13Rrc(620) CAT T--CGA ANA. ATNG CCANGGCN NAGTTATATCCNCACNTGAG( 
S11.14Rit(650) GATA.TG4TCC CCTTCCAGAA. GGTT 	-JAA CCATNGAACCTGAG( 
connsus(680) GATACT A TC G TATG GA G G A AGAA 	TA 	ACTTGAG( 
Figure 4.19: Sequence alignment of cycle 11 clones. Alignment was made using 
the ClustalW algorithm, little conservation appears amongst the clones. The data 
contains a number of undefined residues. 163 
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As the PCR products could be inserted into the vector in either direction, sequencing 
of flanking regions around the 40 base randomised regions provided information of 
the aptamer direction, useful for alignment. The data presented from the cycle 11 
consensus in Figure 4.19, allowed a clone to be produced using what ClustalW 
interpreted to be a consensus pattern. The sequencing data contained many 
unidentified residues; however enough information was contained to test for 
enrichment. As discussed in Chapter 2, aptamers containing G-quartets are relatively 
common motifs from ssDNA SELEX, and indeed a couple of the clones sequenced 
contained G-rich sequences. However, taking the whole library into consideration, 
there was nothing to suggest that, guanine was being favoured over any other base in 
the selection process. It should be noted that successful T-rich libraries have also 
been produced so not having a G rich library is not necessarily indicative of a bad 
result. "5  
At this stage I elected to evaluate one of the sequences using SPR. The interaction of 
a cycle 11 aptamer with (His)614-3-3'y was examined using the starting library 
00977R as a control. SPR had already been used to evaluate antibodies against 14-3- 
3, thus substituting the antibody for an aptamer would provide a quick method for 
analysis. The clone S11. 11  contained the majority of the consensus motifs within, 
thus the consensus aptamer Si 1 was based largely on this particular clone. 
The sequence to be cloned for SPR analysis, named Si 1 is shown in Figure 4.20. 
The clone is similar to sequence S11. 11,  with unknown residues replaced by the 
consensus base. 
GATACT\TGCGTTTATGGAGGATTGACiGGAACiAAGGGAACTAGATTAC 
Figure 4.20: Aptamer Si!. The residues highlighted in red are those from the 
consensus motif, the green residues are the bases copied from the cloning vector and 
blue residues are engineered bases that were not contained within the original 
sequence Si 1.11. 
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The ssDNAs anticipated structure was computed using mfold software provided by 
Zuker and Turner. 164  The folded DNA structure (Appendix I) of the cycle ii 
aptamer was encouraging as the clone appeared to have the potential to adopt a 
definite tertiary structure. Successful aptamers have, in general, a strong folded 
structure similar to tRNA, and as such this clone was synthetically produced. 
Si 1 was compared against the starting library (00977R) using SPR (shown in Figure 
4.21). The analysis of this clone used a BiacoreX containing a Ni-NTA chip loaded 
with expressed recombinant 14-3-3 ' . This result suggests that by the end of cycle 
11, the aptamers selected, or at least the apparent consensus sequence represented by 
Si 1, shows an improved affinity towards the 14-3-3 y  which was an encouraging 
result as it showed that the selection was being driven towards aptamers that bind to 
the expressed 14-3-3 y.  The cycle ii clone has a definite early association as can be 
seen in the increase in response units from around 0 to 125 RU. The starting library 
shows no association to the 14-3-3 ? chip. The initial spike is related to the two 
samples being in different buffers. 
RU 	
Cycle 11 clone 
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Figure 4.21: Comparison of the cycle 11 SELEX (Si!) clone against the aptamer 
starting library. 
The flow rate was set to lOjil per minute and a 3 minute, lO.tM load was injected with either the 
starting library or with the cycle 11 clone (both had been heated to 95°C then cooled on ice pre-load). 
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With this result in hand, the decision was made to continue the SELEX approach until 
16 rounds had been completed. However after 16 rounds, there was no significant 
change in the amount of eluted radioactivity or of the concentration of ssDNA in the 
eluted fraction to suggest that SELEX should be halted at this point. If the results had 
suggested that at least 75% of the pool loaded was contained in the eluted fraction, 
this would have indicated saturated enrichment of the aptamer pool. 
The library pool used for sequencing was continued forward from cycle 11, not just 
those aptamers who had been cloned at that period. That is to say that the apparent 
consensus clone (S 11) even though showed promise, was not included in the further 
rounds and all the clones that had successfully completed the previous 10 rounds (or 
were evolved from clones that had) were given the opportunity to complete the 
SELEX process. 
At the end of the process, after the final PCR (using the non.-biotinylated 3' primer), 
124 "positive" clones were picked and grown overnight for further plasmid 
extraction/digest. Of the 124 clones, 112 contained an appropriate insert and were 
sequenced. Ninety two of these gave readable data. The sequence alignment is 
shown in Figure 4.22. 
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Figure 4.22: The sequence alignment of cycle 16 clones. Of 112 clones, 92 
returned with readable data. The sequence alignment performed by ClustalW. 
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Clone 
(S16-) A C G T N 
No. 
Bases 
1 4 5 17 11 37 
2 13 3 16 8 40 
3 8 6 13 13 40 
4 11 8 II 10 40 
6 12 10 7 12 41 
7 II 4 11 14 1 41 
8 7 5 18 11 41 
9 8 10 14 4 36 
10 8 5 15 11 39 
11 7 5 11 15 2 40 
12 12 8 15 5 40 
13 10 6 15 9 40 
14 8 9 11 12 40 
16 6 8 12 14 40 
17 12 4 18 6 40 
18 8 9 11 12 40 
19 6 13 10 11 40 
20 7 9 10 12 38 
21 11 4 17 8 40 
22 11 7 14 8 40 
23 14 5 9 9 3 40 
24 11 6 12 7 4 40 
25 11 4 11 15 41 
26 8 7 16 9 40 
27 7 1 12 4 5 29 
28 7 10 20 3 40 
29 10 6 14 10 40 
30 10 7 12 11 40 
31 9 7 11 13 40 
32 7 3 15 14 1 40 
33 8 7 11 14 1 41 
34 7 4 23 7 41 
35 9 7 16 8 40 
36 10 6 11 13 40 
37 10 3 10 17 40 
38 11 4 17 8 40 
39 6 6 10 14 4 40 
40 11 8 12 9 40 
41 10 7 10 12 39 
Clone 
(S16-) A C 0 T N 
No. 
Bases 
42 4 10 9 18 41 
43 8 6 14 12 40 
44 8 6 18 8 40 
45 13 5 12 9 1 40 
46 9 7 13 101 40 
47 9 10 8 13 40 
48 7 3 15 124 41 
49 13 8 10 6 37 
50 9 2 16 13 40 
51 9 10 9 12 40 
55 11 9 7 13 40 
56 8 7 15 10 40 
57 11 5 13 11 40 
59 13 4 14 9 40 
60 7 7 18 8 40 
61 13 14 6 7 40 
63 12 9 12 7 40 
64 9 8 9 14 40 
66 12 6 14 8 40 
67 7 10 8 14 1 40 
68 11 7 11 11 40 
70 5 8 13 14 40 
71 6 11 10 11 3 41 
72 6 12 9 13 40 
73 11 9 10 10 40 
74 8 5 10 17 40 
76 13 9 11 7 40 
78 11 6 13 10 1 41 
81 11 4 13 11 1 40 
83 11 6 9 6 32 
86 8 6 17 9 40 
87 7 6 17 10 40 
91 10 5 10 13 2 40 
92 13 7 6 14 40 
93 7 3 16 13 39 
95 12 11 11 5 1 40 
97 9 7 12 10 38 
707 514 956 801 39 3014 
23.7% 17.3% 32.1% 26.9%  
Table 4.3: Clones 1 to 97 with their ratio of nucleotides determined. 
Guanine is most abundant nucleotide, almost twice as common as cytosine in the final 
pool. The DNA sequencing was largely successful with very few unknown bases. 
This may be an anomaly however many ssDNA aptamers published to date contain 
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Figure 4.23: Phylogenetic tree of Aptamer sequences. The phylogenetic tree was 
built using the sequence distance method and the Neighbor Joining tree reconstruction 
algorithim, and displayed using Align X available on Vector NTI suite 9165  Branch 
lengths are proportional to the amount of inferred evolutionary change. 
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The sequence data obtained from the 92 clones indicated that the library was not 
being driven to a convergent sequence or even to a series of aptamer families. A 
comparison of the cycle 11 clones and those of cycle 16 would suggest that the library 
was perhaps even more divergent after further cycles. These facts, together with the 
indications of binding from the radioactive experiment were a cause for concern. 
However I had the opportunity to discuss the matter with Sergey Krylov, a visiting 
speaker at the University of Edinburgh. Krylov pointed out that many of his own 
results had led towards families of aptamers rather than towards specific motifs or 
quartet enrichment [private communication]. It was improbable that aptamers with no 
association with 14-3-3 managed to make it so many rounds of selection, when there 
were thorough and relatively harsh (1M NaCl) washing steps, along with counter 
selection steps that should eliminate any probes that bind the Ni-NTA or 
microcentrifuge tubes. 
The data presented in Table 4.3, shows what was once a completely random library 
(which should have roughly 25% of each nucleotide) was now a weighted library 
where cytosine residues (17.3%) had become less common, predominantly at the 
expense of guanine (32.1%). Comparing Table 4.3 and Figure 4.22 suggested that 
perhaps all sequences should not be aligned together and breaking the sequences 
down further into phylogenic groups, from Figure 4.23 might lead to more 
encouraging results. The T-rich tubulin specific aptamers described by Fukusaki et 
al. contain little sequence alignment. 114  They broke their sequenced into four 
families, T rich, G rich, G/T rich and other, neither family has a high degree of 
sequence analogy but they still managed to screen for an aptamer with a dissociation 
constant in the order of 10tM. In addition, Sayer et al. selected 12 aptamers to the 
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HIV-1 SU glycoprotein, gpi2O, all with an affinity in the order of iOOnM, most of 
which share little sequence convergence. 166 
A decision had to be made at this point; whether to continue the SELEX process or to 
attempt to pick out a 14-3-3 ' aptamer from the 92 member library. The fact that 
there was little sequence convergence militated against the first option. To analyse 
how cycle 16 aptamers associated with 14-3-3 y,  different experimental techniques 
were available. Surface plasmon resonance, ELONA and affinity purification could 
all be used to determine the most suitable aptamer across all applications. 
To carry out binding assays three points would have to be covered: (1) the clones 
would have to be synthetically produced; (2) truncation: including the flanking 
regions, aptamers would be around 65 bases long, making perhaps unnecessarily 
costly probes, thus where to truncate the aptamer would be important and (3) a tag 
would be necessary for ELONA and affinity purification. 
For a trial of cycle 16 aptamers, aptamer S16.1 had its invariant region synthetically 
produced untagged, for analysis by SPR. As a cycle 11 consensus clone had been 
previously synthesised, the first experiment that was set up was to see if there was 
enrichment during the final five cycles. 
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Figure 4.24; Comparison of the cycle 11 consensus clone (Sil) versus S16.1. 
Again the consensus Si I clone gives a response around 150 RU whereas the cycle 16 
clone shows an initial association of 400 RU, increasing to 550 RU over 180 seconds. 
Figure 4.24 shows a positive result, however this does not necessarily reflect an 
enrichment. Si 6-1 is not related to the cycle 11 clone through enrichment, it was a 
completely different clone that was being analysed. The definitive result coming 
from Figure 4.24 is that there is a definite association event happening when both 
aptamers are passed down the Biacore, containing the immobilised 14-3-37. The next 
logical step would be to see if the response is concentration dependant. S16-1 (16 
cycle-clone 1), was diluted to range of concentrations and equal volume aliquots were 
passed across the flowcells. Results are shown in Figure 4.25. 
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Figure 4.25: Cycle 16 Clone 1 concentration analysis. Clone I (S16-1), was 
analysed using 5 different concentrations to see if the response was concentration 
dependant. The I OtM sample was carried out in duplicate to show that that the 
results were repeatable. The clone gave concentration dependant responses against 
the 14-3-3 ,y. 
Figure 4.25 shows that SPR of different concentrations of S16.1 leads to 
approximately concentration dependant curves. The 1OM clone was carried out in 
duplicate to prove that results were repeatable. The figure leaves some outstanding 
questions regarding the kjk0ff of clone S16-1. All clones have an initial association 
event, followed by a gradual decline in the response difference. This would suggest 
that this particular aptamer "recognises" 14-3-3 i  however is not showing any 
strength of binding to the 14-3-3 protein. Again spikes in the curves are related to the 
difference in buffer between the running buffer used and the aptamer solution. 
With the two previous figures in mind, trial aptamer S16-1 gave encouraging results 
using SPR thus the decision was made to synthesis more of the sequenced cycle 16 
aptamers for further analysis. 
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With so many different sequences contained within the library, and no conserved 
motif, the next difficulty was to find which of the clones had the apparent best affinity 
to 14-3-3 y.  The decision was made to produce twenty of the 92 sequenced clones for 
further analysis. 
There is a problem associated with using truncating aptamers. It was decided to 
truncate to the randomized 40 region, a decision that could prevent aptamers folding 
into the relevant 3-D structure, an unavoidable risk due to cost. 40 bases provided 
scope for tertiary structure, the theophylline aptamer contains 15 nucleotides, so 40 
provided enough room for the relevant structure to form. 
The truncated aptamers were 5' biotinylated, the tag is necessary for further 
experiments, however there is the problem that the modification may cause steric 
hindrance to the epitope. The modification is unlikely to enhance the binding but it is 
a real possibility that the bulky biotin group could block it. 
A cost and time problem was posed with regards to which of the 92 clones should be 
further analysed for 14-3-3 association. The first 20 clones were produced for 
analysis by SPR, and those that gave promising results were synthesised with a 
modification for further analysis by ELONA (enzyme linked oligonucleotide assay). 
If more time had been available then instead of simply truncating all aptamers to the 
initial randomized 40 bases. 
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4.4 Cycle 16 Clone Analysis by Surface Plasmon Resonance 
All experiments were carried out using a Ni-NTA chip that had been preloaded with 
1433? 
An experiment was devised to analyse the impact of the biotin tag on the SPR result. 
Clone S16.1, produced with and without a biotin tag attached, had 1 0iM, 60.il 
injections were compared. Untagged S16.1 gave a large response difference, around 
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Figure 4.26: S16-1, Biotinylated comparison. The unbiotinylated S16-1 (red) and 
biotinylated S16-1 (blue) response compared using SPR, both ran at 1 Oj.tl, 60p1 
injections. 
Figure 4.26 shows that biotinylation of the clone S16-1 significantly alters the SPR 
response. Unbiotinylated S16-1 shows a definite recognition event with weak 
binding, biotinylated S16-1 gives no association event. Although this may have 
appeared disappointing, it was inevitable that biotinylation of some probes would lead 
to poor results using a specific assay. 
8  The running buffer used was PBSM, the washing buffer used in between injections was glycine (as 
had been successful in the previous antibody study). The temperature was maintained at 25°C, and 
unless otherwise stated, the flow rate was kept at lOtlImin. All aptamer samples were heated to 95°C 
for two minutes and cooled on ice before application. The concentration of the aptamer solution will be 
shown. 
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Figure 4.27; SPR of biotinylated aptamers. The result of passing five of the 
biotinylated aptamer sequences across the 14-3-3 loaded Ni-NTA chip is shown. 
Each aptamer is shown in the legend. 
Biotinylated cycle 16 aptamers were providing poor responses using SPR. From 
Figure 4.27, each aptamer has some sort of immediate association, however the curve 
suggests that there is no binding event and the aptamers are quickly washed from the 
immobilised protein. 
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4.5 Aptamer characterisation using Enzyme Linked Assay 
4.5.1 ELISA 
The enzyme linked immunosorbent assay was developed in 1971 for the simple and 
rapid measurement of a variety of analytes with exceptional specificity and 
sensitivity. '36 ELISA's are commonly used in a sandwich assay format, requiring the 
use of 2 antibodies or binding proteins that bind the analyte at the same time. The 
capture antibody is immobilised on a surface, the detection antibody is coupled to an 
enzyme compatible with the desired method of detection. The term sandwich assay is 
relevant because the analyte is sandwiched between the two antibodies in the system. 
ELISA is one of the most frequently used techniques for affinity analysis using 
antigen-antibody interactions, although it is not suitable for kinetic analysis. 
Before attempting the interaction of an aptamer with 14-3-3 'y using a sandwich assay 
(ELONA, see below), an ELISA using 14-3-3 and antibodies was set up to prepare a 
protein standard curve (shown in Figure 4.28). Recombinantly expressed 14-3-3 ' 
was subjected to serial doubling dilutions from a 4000tg/ml standard using unspiked 
buffer as a background control, 1 OOpi added to each well. Following this incubation, 
the plate was washed with a 96 well plate washer using a wash buffer. The wash 
program directed six 200p1/well wash cycles with 30 second soak periods between 
washes. During the soak period the plate was agitated. K-19 anti-14-3-3 antibody 
(rabbit polyclonal IgU) diluted 1:1000, 50jil was added to each well, incubated for 1 
hour, before a further washing step followed by addition of 50p1 goat anti-rabbit HRP 
conjugate antibody, diluted (1:10 000), which was allowed to incubate for 1 hour. 
The plate was subjected to a further washing step before addition of 3,3,5,5 
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Tetramethylbenzidine (TMB) substrate, incubated for 15 minutes, and the reaction 
was quenched with the addition H2SO4 and the absorbance at 450nrn measured. 
His 14-3-3 ELISA 
3.5 
0.0001 	0.001 	0.01 	0.1 	1 	10 
Protein Conc. mg/mi 
Figure 4.28: The 14-3-3y ELISA standard curve. Curve prepared using doubling 
dilutions of 14-3-3 y in triplicate. K19 antibody used in analysis. 
4.5.2 ELONA 
The enzyme linked oligonucleotide assay (ELONA), first described by Drolet et al. is 
a rapid assay that can give the relative binding abilities of the aptamers to protein, 
based on the sandwich ELISA. 137  The precision, specificity and accuracy of Drolets 
method are similar to those of a typical enzyme linked assay (ELISA). Typically the 
ELONA assay has a theoretical minimum detection limit of 25pg/ml (protein to be 
detected). ELONA has been used for a number of aptamer targets including 
cytokines,'67 ricin toxin,'68 kinetoplastid membrane protein- li (KMP- 11), 
169  TTF 1 ,' 
and C595,'7° (an anti-MUC1 monoclonal antibody). 
The 143-3y assay was set us as a typical sandwich enzyme linked assay. The anti 14-
3-3 antibody K-19 was used as the microtitre plate bound capture reagent to 
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immobilise 14-3-3 y in a 96 well plate. Addition of the biotinylated aptamer was 
followed by addition of a streptavidin fusion with horse radish peroxidase (HRP). 
The amount of bound HRP was then assayed colorimetrically by addition of o-
phenylenediamine dihydrochioride (Drolet's work used a fluorescein labelled aptamer 
and Alkaline phosphatase (AP) conjugated anti-fluorescein FAb fragments). The 
ELONA was carried out in triplicate using doubling dilutions of the aptamer. The 
protein concentration was maintained at 0.5mg/mi. 
Using ELONA we could screen all synthetically produced biotinylated aptamers, 
allowing comparison of their apparent association. From the protein standard curve in 
Figure 4.28, the minimum dilution of 14-3-3 necessary for maximum response was 
0.5 mg/mi. A 96-well plate was coated with capture antibody K-19 and subsequently 
50pJ of (His)614-3-3 y (0.5mg/mi) was added. The biotinylated aptamer was added9 
and incubated at 37°C for 2 hours followed by addition of a streptavidin-HRP 
conjugate enzyme. Similar to the ELISA, the amount of bound HRP was then 
assayed. 
ELONA clone Analysis 
2- 
Clone S16- 
Figure 4.29: Analysis of 10 different SELEX clones by ELONA. All samples were 
at a concentration of 20.tM. 50p1 of each was added to each well. Experiments were 
conducted in triplicate. 
9 All aptamers heated to 95°C for 5 minutes and cooled on ice before addition. 50111 of 1011M 















Clones S16-1 and S16-8 appear to have the greatest responses using this ELONA 
method. Ten clones are not represented in Figure 4.29 because they had an affinity 
lower than the set threshold. 
Following from the results obtained in Figure 4.29, the three best ELONA aptamers, 
(S16-1, S16-2 and S16-8) were used to characterise quantitatively immunocomplex 
formation. K-19 capture antibody coated to the 96-well plate was used to immobilise 
(His)614-3-3'y allowing a saturation curve to be obtained. The relative saturation, i, is 
displayed as a function of the aptamer concentration. To determine the Kd of the 
interaction between aptamer and protein, a linearization method was followed.'71  
Following the work of Liliom and that of Orosz the KP were calculated. 
172  The 
K, the apparent dissociation constant of the immunocomplex, can be obtained from 
the reciprocal slope of the plot 11(1-i) vs. Aptt0t/i where Apttot is the total 
concentration of aptamer. 
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Figure 4.30: ELONA saturation curve. The relative saturation against the aptamer 
concentration is shown. 
Table 4.4: 	The 	of selected cycle 16 aptamers. 	The three most promising 
ELONA aptamers were selected for further analysis, their saturation curves allowed 
calculation of the apparent K. 





4.5.3 14-3-3 Isoform analysis using ELONA 
Following on from the work where the best (His)614-3-3y aptamers were selected and 
their Kd calculated, the two aptamers showing with the lowest Kd, S16-8 and S16-2, 
were used for further analysis to compare the aptamer response with respect to the 
different 14-3-3 isoforms. Antibody K-19 was coated onto a 96 well plate and used to 
capture 14-3-3 proteins, all proteins were loaded at a concentration of 100iM. The 
aptamers were used to complete the 14-3-3 "sandwich" allowing detection, the 
aptamer concentrations were fixed at 1 Oj.M. 
Isoform S16-8 S16-2 
His Gamma 2.472 0.441 
GST Gamma 2.047 0.441 
Zeta 1.886 0.47 
Beta 2.091 0.409 
Sigma 1.902 0.384 
Tau 1.925 0.396 
Eta 2.184 0.511 
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Figure 4.31: Comparison of the different 14-3-3 isoforms by ELONA. The S16.8 
clone gives a significantly greater response to all the isoforms than the Si 6-2 clone. 
Aptamer S 16-8 consistently gives a higher response than the S 16-2 clone. It gives the 
greatest response against his tagged 14-3-3 y  but it also interacts with other isoforms 
in the 14-3-3 family. 
To ensure that the secondary antibody was not responsible for the results, a further 
control experiment was set up to analyse this. A 96 well Immulon 4HBX 96 well 
plate was coated with K-19 capture antibody overnight. The plate was then blocked 
with 5% BSA and washed thoroughly before addition of the protein samples (4jig 
protein added to each well). The plates were washed, aptamer S 16-8 (50j.il, 100pM) 
was added to wells 1-3/A-H, and all other wells had buffer added. After 1 hour 
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incubation, the secondary antibody was added to all the wells and ELONA procedure 
carried out. 
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C 0.061 0.050 
D 0.068 0.051 
E 0.064 0.050 
F 0.066 0.048 
G 0.066 0.048 
H 0.072 
Figure 4.32: Comparison of 14-3-3 isoforms with aptamer S16-8 in sandwich 
enzyme assay. 14-3-3 7 gives the greatest response however all isoforms give 
measurable responses above background. 
The results from Figure 4.32 indicate that aptamer S16-8 is detecting all 14-3-3 
isoforms and it is not the secondary antibody responsible for results, nor is S16-8 
forming a complex with the 96-well plate. This means that the previous ELONA 
studies can be regarded as being solely due to the interaction of aptamer and protein. 
Similar to the ELONA study against all 14-3-3 isoforms, the (MS)614-3-3y shows the 
greatest response using this method of protein detection. 
S16-8 was the best aptamer using the ELONA method. Other techniques were used 
to determine if S16-8 was as robust using alternate assays. The interaction of 
different 14-3-3 isoforms with S16-8 was analysed further. 
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4.6 Protein Blot Analysis with Aptamer S16-8 
The interaction of S16-8 with all seven human 14-3-3 isoforms was also analysed by 
protein blot analysis. Protein samples, all 2ig, were prepared for SDS page by 
boiling in Llamealli sample buffer then separated electrophoretically on a 4-12% Bis-
Tris gel. One gel was stained with GelCode blue, the second had its proteins 
transferred to a PVDF membrane, and was subsequently blocked overnight at 4°C 
with 5% BSA. The membrane was probed with biotinylated S16-8 diluted to 100 jtM, 
in 1 Omi of PBS-T, before treatment with streptavidin-HRP (1:10 000) in PBS-T. The 
membrane was thoroughly washed before addition of ECL plus (Amersham 
Biosciences) western blotting detection system and imaging on a HyperfilmTM MP 
film. The results are shown in Figure 4.33. 
S16-8 bound to all 14-3-3 isoforms, but not to the His-tagged GST used as a control 
was not illuminated by this method of detection. The surface plots 10  can be used to 
determine the ratios of peaks to each other. The Western blotted surface plot suffers 
from high background although data can still be obtained. The most significant point 
may be that there is no peak is shown for His-tagged GST protein in the western 
surface plot. The Western image suffers from high background levels, even though 
the membrane was blocked thoroughly with BSA. 
'° Surface plots carried out using ImageJ 1.36'°  
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Figure 4.33: Protein blot analysis of different 14-3-3 isoforms with S16-8. The 
GelCode stained (A) and the Western blotted membrane (B) and the corresponding 
surface plots (C) and (D) are shown. 
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47 Gel Filtration Analysis 
Gel filtration analysis of the interaction of (His)614-3-3y with S16-8 could provide 
data regarding the binding of the two species. Analysis of spectra could provide 
details regarding if the aptamer binds to each monomer unit in the dimer or just one. 
Recombinant 14-3-3 y  added to aptamer S16-8 was passed down a gel filtration 
column (16 60 SuperdexTM 75 (Amersham Biosciences)) to analyse for a binding 
species. 
For controls, 25pl  of 14-3-3 (14.2 mg/ml) added to 975tl Tris HC1 pH 7.5, NaCl 
(0.15M) (running buffer), (A) and passed down column, the other control had 25p.l of 
100M S16-8 made to 1 ml with running buffer (B), passed through the same column. 
To analyse for binding between the two species, 25tl protein, incubated with 25tl 
100tM S 16-8, was made to 1 ml with running buffer (C). The solution was incubated 
with gentle agitation overnight and ran on the same gel filtration column, using the 
same programme as both controls. Results displayed in Figure 4.34. 
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The chromatograms observed in Figure 4.34 did not provide the results that were 
hoped for. The protein peaks in the 14-3-3 control were eluted at 40 ml for the dimer 
and 46 ml for the monomer unit. It was hoped that after addition of the aptamer to 
14-3-3, the peaks would shift suggesting the addition of a 12kDA unit (the mass of 
the aptamer). Analysis of the protein/aptamer led to the conclusion that the protein 
peaks had shifted but to smaller peaks. The peak previously observed at 58kDa 
(representing the dimer unit) had shifted to representing a smaller mass particle. The 
monomer peak was also shifted in the direction to represent a smaller mass particle. 
The result of the chromatograms, comparing the timing of the peaks, suggest that the 
3 peaks shown in image C relate to the monomer and dimer units of 14-3-3 (from A) 
and of free S16-8 aptamer (from B) and not, as had been hoped, from a binding 
species. 
To try to understand this result, textbooks explaining the gel filtration technique have 
been studied, although no comparison of this result have been found to date. The 
result observed for the protein/aptamer shift remains unanswered and requires further 
analysis. 
127 
4.8 Affinity Purification 
To analyse the interaction between proteins and their specific antibodies, 
immunoprecipitation, a form of affinity purification can be used to rapidly separate 
proteins from plasma and whole cell lysates. 
The method can be adapted to use an aptamer to purify a protein instead of the 
antibody. Aptamer affinity purification has is used in a number of systems including 
the StreptoTag system, a neat method for isolating RNA binding proteins, and aiding 
purification of 48S, a translation initiation complex. 
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To analyse 14-3-3 interaction, 10[d of biotinylated 1 Oj.iM S16-8 (heated to 95°C for 2 
mins then cooled on ice for 5 minutes) was added to 50pl of homogenised mouse 
brain, and the resultant solution was agitated gently for 1 hour at room temperature. 
Subsequently, magnetic streptavidin beads were added and the unbound protein was 
washed from the immobilised aptamer. The immobilised fraction and the wash 
fractions were collected, denatured by boiling in Llaemmeli buffer, then resolved on a 
4-12% Bis-Tris gel (Invitrogen), and either stained with GelCode Blue (Pierce), or 
transferred to PVDF for use in Western blotting. 
A similar experiment was set to check if the aptamer could associate with 14-3-3 in 
CSF, iOpJ of iOiM biotinylated S 16-8 was added to 100 jil of Ovine CSF pre-spiked 
with recombinantly expressed 14-3-3 'y.  Again the gel was either stained with 
GelCode blue or transferred for Western blotting. 
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Mouse Brain Homogenate 









Figure 4.35: The Mouse Brain Homogenate immunoprecipitation reaction. MBH 
(mouse brain homogenate), S(supernatant), wash fractions 1 to 5 (WI to W5) are 
shown along with the aptamer/immunoprecipitated fraction I. The marker (M) is 
shown on the left. The red circle highlights a barely visible band for 14-3-3. Gel 
stained with GelCode Blue. 
Spiked Ovine CSF 











Figure 4.36: Ovine cerebrospinal fluid spiked with 14-3-3 immunoprecipitation. 
Lanes as follows: Unspiked ovine CSF -(CSF), recombinant (His)614-3-3' -14-3-3, 
the spiked CSF supernatant (S), wash fractions WI to W5) along with the 
aptamer/immunoprecipitated fraction- I. Gel stained with GelCode Blue. 
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The Western blot of the spiked ovine CSF purification and the purified mouse brain 
homogenate are shown in Figure 4.37. The anti 14-3-3 antibody K-19 was used for 
detection. 
MBH 	 Spiked Ovine CSF 









Figure 4.37: Western Blot amalgamation of the affinity purified mouse brain 
homogenate and spiked ovine CSF. The corresponding untransferred gels stained 
by GelCode blue are shown in Figures 4.35 and 4.36. Red circles highlight 14-3-3 
contained in the immunoprecipitated fractions and thus the aptamer can successfully 
and specifically pull 14-3-3 from CSF and from mouse brain homogenate. The same 
abbreviations are used as that in Figures 4.35 and 4.36. 
The circled bands in both Figure 4.35 and Figure 4.36, indicate a band slightly visible 
to the naked eye on the gel, however less apparent upon scanning on the gel. Both 
were extracted from the gel, digested by Trypsin (Trypsin sequencing grade, bovine 
pancreas, Roche) and analysed by MALDI-TOF MS. Figure 4.37, the Western blot 
amalgamation of 4.35 and 4.36 is a clear indication that clone S16-8 successfully 
130 
affinity purified 14-3-3 from mouse brain homogenate, and recombinant 14-3-3 ' 
spiked into Ovine CSF. The analysis confirmed that both were 14-3-3 proteins as was 
expected. The band around 50kDa was treated to the same analysis, it was found to 
be albumin. MALDI-MS data for the 14-3-3 protein and the albumin protein are 
contained in Appendix II. 
131 
4.9 Scrapie CSF Analysis 
CSF from Scrapie infected sheep was obtained from H. Baxter. Scrapie is detectable 
using 14-3-3 as a surrogate marker. 175 
Scrapie sample F125 was analysed for 14-3-3 content using electrophoresis to 
separate proteins then staining or western blotting of the gels for visual analysis. The 
stock sample was subjected to seven doubling dilutions, from neat, to analyse what 
the minimum dilution necessary to visualise a 14-3-3 band. 20p1 of each was boiled 
and then ran on gel, shown in Figure 4.38. The antibody used in the western blotting 
was K-19 (Santa-cruz). The figure shows in both stained and blotted images, that 14-
3-3 (circled red) is slightly visible in the neat fraction but in no other samples. The 
large band around 64kDa, was cut from the stained gel, treated to tryptic digest and 
subsequent MALDI-TOF. The result of which suggested the band related to Ovine 
serum albumin. 
Aptamer S16-8 10tl was added to Scrapie fraction F125, the solution was mixed 
overnight before the solution was subjected to the standard affinity purification assay. 
Collected wash fractions and the purified fraction were run on a Bis-Tris gel and 
either stained with GelCode blue or transferred to a membrane for Western blotting. 
The western blotting gel used the antibody K-19 as the detection agent. The stained 
gel and the blotted membrane are shown in Figure 4.39. All bands observed in the 
stained gel were excised and analysed with tryptic digest MS. The band around 
60kDa was ovine serum albumin, 28kDa was 14-3-3 protein, and lOkDa was a 
streptavidin related protein (data shown in appendix III), presumably obtained in the 
process of removing the bound aptamer, involving boiling the streptavidin beads. 
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Figure 4.38: Analysis of Scrapie fraction F125. Numbered lanes indicate the 
diluted fractions of fl25. 1-neat, 2-diluted '/2, 3-diluted ¼, 4-diluted 1/8, and so forth. 
M indicates the marker lane. Red circles highlight the lightly visible band 
corresponding to 14-3-3 protein. Relevant bands were excised from the stained gel 
and their composition analysed by tryptic digest MS, fingerprinting observed using 
the SwissProt search engine. 








Figure 4.39: Scrapie affinity purified 14-3-3 protein. The GelCode blue and the 
Western blotted membrane are shown. Lanes are as follows; M-marker, E-eluted 
fraction, W4 and WI- wash fractions 4 and 1, and S-supernatant fraction. 14-3-3 can 
be shown as the band above the 28kDa marker. The prominent band below l4kDa 
was checked by tryptic digest MALDI-TOF, it was a streptavidin related product. 
Aptamer S16-8 was successful in concentrating 14-3-3 protein in scrapie positive 
ovine CSF. The probe could be used to aid detection of neurodegenerative disease in 
aTSE. 
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4.10 Summary, conclusions and suggestions 
In this thesis I have described the selection of members of a randomised 40 base 
oligodeoxynucleotide library as affinity ligands for human 14-3-37, the demonstration 
that some of these do have micromolar binding affinities for this target and to other 
14-3-3 isoforms and that at least one of these can be used to selectively bind wild type 
14-3-3 protein(s) in mouse brain homogenates and ovine scrapie CSF. 
The preliminary steps in the project required construction of a modified gene for the 
N-terminal (His)6 clone of 14-3-37 and expression and purification of the tagged 
protein, and the synthesis of a oligonucleotide library containing ca 10 5 different 
molecules by solid phase synthesis. The choice of N-tagging rather than C-tagging is 
noteworthy. Currently the better antibodies for 14-3-3 immunoassay are those raised 
against N-terminal epitopes which is a region which has a large degree of sequence 
homology across the family. It could be argued that using a N-terminal tag places 
might occlude this region by placing it close to the resin and allow preferential 
selection of ligands specific for other regions of the protein. Gratifyingly, as discussed 
in Chapter 4, at least one of the selected oligonucleotide ligands (S 16-8) bound to 14-
3-37 without perturbing K19 antibody binding to the same protein molecule. 
The SELEX process used here was adapted from, and combined techniques from, 
earlier work in the field. Immobilisation of the target protein to a resin (in this case a 
nickel resin) allowed unbound aptamers to be washed out and concentration of the 
bound aptamers. Molecules with an affinity for the resin or the his tag region of the 
protein were screened out by counter-selection. The SELEX process was monitored 
by incorporation of radioactivity and this allowed monitoring on a cycle by cycle 
basis. Basically this was adapted from the approach used by Fitzwater and Polinsky 
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but here I incorporated the radioactivity during the PCR step which is safer and 
quicker. 176  The use of resin—based selection, rather than the membrane immobilization 
system used previously, allowed measurement of the radioactivity by scintillation 
counting. 67, 160 
Since the genes for all seven of the human 14-3-3 isoforms are available it would 
have been possible to have built in a counter-selection step to screen out forms 
binding to isoforms other than 'y.  Since the eventual aim of the study was to enable 
detection of elevated 14-3-3 in diseased tissue and not that of one isoform specifically 
this was not considered worthwhile. Indeed, in the current protocol for vCJD 
diagnosis by detection of 14-3-3 in CSF by western blotting with antibodies, the 
levels of 14-3-3 involved are ca 3.l±2.9ng/ml which is lower than that found in ovine 
scrapie and lies at the limit of antibody detection. For this reason an oligonucleotide 
probe with some affinity for all the 14-3-3 isoforms would be preferred. However it 
should also be noted that the process could have produced a 'y-isoform specific ligand 
even without counter-selection. Two groups have managed to select aptamers which 
bind to PrPC  and not to PrPSC  without using a procedure involving a counter-selection 
step.'77"78  Here is should be noted that these proteins have identical sequences but 
differ in conformation. Another well-cited example is that of the L-arginine specific 
aptamer described by Geiger et al. 179  This aptamer was selected without counter 
selection for D-arginine but binds has 16,000 fold higher affinity for the L-isomer. 
Although there were preliminary indications of sequence convergence after 10 cycles, 
the hundred oligonucleotides selected and sequenced after sixteen cycles of the 
SELEX procedure had very divergent sequences. However twenty of these 
sequences, which were all synthesized as biotinoylated probes, bound to 14-3-3 y  with 
Kd'S in the lO 5-10 7M range. Just why no convergence is evident is unknown. The 
135 
possibility that the library synthesis was biased enough to have a meaningful effect is 
unlikely. It could be argued that continuing the SELEX for several more cycles and/or 
using more stringent washing conditions could have seen the emergence of some 
consensus. However the lack of similarity between the candidate sequences after 
sixteen cycles suggests no clustering into 'families' and this suggests that more cycles 
would only have cut down the number of ligands without necessarily resulting in the 
emergence of one or two very high affinity types. A possibility which seems likely is 
that this protein has no single overwhelmingly attractive site for ssDNA binding and 
that we are observing several series of aptamers which dock in just slightly different 
conformations to a variety of sites. Ultimately only structural studies for example by 
X-ray crystallography or NMR will be able to throw light on this aspect. I had the 
opportunity to discuss this with Professor Krylov at the conference and he indicated 
that the phenomenon of a 'library' of DNA (or RNA) ligands with no striking 
sequence homology had also occurred in his laboratory. 
In this work only a few (20%) of the possible aptamers have been evaluated for 
binding and the aptamer-protein interactions of only a few of these have been 
characterised further. S16-1 and S16-8 both proved to be non-selective for the y-
isoform and were shown to bind (albeit slightly less strongly) to other 14-3-3 
isoforms. This justifies, to some extent, the decision not to include counter-selection 
steps in the SELEX procedure. The best 14-3-3 ligand examined so far, S16-8, has 
proven to bind wild type 14-3-3 in both brain homogenate and ovine scrapie CSF 
although in the latter case it also appears to show some binding with high molecular 
weight material which also interacts with the 14-3-3 antibody, K-19. The reason for 
this is unclear and this will have to be examined further. 
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The results obtained in this project lay the foundation for future development of 
assays for 14-3-3 in the diagnosis of neurodegenerative diseases. The S16 library 
prepared in this work may prove a valuable source of ligands which can be developed 
as tools for investigation of protein-DNA interactions and of non-antibody based 
diagnostic 14-3-3 assays. 
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Appendix I: Structural Comparison of CLONES 
Questions posed by this study are (a) why do the selected aptamers interact with 14-3-
3 proteins? (b) Why different aptamers show different association to 14-3-3 proteins? 
The answer to both questions may be related to the tertiary structure adopted by each 
aptamer species. The tertiary structure can be obtained by either analysing the X-ray 
crystal structure of the protein/aptamer complex, or the NMR result observed for the 
complex. Ideally the interaction of S16-8 with (His)614-3-3i could have been 
analysed using either method. 
A possible secondary structure for ssDNA folding can be anticipated using the mfold 
algorithm and as such, the structures of the two best aptamers, S16-8 and S16-1 had 
their possible secondary structures computed (shown in Figure I). 
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Figure I: Aptamer S16.1 and S16.8. The folded S16.1 (A) structure has a dG -1.53 
kcallmol and was the aptamer used in the above SPR analysis. S 16.8 (B) was a clone 
that consistently showed promise in the aptamer linked enzyme assay dG - 
1. 12.kcal/mol. 
The actual secondary structures may differ from those presented. There may be a 
number of weaker stabilising interactions, not considered by the miold algorithm that 
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relies heavily on Watson-Crick pairing when calculating the secondary structure of 
ssDNA. Sequence S 16-land S 16-8 look to provide scope for G-quartets although of 
all possible mfold structures, none contain that motif. The algorithm used in mfold 
does not allow for g-quartets. 
S 16-1; agcg ccgg tggt ggtg gggg ttgt tacg cggt atta t. 
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Fig II: A diagrammatical representation of aptamer 
S16-8 forming a g-quartet structure. The g-quartet is 
highlighted in red, is to emphasise one of many possible 
secondary structures. 
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While analysing the cycle 16 sequencing data, an aptamer not synthetically produced 
for further analysis, stood out due to its high guanine content. Sequence 5 16-28, looks 
to potentially provide a g-quartet structure although this is not suggested by the mfold 
algorithim The structure that is predicted, does still had a strong secondary structure 
however (dG -6.57 kcallmol). 
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Figure III: The mfold predicted structure for S16-28 and diagrammatical 
representation of a possible G-Quartet structure. The structure has a dG - 
6.57kcal/mol, and a more definite structure than S 16-1 and S 16-8. 
The example of S16-28, provides the kind of result that hoped for at the start of the 
SELEX process. S 16-8 is not however, is not representative of the remaining aptamer 
pool in general and was perhaps undeserving of additional attention. The SELEX 
process had dictated which aptamers were to be successful and all those collected at 
the end of cycle 16 have a realistic chance of having the best association to the 
expressed 14-3-3i. Trying to second guess what aptamers may be best from a 
probable structure was unlikely to yield profitable results. A far more effective 
method was likely to be finding out binding by SPR or by ELONA. 
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Appendix II - Tryptic digest MS Data 
Analysis of the bands removed from the MBH affinity purification and the scrapie 
affinity purification led to the following results. 
Database searched: SwissProt.200406 
Molecular weight search (1000 - 100000 Da) selects 187433 entries. 
Full p1 range: 198834 entries. 
Combined molecular weight and p1 searches select 187433 entries. 
MS-Fit search selects 2933 entries (results displayed for top 15 matches). 
Result Summary 
5.56e+007 	12/98(12%) 	69188.7 / 5.80 SHEEP P14639 Serum albumin 
precursor 
2 	1.21e+005 	8/98(8%) 	69293.9 / 5.82 BOVIN P02769 Serum albumin 
precursor (Allergen 	Bos d 6) (BSA) 
3 	3.72e+004 	8/98(8%) 	80364.1 /5.97 MOUSE 	09D6Y9 	1,4- 
alpha-glucan branching enzyme (Glycogen branching enzyme) (Brancher enzyme) 
4 	2.21 e+004 	9/98(9%) 	99428.2 / 4.95 RAT 035550 Rab GTPase-binding 
effector protein 1 (Rabaptin-5) (Rabaptin-5alpha) 
5 	2.2e+004 	9/98(9%) 	99552.4 / 4.97 MOUSE 	035551 Rab GTPase- 
binding effector protein I (Rabaptin- 	5) (Rabaptin-Salpha) 
Detailed Results 
1. 12/98 matches (12%). 69188.7 Da, p1 = 5.80. Acc. # P14639. SHEEP. Serum albumin precursor. 
Database searched: SwissProt.200406 
Molecular weight search (1000 - 100000 Da) selects 187433 entries. 
Full p1 range: 198834 entries. 
Combined molecular weight and p1 searches select 187433 entries. 
MS-Fit search selects 2933 entries (results displayed for top 5 matches). 
- 	Result Summary 
1 	6.09e+006 	11/82(13%) 	28252.7 / 4.80 BOVIN P68252 14-3-3 protein gamma 
(Protein kinase C inhibitor protein 1) (KCIP- I) 
6.08e+006 	11/82(13%) 	28302.7 / 4.80 RAT 	P61983 14-3-3 protein 
gammagiI48428722spP6 1 982 1433G_MOUSE 14-3-3 protein gammagi4842872 fl 
spP61981I1433G_HUMAN 14-3-3 protein gamma (Protein kinase C inhibitor protein 1) 
(KCIP-1 )gi68565 1 33spQ5RC20 l433G_PONPY 14-3-3 	protein gamma 
3 	5.78e+005 	10/82(12%) 	28230.7 / 4.84 CHICK Q5F3W6 14-3-3 protein 
gamma 
4 	9.23e+004 	9/82(10%) 	28244.7 / 4.80 XENLA 06NRY9 14-3-3 protein 
gamma-13 
5 	9.22e+004 	9/82(10%) 	28273.7 / 4.80 XENLA O6PCGO 14-3-3 protein 
gamma-A 
Detailed Results 
1. 11/82 matches (13%). 28252.7 Da, p1 = 4.80. Acc. # P68252. BOVIN. 14-3-3 protein gamma 
(Protein kinase C inhibitor protein 1) (KCIP-1). 
Figure IV: MALDI ToF data from affinity purified gel. The bands excised from 
the gel, figure 4.35, with a molecular weights around 60kDa and 30kDa were 
identified following tryptic digest MS as ovine serum albumin and 14-3-3 y, 
respectively. 
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Database searched: SwissProt.200406 
Molecular weight search (1000 - 100000 Da) selects 187433 entries. 
Full p1 range: 198834 entries. 
Combined molecular weight and p1 searches select 187433 entries. 
MS-Fit search selects 2933 entries (results displayed for top 5 matches). 
- 	Result Summary 
I 	9.37e+005 6/69(8%) 18833.8 / 7.94 STRAV P22629 Streptavidin precursor 
2 	2.45e+005 5/69(7%) 10051.4 /5.83 RICCO 004066 Acyl-CoA-binding 
protein (ACBP) 
3 	4.91e+004 7/69(10%) 79898.5 / 6.05 HUMAN 	Q9NVUO 
DNA-directed RNA 	polymerases 111 80 kDa polypeptide (RNA polymerase III subunit 
5) (RPC5) 
4 	4.85e+004 4/69(5%) 10018.5 / 5.83 GOSHI Q39779 Acyl-CoA-binding 
protein (ACBP) 
5 	4.2e+004 8/69(11%) 86877.5 / 6.54 MOUSE 	Q9D4118 
Cullin-2 (CUL-2) 
Detailed Results 
1. 6/69 matches (8%). 18833.8 Da, p1 = 7.94. Acc. # P22629. STRAy. Streptavidin precursor. 
Figure V: MALDI ToF data from scrapie affinity purified gel. The band excised 
from the gel, figure 4.39, with a molecular weight around lOkDa was identified 
following tryptic digest MS as a streptavidin precursor. The streptavidin beads were 
boiled to remove bound biotinylated aptamer during the process, releasing 
streptavidin which was detected after separation by electrophoresis and staining. 
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APPENDIX III: Publication 
Discovery of glutathione S-transferase inhibitors using dynamic 
combinatorial chemistry 
Balou Shi, Ross Stevenson, Dominic J. Campopiano, Mike F. Greaney 
Journal of the American Chemical Society, 2006 Jul 5, 128(26):8259-67 
During the course of my PhD studies I have researched and published work on 
glutathione S-transferase and its inhibitors181 . 
The paper is attached at back of thesis. 
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Abstract: Protein-directed dynamic combinatorial chemistry (DCC) relies on reversible chemical reactions 
that can function under the near-physiological conditions required by the biological target. Few classes of 
reaction have so far proven effective at generating dynamic combinatorial libraries (DCLs) under such 
constraints. In this study, we establish the conjugate addition of thiols to enones as a reaction well-suited 
for the synthesis of dynamic combinatorial libraries (DCLs) directed by the active site of the enzyme 
glutathione S-transferase (GST). The reaction is fast, freely reversible at basic pH, and easily interfaced 
with the protein, which is a target for the design of inhibitors in cancer therapy and the treatment of parasitic 
diseases such as schistosomiasis. We have synthesized DCLs based on glutathione (GSH, 1) and the 
enone ethacrynic acid, 2a. By varying either set of components, we can choose to probe either the GSH 
binding region ("G site") or the adjacent hydrophobic acceptor binding region ("H site") of the GST active 
site. In both cases the strongest binding DCL components are identified due to molecular amplification by 
GST which, in the latter system, leads to the identification of two new inhibitors for the GST enzyme. 
Introduction 
Dynamic Combinatorial Chemistry (DCC) is a powerful 
approach to the discovery of small molecule ligands for large 
biomolecules.1 The method uses the biomolecular target to direct 
the reversible, in situ assembly of a small molecule library and 
as such can be considered, in the wider context of target-guided 
synthesis (TGS), an umbrella term that covers a variety of 
systems that feature small-molecule synthesis orchestrated by 
a large biomolecule (usually a protein).2 ° DCC contrasts with 
the majority of TGS methods by using reversible reactions to 
assemble the prospective ligands. Whereas kinetic methods use 
the interior of proteins to direct and accelerate an irreversible 
reaction, usually between isolated sets of reactants, a dynamic 
combinatorial library (DCL) of compounds is designed such 
(1) Reviews: (a) Cheeseman, J. D.; Corbett, A. D.; Gleason, J. L,; Kazlauskas, 
R. J. Chern.—Eur. .1. 2005, ii, 1708-1716. (b) Otto, S. Cur,-. Opin. Drug 
Discovery Dec. 2003, 6, 509-520. (c) Otto. S.; Furlan, R. L. E.; Sanders, 
J. K. M. ('urr. Opin. Chem. Biol. 2002. 6, 321-327. (d) Lehn, J.-M, 
Chem.—Eur. J. 1999, 5, 2455-2463. 
(2) Rideout, D. Science 1986, 233, 561-563. 
(3) Nguyen, R.; Hue, t. Anger,. Chem., lot. Ed. 2001, 40, 1774-1776. 
(4) Nicolaou, K. C.; Hughes, R.; Cho, S. Y.; Winssinger, N.; Smethurst, C.; 
Labischinski, H.; Endermann, R. Angew. Chem., in!. Ed. 2000, 39,3823-
3828. 
(5) Nicolaou, K. C.; Hughes, R.; Cho, S. Y.; Winssinger, N.; Labischinski, 
I-i.; Endermann, R. Chem.—Eur. J. 2001, 7. 3824-3843. 
(6) Erlanson, D. A.; Braisted, A. C.; Raphael, D. R.; Randal, M.; Stroud, R. 
M.; Gordon, E. M.; Wells, J. A. Proc. Nat!. Acad. Sci. U.S.A. 2000, 97. 
9367-9372. 
(7) Lewis, W. G.; Green, L. 0.; Grynszpan, F.; Radii, Z.; Carlier, P. R.; Taylor, 
P.; Finn, M. G.; Sharpless, K. B. Angew. C/inn.. lot. Ed 2002, 41, 1053-
1057. 
(8) Mocharla, V. P.; Colasson, B.; Lee, L. V.; Roper, S.; Sharpless, K. B.: 
Wang, C.-H.; Kolb, H. C. Angem c/ic,,,., hit. Ed. 2005, 44, 116-120. 
(9) Bourne. Y.: Kolb, H. C.; Radii, Z.: Sharpless, K. B.; Taylor, P.; Marchot, 
P. Proc. Nail. Acad. Sri. U.S.A. 2004. /01. 1449-1454. 
(10) Krasinski, A.; Radii, Z.; Manetsch, R.; Raushel, J.; Taylor, P.; Sharpless, 
K. B.; Kolb, H. C. J. Am. Chem. Soc. 2005, /27, 6686-6692. 
that it can equilibrate in the presence of the target. Since the 
library population distribution is under thermodynamic control, 
stabilization of one member through selective binding to the 
protein is expected to amplify that species at the expense of 
other (nonbinding) species, generating hit structures that can 
be identified through analysis of the DCL population distribu-
tion. DCC thus bridges the gap between chemical synthesis of 
drug candidates and their biological binding assay, meshing the 
two operations into a single process whereby the structure of 
the biological target directs the assembly of its own best inhibitor 
in situ. 
The set of chemical reactions that have been successfully 
applied to the construction of DCLs in the presence of a 
biological target is currently rather small, centering on C=N 
and S—S bond-forming processes.14  This lack of diversity 
(II) C=N bond formation: (a) Hue, I.; Lehn, J.-M. Proc. Nat. Acad Sci. U.S.A. 
1997, 94, 2106-2110. (b) Bunyapaiboonsri, T.; Ramströrn, 0.; Lohmann, 
S.; Lehn, J.-M.; Peng, L.; Goeldner, M. Che,,,BioChe,,, 2001, 2, 438-
444. (c) Hoclsgiirtel, M.; Kroth, H.; Piecha, 0.; Hofmann, M. W.; Nicolas, 
C.; Krause, S.; Schaaf, 0.; Sonnenrnoser, G.; Eliseev, A. V. Proc. Nat. 
Acad. Sri. U.S.A. 2002, 99, 3382-3387. (d) Gerber-Lemaire, S.: Popowycz, 
F.; Rodriguez-Garcia, E.; Asenjo, A. T. C.; Rohina, 1.; Vogel. P. 
ChemBioCl,em 2002, 3, 466-470. (e) RamstrOm, 0.; Lolimann, S.; 
Bunyapaiboonsri, T.; Lehn, J.-M. Chem.—Eur. J. 2004, 10, 1711-1715. 
(F) Bugaut, A.; Toulmd, J.-J.; Rayner, B. Angew. Chen,., 1,,t. Ed. 2004, 43. 
3144-3147. (g) Zameo. S.; Vauseilles. B.; Beau, J.-M. Angew. Che,n,, 
In!. Ed. 2005. 44, 965-969. (h) Bugaut. A.; Bathany, K.; Schmitter, J.-
M.; Rayner, B. Tetrahedron Let!. 2005, 46, 687-690. 
S—S bond formation: (a) Ramström. 0.; Lehn, J.-M. C/,e,nBioChem 2000, 
1, 41-48. (b) Krishnan-Ghosh, V.; Balasubramanian, S. Angew. Chem., 
In!. Ed. 2003, 42, 2171-2173. (c) Whitney. A. M.; Ladaine, S.; Bala-
subramanian, S. Angew. Chem., hit. Ed. 2004, 43. 1143-1146. (d) 
Hotchkiss, T.; Kramer, H. B.; Doores, K. J,; Gainblin, D. P.: Oldham, N. 
J,; Davis, B. G. C'he,n. co,,,,,,un. 2005, 4264-4266. (e) Ladame, S.: 
Whitney, A. NI.; Balasubramanian, S. Angew. Client., in!. Ed. 2005, 44, 
5736-5739. 
Tlstoester formation: Larsaon. R.; Pei, Z.; RamstrOm, 0. Angew C/ic,,,., 
mt. Ed. 2004, 43, 3716-3718. 
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Scheme 1. DCL Composed of EA Analogues and GSH, 18 
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10 eq of 2f added to pre-equilibrated DCL a) at pH 4 
Glutathione, I, adds to the five enones 2a—e to set up a DCL that has an equitable distribution of thiol conjugates 3a—e and starting enones (chronsatograni 
a). The reversibility of the DCL is proven by adding an additional enone component, 2f, to the pre-equilibrated library and observing the incorporation of 
adduct 3f (chromatogram b). The p1-I control of the DCL is illustrated by pre-equilibration, acidification to p1-I 4, and subsequent addition of a large excess 
of enone 2f, which is not incorporated into the library as the conjugate addition reaction has been switched off (chromatogram c). 
is unsurprising, as the successful reaction must meet two sets 
of exacting criteria; it must proceed under the near physiological 
conditions required by the protein target as well as fulfilling 
the thermodynamic condition of reversibility inherent to the 
DCC process. An increase in the number of chemical reactions 
available for DCC is necessary to enable greater functional group 
diversity and increased applicability of DCLs as a target-guided 
synthesis methodology. With this in mind, we have recently 
introduced the conjugate addition of thiols to enones as a new 
method for DCL synthesis. 5 The reaction is well-suited to DCC 
being fast, freely reversible, responsive to pH change, and 
proceeding in water under mild conditions with no external 
reagents (Scheme 1). In addition, the choice of the tripeptide 
glutathione ()/-Glu-Cys-Gly, GSH, 1) as the thiol in our 
preliminary studies creates DCLs that are biologically relevant 
and amenable to targeting by a variety of proteins, the most 
relevant being the enzymes responsible for mediating the 
conjugate addition chemistry of GSH in the cell: the glutathione 
S-transferases (GSTs). 
The GSTs are a large family of dimeric enzymes responsible 
for cell detoxification, thereby protecting the cell from cytotoxic 
and oxidative stress 	They catalyze the conjugation of GSH 
to a wide variety of xenobiotic electrophiles such as quinones, 
Enzymatic aldol reaction: (a) Lins, R. J.; Flitsch, S. L.; Turner, N. J.: trying, 
E.: Brown, S. A. Angew. C'hern., In!. Ed. 2002, 41, 3405-3407. (b) Lins, 
R. Flinch. S. L.; Turner, N. J.; Irving, E.; Brown, S. A. Tetrahedron 2004, 
60, 771-780. 
Shi, B.: Greaney, M. F. Chem. Co,n,nun. 2005, 886-888. 
Mannervik, B.; Danielson, U. H. CRC Oil. Rev. Bioche,n. 1988, 23, 283-
337. 
(t 7) Hayes, J. D.: Flanagan, J. U.; Jowsey, 1. R. Annii. Rev. Phar,nacol. Toxicol. 
2005, 45, 51-88. 
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prostaglandins, and base propenals, making them more water 
soluble and easily eliminated from the cell. The GSTs are 
potential drug targets in cancer therapy, where resistance to 
chemotherapeutic drugs has been directly correlated with the 
overexpression of GSTs in tumor cells, and parastic diseases 
such as malaria and schistosomiasis.tt  We now describe the 
application of our GSH-based DCLs to the discovery of GST 
inhibitors. 
Results and Discussion 
We initially designed a biased DCL to examine the compat-
ibility of our conjugate addition methodology with GST and to 
see whether the enzyme could effectively amplify the best 
binding component from a DCL. Since DCL synthesis requires 
large amounts of highly purified enzyme, we selected GST from 
the helminth worm Schisiosoma japonica (SjGST, 26kDa 
monomer) as our target transferase, as it is well characterized 
and amenable to recombinant overexpression in E. co/i as an 
affinity-tagged construct.t 9 The DCL is shown in Scheme 2 and 
consists of GSH, 1, three tripeptide GSH analogues 4-6, and 
the enone ethacrynic acid, 2a (LA). The tripeptide analogues 
were synthesized using standard solid-phase synthesis methods 
and differ from GSH at the y-glutamyl residue. As a result, the 
three analogues are expected to be poor fits for the GSH binding 
region of the GST active site, as the y-glutarnyl residue is 
thought to be critical for binding,20 thus biasing the DCL toward 
Mahajan, S.; Atkins, W. M. Cell. Mo!. L(Jè Sri. 2005, 62. 1221—I233. 
Waugh, B. S. Trends Biotechnol. 2005, 23, 316-320. 
Andersson, C.; Mosialou, E.; Adang, A. E.; Mulder. G. J.; van Der Gen, 
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The four tripeptides 1, 4-6 undergo reversible conjugate addition to EA, 2a, at pH 7.5. Chromatogram (a) shows the blank DCL after lii; chromatogram 
(b) shows the DCL after 10 min in the presence of SjGST; chromatogram (c) shows the DCL after pre-equilibration and then addition of SjGST, after 2 days; 
chromatogram (d) shows the same system as (c) after 6 days. Although each EA adduct is formed as a mixture of diastereoisomers upon conjugate addition, 
giving a total of eight adducts in the DCL, the dissteromeric adducts are not separable under the LC conditions. 
the GSH adduct 7. The enone ethacrynic acid is a known 
inhibitor of GSTs and provides a motif for further structural 
elaboration. 
The blank DCL, assembled in the absence of any enzyme, 
equilibrates in 1 h to give the distribution of each of the four 
conjugates 7-10 shown in chromatogram 2a (Scheme 2). Upon 
incubation of the same components with 0.8 equiv of SjGST 
for 10 mm, the DCL collapsed to essentially one adduct, the 
expected GS-EA, 7 (chromatogram 2b), and remained un-
changed thereafter. The rapid equilibration in the presence of 
SjGST indicates that the enzyme is accelerating the conjugate 
addition, as would be expected given its catalytic function as a 
trartsferase in GSH biochemistry. To verify that the composition 
shown in chromatogram 2b represented true equilibrium and 
not a metastable distribution generated by target-accelerated 
synthesis in the presence of the enzyme, we added SjGST to 
the pre-equilibrated DCL shown in chromatogram 2a. Strong 
amplification of adduct 7 was again observed, but at a far slower 
rate. After 2 days 7 was present in 55% of total adduct 
concentration (chromatogram 2c), and after 6 days the DCL 
had equilibrated to an identical distribution to that of chromato-
gram 2b, where adduct 7 is by far the dominant species. These 
results indicate that catalysis of the conjugate addition reaction 
by SjGST does not effect the equilibrium distribution of the 
DCL and that the amplified compound 7 is the thermodynami-
cally preferred binder. 
The expected adduct 7 has been amplified from 35% of total 
conjugate concentration to 92% at equilibrium, a large ampli-
fication that ought to reflect correspondingly large differences 
in binding affinity between 7 and those peptides lacking the 
y-glutamyl residue. To verify that amplification and binding 
affinity are indeed correlated in this system, we quantified the 
inhibitory activity of 7 and 10 for SjGST using the standard 
chlorodinitrobenzene (CDNB) GST inhibition assay.2' Measured 
IC50 values of 0.32 M for 7 and 88 uM for 10 differ by over 
2 orders of magnitude, demonstrating that the extent of 
molecular amplification for each component in the biased DCL 
can be clearly related to their binding affinity for the protein 
target. Similar strong amplification was also observed in slightly 
larger DCLs based upon seven starting tripeptides (vide infra). 
Control experiments using bovine serum albumin as the protein 
target in place of SjGST produced no changes to the blank DCL 
composition, indicating that the active site of SjGST is directing 
the amplification of the DCL. The success of these biased DCLs 
(2 1) (a) Habig, W. H,: Pabst, M. J.; Jakoby, W. B. .1. Biol. C/tern. 1974, 249, 
7130-7139. (h) Burg, D.; Filippov, D. V.; Hermanus, R.; van der Marcl, 
G. A.; van Boom, J. H.; Mulder, G. J. Bioorg. Med. Che,n. 2002, 10, 95-
205. 
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Scheme 3. A DCL Made from GSH and 14 EA Analogues 
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encouraged us to extend the thiol addition methodology to the 
discovery of new GST inhibitors through the synthesis of larger, 
nonbiased DCLs. 
All OSTs contain two recognition areas for GS—R conju-
gates: a highly conserved GSH binding site and a hydrophobic 
binding region for the electrophilic substrate, called the H-site, 
which varies across the different UST isoforms. The design of 
inhibitors which target the H-site is a promising strategy in terms 
of isozyme discrimination,'8 so we elected to use DCC to 
explore the H-site of SjGST with a series of EA analogues. We 
prepared a DCL with reversed stoichiometry from that in 
Scheme 2, whereby n EA analogues react with GSH to afford 
n GS-EA adducts. The EA analogues were prepared from EA 
via EDC-mediated amide bond formation at the carboxylic acid 
group, producing a series of compounds ha—n that display a 
variety of randomly selected functional groups (Scheme 3). The 
fourteen EA analogues were equilibrated with GSH in both the 
absence and presence of SjGST (2 equiv). Figure 1 shows the 
LC traces of each DCL, along with an overlay for comparison 
purposes. The large peak eluting at -5.9 min in the amplified 
trace is due to trace amounts of SjGST still present in the 
reaction mixture. We verified that all of the expected GSH 
conjugates were present in the DCL using ESI-MS analysis and 
then looked to identify only those components that have been 
amplified by the enzyme. 
Looking at the overlay trace in the area of the GSH conjugates 
we can see that a single peak has been amplified, marked with 
a star at RT = 4.8 min. This amplification is at the expense of 
the first peak at R1  = 3.3 inin, which is reduced in intensity. 
MS analysis of the amplified peak indicated four adducts, 12a, 
d, m, and n, while the reduced peak is due to adduct 121. 
Deconvolution studies established that each of the adducts 
12a, m, and n were being amplified in the presence of SjGST, 
whereas 12d was not.22 Identical amplification results were 
(22) See Supporting Information. 
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obtained when SjGST was added to the pre-equilibrated DCL, 
indicating that the thermodynamic reversibility inherent to the 
thiol conjugate addition in the absence of any target is 
maintained in the presence of GST. To ascertain whether the 
hit structures generated from DCC were in fact active inhibitors 
of SjGST, we synthesized the amplified adducts 12a and 12n, 
a nonamplified adduct 12b, and the depreciated adduct 121 
separately and measured their IC50 values (Figure 2). 
Both piperidine (12a) and leucine (12n) derivatives of RA 
inhibit SjGST at the low micromolar/high nanomolar level, with 
the piperidine derivative 12a being slightly more potent (IC50  
= 0.61 /1M versus IC50 = 1.40 tiM). The more polar lysine 
amide 121 is, as expected, the least active, with an 1050 value 
more than 10-fold lower than 12a at 8.20 1tM. The morpholine 
amide 12b lies halfway between 12a and 121 with all tCso value 
of 4.30 uM, approximately 7-fold lower than the piperidine 
amide. These figures indicate that the extent of DCL amplifica-
tion not only reflects the relative binding affinities of DCL 
components for the protein target but is also discriminatory 
across an order of magnitude range of IC50 values. The 
piperidine and leucine amides 12a and 12n are amplified from 
the library at the expense of the lysine amide 12f, which being 
an approximately 10-fold weaker binder is removed from the 
equilibrium composition of the DCL. The reversibility inherent 
to the thiol conjugate addition is enabling the SjGST target to 
amplify relatively weak-binding compounds from a nonbiased 
selection of small molecules, demonstrating that this TUS 
methodology can be applied in a medicinal chemistry lead-
finding context. 
As EA is known to inhibit GSTs both on its own and as a 
GSH conjugate,23 we were interested in acquiring IC5,, data for 
some of the enone starting materials. We assayed the five enones 
2a, ha, lib, III, and un, the corresponding Michael acceptors 
(23) Oakley, A. 3.; Rossjohn, J.; Lo Bello, M.; Caccurs, A. M.; Federic,, G.; 
Parker, M. W Biochemistry 1997, 36, 576-585. 
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Figure 1. HPLC chromatograms for the targeted DCLof EA analogues. Chromatogram (a) shows the blank DCL distribution after I h, chromatogram (b) 
shows the DCL composition in the presence of SjGST after 30 mm and chromatogram (c) shows an overlay of (a) and (b). The two dotted lines indicate the 
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Figure 2. Inhibition profiles and IC50 values for amplified adducts 12a and 12n, nonamplified adduct 12b, and depreciated adduct 12f along with GS—EA, 
7, for comparison purposes. 
to the five GSH conjugates we had previously investigated. The 
inhibition data are shown in Figure 3 and follow a similar trend 
to that of the conjugates, with 2a 	ha > un > lib > hf. 
Additionally, the quantitative IC50 values are similar for each 
enone and its corresponding GSI-I conjugate, a common 
observation across a number of GST isozyrnes.2325 The absence 
of any significant augmentation of binding in the case of the 
GS—EA conjugates relative to the EA analogues suggests that 
the EA moiety of the conjugate may bind in different orienta-
tions and/or positions within the Fl-site relative to the parent 
Ploemen, J. H. T. M.; van Ommen, B.: van Bladeren, P. J. Bioche,n. 
Phar,nacol. 1990, 40, 1631-1635. 
Awasthi, S.; Srivastava, S. K.; Abroad, F.: Ahmad, H.; Ansari, G. A. S. 
Biochim. Biophv.s.Acla 1993, 1164, 173-178. 
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Figure 3. Inhibition profiles and IC50 values for enone starting materials ha, b, f, and n along with EA, 2a. 
compound. This phenomenon has been observed in the crystal 
structures of EA and GS—EA bound into the active site of 
GSTPI-l 23 and is perhaps to be expected, given that the two 
binding fragments of GSH and EA are linked in the conjugate 
by a single covalent bond which offers little flexibility for the 
EA group to explore analogous optimal binding modes to the 
individual enones. 
It is important to note that GST assays use the non-natural 
CDNB as a substrate and the exact nature of binding of this 
substrate to SjGST is not known. Moreover, the details of GSH-
EA binding to SjGST are also lacking since a high-resolution 
structure of the SjGST/GS—EA complex has not been deter-
mined. A model structure of the SjGST GSH EA Michaelis 
complex was recently proposed based on structures of SjGST 
bound to a series of glutathione derivatives (glutathione sul-
fonate, S-hexyl glutathione, and S-2-iodobenzyl glutathione).26 
This model identifies a series of residues (Arg 103, Tyrl 11, 
Ser107, Gin 204) that could interact with the EA carboxylic 
acid group and proposes that the enzyme must undergo 
conformational changes to allow conjugate addition of the GSH 
thiol onto the enone of EA. Interestingly, our identification of 
the amplified amide compounds 12a and 12n from our DCLs 
indicates that the carboxylic acid group of EA is not essential 
for binding in the SjGST H site and may be successfully 
extended without significant loss of inhibitory activity. 
Conclusions 
We have established the conjugate addition reaction of thiols 
to enones as a new reaction for enzyme-directed DCC. Using 
the enzyme SjGST, we could investigate either the GSH- or 
the H-regions of the enzyme active site by varying DCL 
stoichiometry between ii thiols/one enone and one thiol/n 
enones. DCL amplification was successful for both approaches, 
with the amplified compounds corresponding to the best 
inhibitors as measured by a competition assay. While the degree 
of amplification from the EA-based DCL is quantitatively far 
lower than that observed in the biased GSH-based DCLs, it 
represents a more significant application of DCC. The power 
(26) Cardoso, R. M. F.; Daniels, D. S.; Bruns, C. M.; Tamer, J. A. Proteins 
2003, 51, 137-146. 
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of DCC as a TGS method in medicinal chemistry will likely be 
realized early in the drug discovery process, where libraries of 
weak-binding compounds can be rapidly screened to produce 
lead structures for further development. The ability of SjGST 
to amplify the low micromolar inhibitors 12a and 12n from a 
nonbiased thiol conjugate DCL, at the expense of compound 
12f which differs in 1050 by only a single order of magnitude, 
illustrates this discovery process in a microcosm and demon-
strates the power of TGS in combining the chemical synthesis, 
discovery, and biological binding assay of enzyme inhibitors 
into a single operation. Future work will extend our GSH-based 
DCL methodology to the discovery of novel inhibitors for a 
range of human GST isoforms. 
Experimental Section 
General. All reagents were purchased from commercial suppliers 
and used as received. Dichloromethane (DCM) was distilled from Cal-b. 
TLC was performed with Merck aluminum plates silica gel 60 17254 . 
Melting points were recorded on a Gallenkamp melting point instrument 
and are uncorrected. 'H and 'SC NMR spectra were recorded on a 
Broker DPX360 MHz NMR spectrometer unless otherwise specified. 
Chemical shifts d are quoted in ppm relative to the CDC].-, signal as 
reference. Coupling constants are given in Hz. Optical rotations were 
measured on a POLAAR 20 automatic polarimeter using a 2 mL cell. 
Mass spectra were obtained from the EPSRC National Mass Spec-
trometry Service Centre, University of Wales, Swansea. 
Analytical HPLC was performed on an HP1 100 instrument and 
analytical HPLC-MS on a Waters 2790 HPLC with a micromass 
Platform II quadrupole mass spectrometer. Enzyme concentrations were 
determined by Bradford assay on a UNICAM UV—visible spectrometer 
with bovine serum albumin as a standard.27 Enzyme activity assays 
were conducted on a CARY 300 SCAN UV—visible spectrometer. 
Synthesis of Library Components. A. General Protocol for 
Peptide Syntheses: Tripeptides 4-6, 13-15 were prepared using 
standard Fmoc solid-phase synthesis methods. The preparation of 
H-Val-Cys-Gly-OH (4) is illustrative: Fmoc-Gly-Wang (0.6 mmol!g) 
was swollen in DCM at rt for 10 mm. The resin was drained and treated 
with 20% piperidine in dry DMF. The reaction was agitated with 
nitrogen at ii and monitored by Kaiser test. After completion, the resin 
was washed with DMF. DCM. and MeOH and dried in vacuo. The 




resulting H-Gly-Wang resin was then swollen in DCM at rt for 10 mm 
and drained. Fmoc-Cys(Trt)-OH (5 equiv), HBTU (4.9 equiv), and 
HOBtH2O (5 equiv) were mixed in dry DMF and added to the resin. 
The mixture was agitated with nitrogen, while DIPEA (10 equiv) was 
added. The reaction was monitored by Kaiser test. After completion, 
the resin was washed with DMF, DCM, and MeOH and dried in vacuo 
to afford Frnoc-Cys(Trt)-Gly-Wang. Frnoc removal from the cysteine 
residue was accomplished as described for the dcprotcction of Gly, 
followed by coupling to Fmoc-Val under the same conditions as those 
used for coupling to cysteine with the exception that DIPEA was added 
to the mixture of peptide, FIBTU, and FIOBt1120 for the activation. 
Fmoc removal from Fmoc-Val-Cys(Trt)-Gly-Wang was carried out as 
before, and the resin finally dried in vacuo over KOH. Cleavage and 
deprotection were accomplished by adding aqueous TFA solution 
(94.5% TFA, 2.5% 1120, 2.5% EDT, 1% TIS) to the resin followed by 
gentle filtration and washing with TFA solution (x2). All of the filtrate 
was collected and added dropwise to a 10-fold excess of cold ether in 
a centrifuge tube. After centrifugation, ether was carefully decanted, 
and the centrifugation was repeated twice. Water was then added to 
the white residue, and the aqueous solution was transferred to a 
separatory funnel. The aqueous phase was washed with DCM 3 times 
and then lyophilized to give the pure tripcptidc 4 (11 rng, 35%) as a 
fluffy white solid: '1-I NMR (360 MHz, D20) a = 1.06 (6H, dd, J = 
6.5, 6.5 Hz, Val (Cl-I3)2), 2.27 (lI-I, m, Val Cl-I), 2.91-3.04 (2H, in, 
Cys C1I2), 3.91 (III, d, J = 5.8 lIz, Val CH), 3.97-4.08 (211, m, Gly 
CH2), 4.53 (If!, t, J = 6.5 Hz, Cys Cl-I); °C NMR (91 MHz, D20) 6 
= 17.8, 18.6, 26.2, 31.1, 42.4, 56.8, 59.4, 170.4, 172.7, 174.3; FIRMS 
(ES+) calcd for C10 H2504N3S [M + H] 278.1169, found 278.1171. 
B. Synthesis of EA derivatives. EA derivatives were synthesized 
according to the coupling procedure described in ref 15, followed by 
Boo cleavage with TFA. The preparation of hg is illustrative: 
Ethacrynic acid (151.6 mg, 0.50 mmol), HOBtH20 (84.2 nsg, 0.55 
rnmol), EDCI (105.4 mg, 0.55 rnmol), l-1-Ser(tBu)-0tBwHCl (139.6 
mg, 0.55 mmol), and DIPEA (428 jil, 2.50 rnmol) were dissolved in 
DCM (10 niL), and the reaction was left to stir at room temperature 
overnight. The reaction was worked up in the usual fashion, followed 
by flash column chromatography (Si02, DCM/EtOAc 9:1) to yield the 
tsrz-butyl-protccted amide (156 tug, 62%) as a colorless oil; Rf  = 0.3 
(SiO2, DCM/EtOAc 9:1); 'H NMR (360 MHz, CDCI3) 6 = 1.09-
1.16 (1211, in, Ser 'Butyl + Cl-I3), 1.45 (911, a, Ser 'Butyl), 2.45 (211, 
q, J = 7.4, methylene Cl-I2), 3.54 (if!, dd, Ser Cl-I2, J, = 8.7 Hz, .J, = 
3.1 Hz), 3.85 (1 H, dd, Ser CH2, J, = 8.7 Hz, J2 = 2.7 Hz), 4.54-4.61 
(2H, m, OCH2), 4.66 (IH, in, Ser CH), 5.57 (IH, s, enone H), 5.93 
(11I, s, enone H), 6.85 (IH, d, J = 8.5 Hz, Ph H), 7.17(1H, d, J = 8.5 
Hz, Ph 1-1), 7.58 (IH, d, J = 8.7 Hz, amide H); 3C NMR (91 MHz, 
CDCI3 + CD50D) 6 = 13.4, 24.4, 28.3, 29.0, 53.8, 63.0, 69.0, 74.2, 
83.1, 111.8, 124.1, 128.2, 129.8, 132.4, 135.0, 151.2, 155.6, 167.6, 
169.8, 196.7; 1-IRMS (ES+) calcd for C241-13406NC12 [M + FI] 
502.1758, found 502.1748; [a]2013 = +110 (c = 2.72, chloroform). The 
amide was then taken up into dry DCM (5-10 mL), and TFA (5 mL) 
was added. The reaction was allowed to stir under nitrogen at rt for I 
day, after which time it was partitioned between water and DCM and 
the organic phase was extracted (x3). Drying over MgSO4 and 
concentration in vacuo yielded the acid hg (66 mg, 54%) as a white 
solid; rnp 144-146 °C; 'H NMR (360 MHz, CDCI3 + CD-,OD) 6 = 
1.03 (314, t, J = 7.4 Hz, CH3), 2.34 (2H, q, .1 = 7.4 Hz, methylene 
CH2), 3.78-3.93 (214, m, Ser CH2), 4.49-4.57 (3H, m, OCH2 + Ser 
CU), 5.50 (1H, s, enone H), 5.87 (IH, s, enone H), 6.83 (IH, d, J = 
8.5 Hz, Ph H), 7.07 (If!, d, J = 8.5 Hz, Ph H): '3C NMR (91 MHz, 
CDCI3 + CD30D) 6 = 17.2, 28.3, 59.4, 66.9, 72.9, 116.1, 128.1, 132. 1, 
134.2, 136.2, 138.8, 155.0, 159.7, 172.7, 201.2; HRMS (ES+) calcd 
for C,51-12106N2C12 [M + NH4] 407.077 1, found 407.0771; [a]2 0 = 
+28.10 (c = 1.32, chloroform/methanol 9:1). 
Protein Synthesis. A. Cloning of SjGST as a His-Tagged Fusion. 
The pET-6His-SjGST plasmid was designed to have SjGST fused to a 
6His N-terminal tag which facilitates purification of the SjGST on nickel  
metal-affinity resin, rather than glutathionc-affinity resins which arc 
typically used to purify GST isoforms. This strategy thus provided large 
amounts of SjGST free from large amounts of glutathione (GSH) which 
could interfere with dynamic combinatorial library (DCL) synthesis. 
The Schisiosoma japonica gst gene was amplified by PCR using 
pGEX6P-1 (Amersham Biosciences, Genbank Accession Number 
U78872) plasmid DNA as a template with primers GST-FOR (5' GGA 
AAC AAG CTT CAT GAC CCC TAT 3') which incorporated a BspIII 
site (in bold) and GST-REV (5' GAA CTT COG GGA TCC CAT 
GGG CCC 3') which incorporated a BamHl site (in bold). The PCR 
products were cloned into plasmid pUCI9, sequenced to confirm the 
fidelity of the cloned DNA, and then cloned into plasmid pET-óIIis 
plasmid DNA digested with appropriate restriction enzymes (Ncol and 
BomHl for the pET plasmid and B.spHl and Ba,nHI for pUCI 9/SjGST). 
Clones containing the correct insert were isolated and sequenced to 
confirm the identity of the pET-61 lis-SjGST plasmid. 
B. Expression and Purification of GST. Overcxpression of 
Schistosonia japonica GST was achieved by transforming E. co/i 
BL21(DE3) (Novagen) cells with the plasmid pET-6IIis-SjGST. A 
single colony was used to inoculate 50 mL of LB broth supplemented 
with ampicillin (100 ,ug/rnL) and grown overnight at 37 °C with 
shaking. This overnight seed culture was then used to inoculate 2 L of 
fresh growth medium and grown at 37 0C to 0D600 = 0.8 before 
induction with isopropyl thio-/3-u-galactosidc (IPTG) (1.0 mM final 
concentration). After a further 3 h agitation at 37 °C, the cells were 
harvested by centrifugation (6000 g for 15 min at 4 0C) and frozen at 
—20 'C for 16 11. The defrosted cells were resuspended in 50 mL of 
binding buffer (10 mM Tris/HCI, pFl 7.5, 10 mM NaCl, containing 
one tablet of Complete Protease Inhibitor Cocktail (Roche)) and gently 
agitated for 1 Ii at 4 °C. The cells were disrupted by sonication (15 
pulses of 30 s at 30-a intervals, on ice), and the cell debris was removed 
by centrifugation at 27 000 g for 20 min at 4 °C after which the cell 
lysate supernatant was filtered through a 0.45-pm membrane prior to 
chromatography. 
The cell lysate was applied to a HisTrap HP column (5 mL, 
Amersham Biosciences) pre-equilibrated with binding buffer (50 mM 
Tris/HCI, 0.5 M NaCl, 5 mM imidazole, p1..1  7.5). The column was 
then washed with 20 column volumes of binding buffer (100 mL) before 
bound material was eluted using a linear gradient of 0-100% elution 
buffer (50 mM Tris/HCI, 0.5 M NaCl, 0.5 M imidazole, pH 7.5, over 
20 column columns, 100 mL; see Figure S5.1 in the Supporting 
Information). Fractions were analyzed by SDS-PAGE, and those 
containing GST were pooled and dialyzed overnight against 4 L of 10 
mM Tris/HCI (pH 7.5) at 4 °C. SDS-PAGE analysis suggested that 
the protein was greater than 95% pure (Figure S5.2 in the Supporting 
Information). Further purification was achieved using MonoQ anion 
exchange (1 ml., Amersham Biosciences). The protein was loaded Onto 
the column, washed with 50 mM Tris, p1-I 7.5, and then eluted with a 
linear 0—I M NaCI gradient over 20 mL. Fractions were analyzed by 
SDS-PAGE, and the purest GST fractions were pooled, concentrated 
by ultrafiltration (10 kDa cutoff), and frozen. A I mg aliquot of the 
isolated 6His-SjGST was analyzed by gel filtration chromatography 
(Scphacryl HR-75, Amersham Bioscience) to confirm that it was 
dimeric in solution. 
Electrospray mass spectrometry (ESI-MS) analysis of the pure 
enzyme gave the molecular mass of the 61Iis-SjGST as 28 068 Da (±5 
Da), in good agreement with the predicted value of 28 057 Da for the 
monomer. The final yield of GST using this method was 20 mg per 
L of bacterial culture, and this protein was used for all subsequent 
library synthesis and inhibition assays. 
Dynamic Combinatorial Chemistry. Representative procedure for 
GSH analogue DCL: The seven GSH tripeptides 1, 4-6, 13-15(7 x 
8.2pL, 10 mM aqueous) and ethacrynic acid (0.82/LI, 0.1 M in DMSO) 
were added to tris buffer (200 pL, 50 mM, pH 7.5). The DCL was 
allowed to stand at ii with occasional gentle shaking and monitored 
by HPLC at regular intervals to establish the blank DCL composition 
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Scheme 4. HPLC Analysis of DCL Made from Seven GSH-Based Tripeptides 1, 4-6, 13-15 
SMe 
CO2H 	H 
H2N'( NY.  N''CO2H 	 HSNIN.YU.NCO2H 	
H2N( 	NCO2H 
a H 0 	. o 	
SH 	 'SH 	 SH 
11 SH 




H2N NAN_cOH 	 N"CO2H 
H2N'( NJi.N...CQH 	 0 
a H 	 SH 11 SH 
SH 





EA, 2a 	0 
H 0 
H2N"'( NJ(N.co Nj 
H 
SEA 	 SEA 














Chromatogram (a) shows the blank DCL, and chromatogram (b) shows the DCL in the presence of SjGST. The GSH—EA adduct 7 is amplified from 
35% of total adduct concentration to 88%. 
(HPLC conditions: Column: Luna 5 It C18(2) 30 mm x 4.60 mm, 
flow rate I mL min', wavelength 254 nm, temperature 23 °C, gradient 
H2O/MeCN (0.0 1% TFA) from 80% to 70% over 8 min, then to 40% 
over I min eventually to 20% over 2 mm). 
The DCL was then resynthesized in the presence of SjGST (200 sl, 
160 PM in 50 mM tris buffer pH 7.5), and the HPLC trace was 
compared to that of the blank (Scheme 4). The DCL composition was 
identical in the case of addition of SjGST from the start and the case 
of SiOST addition to a pre-equilibrated library. 
Representative procedure for EA analogue DCL: Reduced gluta 
thione (20 uL, 10 mM aqueous) and the 14 ethacrynic acid derivatives 
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ha—n (14 x 2 juL, 0.1 M in DMSO) were added to tris buffer (3.3 
mL, 50 mM, pH 8). The DCL was allowed to stand with occasional 
gentle shakes at ii and monitored by HPLC at regular intervals. LC—
MS verified that each of the expected adducts was present in the blank 
DCL (Figure S6. 1). HPLC conditions: Column: Luna 5 It C 18(2)30 
mm x 4.60 mm, flow rate I mL min, wavelength 254 nm, 
temperature 23 °C, gradient HiO/MeCN (0.01% TFA) from 80% to 
5% over 10 nun. 
The DCL was then resynthesized in the presence of SjGST (1.1 mL, 
180 1tM in 50 mM tris buffer pH 7.5) and added to tris buffer (2.2 mL, 
50 mM, pH 8), and the HPLC traces were compared (Figure I). The 
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DCL composition was identical in the case of addition of SjGST from 
the start and the case of SjGST addition to a pre-equilibrated library. 
Inhibition Assays. To a 500 yL cuvette were added phosphate buffer 
(415 /2L, 0.1 M p1! 6.6), GST (10 /1L, 0.148 mg/mL), and inhibitor 
(12.5jiL in DMSO), and the solution was mixed well. After incubation 
at ambient temperature for 5 mm, CDNB (12.5 jil, 40 mM in EtOH) 
and OSH (50 /21, 10 mM) were added and quickly mixed well. 
Absorbance was measured at 340 sm at 20 °C for 5 mm. Prior to each 
experiment, the baseline of the UV spectrometer was corrected by 
replacing GST solution with phosphate buffer. For each inhibitor, a 
group of experiments were conducted by varying inhibitor concentra-
tions (0,02-10 PM). After each experiment absorbance against time 
graphs were plotted such that the initial gradients as velocities were  
worked out. To calculate the IC55 of each inhibitor, the ratio of these 
velocities and the velocity without any inhibitor were plotted against 
inhibitor concentrations. 
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